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1 PREAMBLE
Guidelines summarize and evaluate available evidence
with the aim of assisting health professionals in selecting
the best management strategies for an individual patient
with a given condition. Guidelines and their recommenda-
tions should facilitate decision making of health professio-
nals in their daily practice. However, the final decisions
concerning an individual patient must be made by the
responsible health professional(s) in consultation with
the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent
years by the European Society of Cardiology (ESC) and by
the European Society of Hypertension (ESH), as well as by
other societies and organizations. Because of the impact on
clinical practice, quality criteria for the development of
guidelines have been established in order to make all
decisions transparent to the user. The recommendations
for formulating and issuing ESCGuidelines can be found on
the ESC website (http://www.escardio.org/Guidelines-
Education/Clinical-Practice-Guidelines/Guidelines-devel-
opment/Writing-ESC-Guidelines). ESC and ESHGuidelines
represent the official positionof the two Societies on agiven
topic and are regularly updated.
Members of this Task Force were selected by the ESC
and ESH to represent professionals involved with the
medical care of patients with this pathology. Selected
experts in the field undertook a comprehensive review
of the published evidence for management of a given
condition according to ESC Committee for Practice Guide-
lines (CPG) policy and approved by the ESH. A critical
evaluation of diagnostic and therapeutic procedures was
performed, including assessment of the risk–benefit ratio.
The level of evidence and the strength of the recommen-
dation of particular management options were weighed
and graded according to predefined scales, as outlined in
Tables 1 and 2.
The experts of the writing and reviewing panels pro-
vided declaration of interest forms for all relationships that
might be perceived as real or potential sources of conflicts
of interest. These formswere compiled into one file and can
Williams et al.
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be found on the ESC website (http://www.escardio.org/
guidelines). Any changes in declarations of interest that
arise during the writing period were notified to the ESC and
ESH and updated. The Task Force received its entire
financial support from the ESC and ESH without any
involvement from the healthcare industry.
The ESC CPG supervises and coordinates the prepara-
tion of new Guidelines. The Committee is also responsible
for the endorsement process of these Guidelines. The ESC
Guidelines undergo extensive review by the CPG and
external experts, and in this case by ESH-appointed experts.
After appropriate revisions the Guidelines are approved by
all the experts involved in the Task Force. The finalized
document is approved by the CPG and ESH for publication
in the European Heart Journal and in the Journal of
Hypertension as well as in a shortened version in Blood
Pressure. The Guidelines were developed after careful
consideration of the scientific and medical knowledge
and the evidence available at the time of their dating.
The task of developing ESC and ESH Guidelines also
includes the creation of educational tools and implementa-
tion programmes for the recommendations including con-
densed pocket guideline versions, summary slides,
booklets with essential messages, summary cards for non-
specialists and an electronic version for digital applications
(smartphones, APPs, etc.). These versions are abridged and
thus, if needed, one should always refer to the full text
version, which is freely available via the ESC and ESH
websites and hosted on the European Heart Journal and
Journal of Hypertension websites. The National Societies of
the ESC are encouraged to endorse, translate and imple-
ment all ESC Guidelines. Implementation programmes are
needed because it has been shown that the outcome of
disease may be favourably influenced by the thorough
application of clinical recommendations.
Surveys and registries are needed to verify that real-life
daily practice is in keeping with what is recommended in
the guidelines, thus completing the loop between clinical
research, writing of guidelines, disseminating them, and
implementing them into clinical practice.
Health professionals are encouraged to take the ESC and
ESH Guidelines fully into account when exercising their
clinical judgement, as well as in the determination and the
implementation of preventive, diagnostic, or therapeutic
medical strategies. However, the ESC and ESH Guidelines
do not override in any way whatsoever the individual
responsibility of health professionals to make appropriate
and accurate decisions in consideration of each patient’s
health condition and in consultation with that patient or the
patient’s caregiver where appropriate and/or necessary. It is
also the health professional’s responsibility to verify the
rules and regulations applicable to drugs and devices at the
time of prescription.
2 INTRODUCTION
Substantial progress has been made in understanding the
epidemiology, pathophysiology and risk associated with
hypertension, and a wealth of evidence exists to demon-
strate that lowering blood pressure (BP) can substantially
reduce premature morbidity and mortality [1–10]. A num-
ber of proven, highly effective, and well tolerated lifestyle
and drug treatment strategies can achieve this reduction in
BP. Despite this, BP control rates remain poor worldwide
and are far from satisfactory across Europe. Consequently,
hypertension remains the major preventable cause of car-
diovascular disease (CVD) and all-cause death globally and
in our continent [11–14].
These 2018 ESC/ESH Guidelines for the management of
arterial hypertension are designed for adults with hyper-
tension, that is aged at least 18 years. The purpose of the
review and update of these Guidelines was to evaluate and
incorporate new evidence into the Guideline recommen-
dations. The specific aims of these Guidelines were to
produce pragmatic recommendations to improve the detec-
tion and treatment of hypertension and to improve the poor
rates of BP control by promoting simple and effective
treatment strategies.
These joint 2018 Guidelines follow the same principles
upon which a series of hypertension Guidelines were
jointly issued by the two societies in 2003, 2007 and
2013. These fundamental principles are to base recom-
mendations onproperly conducted studies, identified from
an extensive review of the literature; to give the highest
priority to data from randomized controlled trials (RCTs);
to also consider well conducted meta-analyses of RCTs as
strong evidence (this contrasts with network meta-analy-
ses, which we do not consider to have the same level of
evidence because many of the comparisons are
TABLE 1. ESC Classes of recommendations
TABLE 2. ESC Levels of evidence
2018 ESC/ESH Guidelines for the management of arterial hypertension
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nonrandomized); to recognize that RCTs cannot address
many important questions related to the diagnosis, risk
stratification and treatment of hypertension, which can be
addressed by observational or registry-based studies of
appropriate scientific calibre; to grade the level of scientific
evidence and the strength of recommendations according
to ESC recommendations (see Section 1); to recognize that
opinions may differ on key recommendations, which are
resolved by voting; and to recognize that there are circum-
stances in which there is inadequate or no evidence, but
that the question is important for clinical practice and
cannot be ignored. In these circumstances, we resort to
pragmatic expert opinion and endeavour to explain its
rationale.
Each member of the Task Force was assigned specific
writing tasks, which were reviewed by section co-ordinators
and thenby the twochairs, oneappointed by the ESC and the
other by the ESH. The text was developed over approxi-
mately 24 months, during which the Task Force members
met collectively and corresponded intensively with one
another between meetings. Before publication, the docu-
ment was reviewed by European reviewers selected by the
ESC andESH, and by representatives of ESCNational Cardiac
Societies and ESH National Hypertension Societies.
2.1 What is new and what has changed in the 2018 ESC/ESH Arterial Hypertension Guidelines?
Changes in recommendations
81023102
sisongaiDsisongaiD
Office BP is recommended for screening and diagnosis of
hypertension.
It is recommended to base the diagnosis of hypertension on:
• Repeated office BP measurements; or
• Out-of-office BP measurement with ABPM and/or HBPM if logistically
and economically feasible.
Treatment thresholds
Highnormal BP (130 –139/85–89 mmHg): Unless the necessary
evidence is obtained, it is not recommended to initiate
antihypertensive drug therapy at high–normal BP.
Treatment thresholds
Highnormal BP (130 –139/85–89 mmHg): Drug treatment may be
considered when cardiovascular risk is very high due to established CVD,
especially CAD.
Treatment thresholds
Treatment of low-risk grade 1 hypertension:
Initiation of antihypertensive drug treatment should also be
considered in grade 1 hypertensive patients at low–moderate-risk,
when BP is within this range at several repeated visits or elevated by
ambulatory BP criteria, and remains within this range despite a
reasonable period of time with lifestyle measures.
Treatment thresholds
Treatment of low-risk grade 1 hypertension:
In patients with grade 1 hypertension at low–moderate-risk and without
evidence of HMOD, BP-lowering drug treatment is recommended if the
patient remains hypertensive after a period of lifestyle intervention.
Treatment thresholds
Older patients
Antihypertensive drug treatment may be considered in the elderly
(at least when younger than 80 years) when SBP is in the
140–159 mmHg range, provided that antihypertensive treatment is
well tolerated.
Treatment thresholds
Older patients
BP-lowering drug treatment and lifestyle intervention is recommended in
fit older patients (> 65 years but not > 80 years) when SBP is in the
grade 1 range (140–159 mmHg), provided that treatment is well tolerated.
stegrattnemtaertPBstegrattnemtaertPB
An SBP goal of <140 mmHg is recommended. • It is recommended that the first objective of treatment should be to
lower BP to <140/90 mmHg in all patients and, provided that the
treatment is well tolerated, treated BP values should be targeted to
130/80 mmHg or lower in most patients.
• In patients < 65 years it is recommended that SBP should be lowered
to a BP range of 120–129 mmHg in most patients.
Williams et al.
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BP treatment targets in older
patients (65–80 years)
BP treatment targets in older patients (65 –80 years)
An SBP target of between 140–150 mmHg
is recommended for older patients (65–80 years).
In older patients (>_  65 years), it is recommended that SBP should be
targeted to a BP range of 130–139 mmHg.
BP treatment targets in patients aged over 80 years
An SBP target between 140–150 mmHg should be considered in
people older than 80 years, with an initial SBP >_ 160 mmHg, provided
that they are in good physical and mental condition.
An SBP target range of 130–139 mmHg is recommended for people older
than 80 years, if tolerated.
stegratPBD
BP treatment targets in patients aged over 80 years
stegratPBD
A DBP target of < 90 mmHg is always recommended, except in
patients with diabetes, in whom values < 85 mmHg are
recommended.
A DBP target of < 80 mmHg should be considered for all hypertensive
patients, independent of the level of risk and comorbidities.
tnemtaertgurdfonoitaitinItnemtaertgurdfonoitaitinI
Initiation of antihypertensive therapy with a two-drug combination
may be considered in patients with markedly high baseline BP or
at high cardiovascular risk.
It is recommended to initiate an antihypertensive treatment with a
two-drug combination, preferably in a SPC. The exceptions are frail older
patients and those at low risk and with grade 1 hypertension (particularly
if SBP is < 150 mmHg).
noisnetrepyhtnatsiseRnoisnetrepyhtnatsiseR
Mineralocorticoid receptor antagonists, amiloride, and the alpha-1
blocker doxazosin should be considered if no contraindication
exists.
Recommended treatment of resistant hypertension is the addition of
low-dose spironolactone to existing treatment, or the addition of further
diuretic therapy if intolerant to spironolactone, with either eplerenone,
amiloride, higher-dose thiazide/thiazide-like diuretic or a loop diuretic,
or the addition of bisoprolol or doxazosin.
noisnetrepyhrofyparehtdesab-eciveDnoisnetrepyhrofyparehtdesab-eciveD
In case of ineffectiveness of drug treatment, invasive procedures
such as renal denervation and baroreceptor stimulation may be
considered.
Use of device-based therapies is not recommended for the routine
treatment of hypertension, unless in the context of clinical studies and
RCTs, until further evidence regarding their safety and efficacy becomes
available.
Recommendation Grading
IIIedarGbIIedarGaIIedarGIedarG
ABPM = ambulatory blood pressure monitoring; BP = blood pressure; CAD = coronary artery disease; CVD = cardiovascular disease;
DBP = diastolic blood pressure; HBPM = home blood pressure monitoring; HMOD = hypertension-mediated organ damage; RCT = randomized controlled trial;
SBP = systolic blood pressure; SPC = single-pill combination.
New sections/recommendations
When to suspect and how to screen for the causes of secondary hypertension
Management of hypertension emergencies
Updated recommendations on the management of BP in acute stroke
Updated recommendations on the management of hypertension in women and pregnancy
Hypertension in different ethnic groups
The effects of altitude on BP
Hypertension and chronic obstructive pulmonary disease
Hypertension and AF and other arrhythmias
Oral anticoagulant use in hypertension
Hypertension and sexual dysfunction
Hypertension and cancer therapies
Perioperative management of hypertension
Glucose-lowering drugs and BP
Updated recommendations on cardiovascular risk assessment and management: using the SCORE system to assess risk in patients without CVD; the importance of
HMOD in modifying cardiovascular risk; and the use of statins and aspirin for CVD prevention
2018 ESC/ESH Guidelines for the management of arterial hypertension
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3 DEFINITION, CLASSIFICATION, AND
EPIDEMIOLOGICAL ASPECTS OF
HYPERTENSION
3.1 Definition of hypertension
The relationship between BP and cardiovascular and renal
events is continuous, making the distinction between nor-
motension and hypertension, based on cut-off BP values,
somewhat arbitrary [2,4,8]. However, in practice, cut-off BP
values are used for pragmatic reasons to simplify the
diagnosis and decisions about treatment. Epidemiological
associations between BP and cardiovascular risk extend
from very low levels of BP (i.e. SBP >115mmHg). How-
ever, ‘hypertension’ is defined as the level of BP at which
the benefits of treatment (either with lifestyle interventions
or drugs) unequivocally outweigh the risks of treatment, as
documented by clinical trials. This evidence has been
reviewed (see Section 7.2 for detailed discussion of hyper-
tension diagnostic thresholds) and provides the basis for
the recommendation that the classification of BP and defi-
nition of hypertension remain unchanged from previous
ESH/ESC Guidelines (Table 3) [15–17].
Hypertension is defined as office SBP values at least
140mmHg and/or diastolic BP (DBP) values at least
90mmHg. This is based on evidence from multiple RCTs
that treatment of patients with these BP values is benefi-
cial (see Section 7). The same classification is used in
younger, middle-aged, and older people, whereas BP
centiles are used in children and teenagers, in whom
data from interventional trials are not available. Details
on BP classification in boys and girls 16 years or less of
age can be found in the 2016 ESH Guidelines for children
and adolescents [18].
3.2 Classification of blood pressure
Classification of BP
Recommendation Classa Levelb
It is recommended that BP be classified as
optimal, normal, high–normal, or grades
1–3 hypertension, according to office BP.
I C
BP, blood pressure.
aClass of recommendation.
bLevel of evidence.
3.3 Prevalence of hypertension
Based on office BP, the global prevalence of hypertension
was estimated to be 1.13 billion in 2015 [5], with a preva-
lence of over 150 million in central and Eastern Europe. The
overall prevalence of hypertension in adults is around 30–
45% [12], with a global age-standardized prevalence of
24 and 20% in men and women, respectively, in 2015 [5].
This high prevalence of hypertension is consistent across
New concepts
BP measurement
Wider use of out-of-office BP measurement with ABPM and/or HBPM, especially HBPM, as an option to confirm the diagnosis of hypertension, detect
white-coat and masked hypertension and monitor BP control
Less conservative treatment of BP in older and very old patients
Lower BP thresholds and treatment targets for older patients, with emphasis on considerations of biological rather than chronological age (i.e. the
importance of frailty, independence, and the tolerability of treatment)
Recommendation that treatment should never be denied or withdrawn on the basis of age, provided that treatment is tolerated
A SPC treatment strategy to improve BP control
Preferred use of two-drug combination therapy for the initial treatment of most people with hypertension
A single-pill treatment strategy for hypertension with the preferred use of SPC therapy for most patients
Simplified drug treatment algorithms with the preferred use of an ACE inhibitor or ARB, combined with a CCB and/or a thiazide/thiazide-like diuretic, as
the core treatment strategy for most patients, with beta-blockers used for specific indications
New target ranges for BP in treated patients
Target BP ranges for treated patients to better identify the recommended BP target and lower safety boundaries for treated BP, according to a
patient’s age and specific comorbidities
Detecting poor adherence to drug therapy
A strong emphasis on the importance of evaluating treatment adherence as a major cause of poor BP control
A key role for nurses and pharmacists in the longer-term management of hypertension
The important role of nurses and pharmacists in the education, support, and follow-up of treated hypertensive patients is emphasized as part of the
overall strategy to improve BP control
ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker;
CVD, cardiovascular disease; HBPM, home blood pressure monitoring; HMOD, hypertension-mediated organ damage; SCORE, Systematic COronary Risk Evaluation; SPC, single-pill combination.
TABLE 3. Classification of office blood pressurea and definitions of
hypertension gradeb
Category Systolic (mmHg) Diastolic (mmHg)
Optimal <120 and <80
Normal 120–129 and/or 80–84
High normal 130–139 and/or 85–89
Grade 1 hypertension 140–159 and/or 90–99
Grade 2 hypertension 160–179 and/or 100–109
Grade 3 hypertension 180 and/or 110
Isolated systolic
hypertensionb
140 and <90
BP, blood pressure.
aBP category is defined according to seated clinic BP and by the highest level of BP,
whether systolic or diastolic.
bIsolated systolic hypertension is graded 1, 2, or 3 according to systolic BP values in the
ranges indicated. The same classification is used for all ages from 16 years.
Williams et al.
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the world, irrespective of income status, that is in lower,
middle and higher income countries [12]. Hypertension
becomes progressively more common with advancing
age, with a prevalence of more than 60% in people aged
more than 60 years [12]. As populations age, adopt more
sedentary lifestyles, and increase their body weight, the
prevalence of hypertensionworldwidewill continue to rise.
It is estimated that the number of people with hypertension
will increase by 15–20% by 2025, reaching close to 1.5
billion [19].
3.4 Blood pressure relationship with risk of
cardiovascular and renal events
Elevated BP was the leading global contributor to prema-
ture death in 2015, accounting for almost 10 million deaths
and over 200million disability-adjusted life years [3]. Impor-
tantly, despite advances in diagnosis and treatment over the
past 30 years, the disability-adjusted life years attributable to
hypertension have increased by 40% since 1990 [3]. SBP at
least 140mmHg accounts for most of the mortality and
disability burden (70%), and the largest number of SBP-
related deaths per year are due to ischaemic heart disease
(4.9 million), haemorrhagic stroke (2.0 million), and ischae-
mic stroke (1.5 million) [3].
Both office BP and out-of-office BP have an independent
and continuous relationship with the incidence of several
cardiovascular events [haemorrhagic stroke, ischaemic
stroke, myocardial infarction, sudden death, heart failure,
and peripheral artery disease (PAD)], as well as end-stage
renal disease [4]. Accumulating evidence is closely linking
hypertension with an increased risk of developing atrial
fibrillation (AF) [20], and evidence is emerging that links
early elevations of BP to increased risk of cognitive decline
and dementia [21,22].
The continuous relationship between BP and risk of
events has been shown at all ages [23] and in all ethnic
groups [24,25], and extends from high BP levels to relatively
low values. SBP appears to be a better predictor of events
than DBP after the age of 50 years [23,26,27]. High DBP is
associated with increased cardiovascular risk and is more
commonly elevated in younger (<50 years) vs. older
patients. DBP tends to decline from midlife as a conse-
quence of arterial stiffening; consequently, SBP assumes
even greater importance as a risk factor frommidlife [26]. In
middle-aged and older people, increased pulse pressure
(the difference between SBP and DBP values) has addi-
tional adverse prognostic significance [28,29].
3.5 Hypertension and total cardiovascular risk
assessment
Hypertension rarely occurs in isolation, and often clusters
with other cardiovascular risk factors such as dyslipidaemia
and glucose intolerance [30,31]. This metabolic risk factor
clustering has a multiplicative effect on cardiovascular risk
[32]. Consequently, quantification of total cardiovascular
risk (i.e. the likelihood of a person developing a cardiovas-
cular event over a defined period) is an important part of
the risk stratification process for patients with hypertension.
Many cardiovascular risk assessment systems are
available and most project 10-year risk. Since 2003, the
European Guidelines on CVD prevention have recom-
mended use of the Systematic COronary Risk Evaluation
(SCORE) system because it is based on large, representative
European cohort data sets (available at: http://www.escar-
dio.org/Guidelines-&-Education/Practice-tools/CVD-pre-
vention-toolbox/SCORE-Risk-Charts). The SCORE system
estimates the 10-year risk of a first fatal atherosclerotic
event, in relation to age, sex, smoking habits, total choles-
terol level, and SBP. The SCORE system also allows cali-
bration for different cardiovascular risk levels across
numerous European countries and has been externally
validated [33]. A previous limitation of the SCORE system
was that it applied only to patients aged 40–65 years;
however, the SCORE system has recently been adapted
for patients over the age of 65 years [34]. Detailed infor-
mation on cardiovascular risk assessment is available [35].
Factors influencing cardiovascular risk factors in patients
with hypertension are shown in Table 4. Hypertensive
TABLE 4. Factors influencing cardiovascular risk in patients with
hypertension
Demographic characteristics and laboratory parameters
Sexa (men >women)
Agea
Smoking (current or past history)a
Total cholesterola and HDL-C
Uric acid
Diabetesa
Overweight or obesity
Family history of premature CVD (men aged <55 years and women aged
<65 years)
Family or parental history of early-onset hypertension
Early-onset menopause
Sedentary lifestyle
Psychosocial and socioeconomic factors
Heart rate (resting values >80 beats/min)
Asymptomatic HMOD
Arterial stiffening:
Pulse pressure (in older people) 60mmHg
Carotid–femoral PWV >10m/s
ECG LVH (Sokolow–Lyon index >35mm, or R in aVL 11mm; Cornell
voltage duration product >2440mmms, or Cornell voltage >28mm in
men or >20mm in women)
Echocardiographic LVH [left ventricular mass index: men >50g/m2.7;
women >47g/m2.7 (height in m2.7); indexation for BSA may be used in
normal-weight patients; left ventricular mass/BSA g/m2 >115 (men) and
>95 (women)]
Microalbuminuria (30–300mg/24h), or elevated albumin–creatinine ratio
(30–300mg/g; 3.4–34mg/mmol) (preferentially on morning spot urine)b
Moderate CKD with eGFR 30–59ml/min/1.73m2 (BSA)b
Ankle-brachial index <0.9
Advanced retinopathy: haemorrhages or exudates, papilloedema
Established cardiovascular or renal disease
Cerebrovascular disease: ischaemic stroke, cerebral haemorrhage, TIA
CAD: myocardial infarction, angina, myocardial revascularization
Presence of atheromatous plaque on imaging
Heart failure, including HFpEF
Peripheral artery disease
Atrial fibrillation
Severe CKD with eGFR <30ml/min/1.73m2
BSA, body surface area; CAD, coronary artery disease; CKD, chronic kidney disease; CVD,
cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL-C, HDL
cholesterol; HFpEF, heart failure with preserved ejection fraction; HMOD, hypertension-
mediated organ damage; LVH, left ventricular hypertrophy; PWV, pulse wave velocity;
SCORE, Systematic COronary Risk Evaluation; TIA, transient ischaemic attack.
aCV risk factors included in the SCORE system.
bProteinuria and reduced eGFR are independent risk factors. See Table 6 for
cardiovascular risk modifiers.
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patients with documented CVD, including asymptomatic
atheromatous disease on imaging, type 1 or type 2 diabetes,
very high levels of individual risk factors (including grade 3
hypertension), or chronic kidney disease (CKD; stages 3–
5), are automatically considered to be at very high (i.e.
10% CVDmortality) or high (i.e. 5–10% CVDmortality) 10
year cardiovascular risk (Table 5). Such patients do not
need formal cardiovascular risk estimation to determine
their need for treatment of their hypertension and other
cardiovascular risk factors. For all other hypertensive
patients, estimation of 10-year cardiovascular risk using
the SCORE system is recommended. Estimation should
be complemented by assessment of hypertension-mediated
organ damage (HMOD), which can also increase cardio-
vascular risk to a higher level, even when asymptomatic
(see Table 4 and Sections 3.6 and 4).
There is also emerging evidence that an increase in serum
uric acid to levels lower than those typically associated with
gout is independently associated with increased cardiovas-
cular risk in both the general population and in hypertensive
patients.Measurement of serumuric acid is recommendedas
part of the screening of hypertensive patients [36].
The SCORE system only estimates the risk of fatal car-
diovascular events. The risk of total cardiovascular events
(fatal and nonfatal) is approximately three times higher
than the rate of fatal cardiovascular events in men and four
times higher in women. This multiplier is attenuated to less
than three times in older people in whom a first event is
more likely to be fatal [37].
There are important general modifiers of cardiovascular
risk (Table 6) as well as specific cardiovascular risk modi-
fiers for patients with hypertension. Cardiovascular risk
modifiers are particularly important at the cardiovascular
risk boundaries, and especially for patients at moderate-risk
in whom a risk modifier might convert moderate-risk to
high risk and influence treatment decisions with regard to
cardiovascular risk factor management. Furthermore, car-
diovascular risk estimates by the SCORE system may be
modified in first-generation immigrants to Europe and
cardiovascular risk scores in such patients may be adjusted
by correction factors (Table 7). Further details of the impact
of cardiovascular risk modifiers are available from the ESC
2016 CVD prevention Guidelines [35].
3.6 Importance of hypertension-mediated
organ damage in refining cardiovascular risk
assessment in hypertensive patients
A unique and important aspect of cardiovascular risk
estimation in hypertensive patients is the need to consider
TABLE 5. Ten year cardiovascular risk categories (Systematic COronary Risk Evaluation system)
Very high risk People with any of the following:
Documented CVD, either clinical or unequivocal on imaging .
• Clinical CVD includes acute myocardial infarction, acute coronary syndrome, coronary or other arterial revascula-
rization, stroke, TIA, aortic aneurysm, and PAD
• Unequivocal documented CVD on imaging includes significant plaque (i.e. >_ 50% stenosis) on angiography or
ultrasound; it does not include increase in carotid intima-media thickness
• Diabetes mellitus with target organ damage, e.g. proteinuria or a with a major risk factor such as grade 3
hypertension or hypercholesterolaemia
• Severe CKD (eGFR < 30 mL/min/1.73 m2)
• A calculated 10 year SCORE of >_ 10%
High risk People with any of the following:
• Marked elevation of a single risk factor, particularly cholesterol > 8 mmol/L (> 310 mg/dL), e.g. familial hyper-
cholesterolaemia or grade 3 hypertension (BP >_ 180/110 mmHg)
• Most other people with diabetes mellitus (except some young people with type 1 diabetes mellitus and with-
out major risk factors, who may be at moderate-risk)
Hypertensive LVH
Moderate CKD (eGFR 30-59 mL/min/1.73 m2)
A calculated 10 year SCORE of 5-10 %
Moderate risk People with:
• A calculated 10 year SCORE of 1 to <5%
• Grade 2 hypertension
• Many middle-aged people belong to this category
Low risk People with:
• A calculated 10 year SCORE of < 1%
BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; LVH, left ventricular hypertrophy; TIA, transient ischaemic
attack; PAD, peripheral artery disease; SCORE, Systematic COronary Risk Evaluation.
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the impact of HMOD. This was previously termed ‘target
organ damage’, but HMOD more accurately describes
hypertension-induced structural and/or functional
changes in major organs (i.e. the heart, brain, retina,
kidney, and vasculature) (Table 4). There are three impor-
tant considerations: not all features of HMOD are included
in the SCORE system (CKD and established vascular dis-
ease are included) and several hypertensive HMODs (e.g.
cardiac, vascular, and retinal) have well established
adverse prognostic significance (see Section 5) and may,
especially if HMOD is pronounced, lead to a high cardio-
vascular risk even in the absence of classical cardiovascular
risk factors; the presence of HMOD is common and often
goes undetected [38]; and the presence of multiple HMODs
in the same patient is also common, and further increases
cardiovascular risk [39–41]. Consequently, the inclusion of
HMOD assessment is important in patients with hyperten-
sion and helps identify high-risk or very high-risk hyper-
tensive patients who may otherwise be misclassified as
having a lower level of risk by the SCORE system [42]. This
is especially true for the presence of left ventricular hyper-
trophy (LVH), CKD with albuminuria or proteinuria, or
arterial stiffening [43] (see Section 5). The impact of pro-
gression of the stages of hypertension-associated disease
(from uncomplicated through to asymptomatic or estab-
lished disease), according to different grades of hyperten-
sion and the presence of cardiovascular risk factors,
HMOD, or comorbidities, is illustrated in Figure 1 for
middle-aged individuals.
3.7 Challenges in cardiovascular risk
assessment
Cardiovascular risk is strongly influenced by age (i.e. older
people are invariably at high absolute cardiovascular risk).
In contrast, the absolute risk of younger people, particu-
larly younger women, is invariably low, even in those with
a markedly abnormal risk factor profile. In the latter,
relative risk is elevated even if absolute risk is low. The
use of ‘cardiovascular risk age’ has been proposed as a
useful way of communicating risk and making treatment
decisions, especially for younger people at low absolute
risk but with high relative risk [35]. This works by illustrat-
ing how a younger patient (e.g. a 40-year-old) with risk
factors but low absolute risk has a cardiovascular risk
equivalent to a much older person (60 years) with optimal
risk factors; thus, the cardiovascular risk age of the younger
patient is 60 years. The cardiovascular risk age can be
automatically calculated usingHeartScore (www.heartscore.
org).
A second consideration is that the presence of concomi-
tant disease is often recorded in a binary way in cardiovas-
cular risk assessment systems (e.g. diabetes, yes/no). This
does not reflect the impact of the severity or duration of
concomitant diseases on total cardiovascular risk. For
example, long-standing diabetes is clearly associated with
high risk, whereas the risk is less certain for recent-onset
diabetes [34].
A third conundrum specific to hypertension is what BP
value to use in cardiovascular risk assessment in a patient
who is receiving treatment for hypertension. If treatment
was commenced recently, it seems appropriate to use the
pretreatment BP value. If treatment has been long-standing,
using the current treated BP value will invariably underes-
timate risk because it does not reflect prior longer-term
exposure to higher BP levels, and antihypertensive treat-
ment does not completely reverse the risk even when BP is
well controlled. If treatment has been long-standing, then
the ‘treated BP value’ should be used, with the caveat that
the calculated cardiovascular risk will be lower than the
patient’s actual risk. A fourth conundrum is how to impute
out-of-office BP values into risk calculators that have been
calibrated according to office BP readings. These various
limitations should be kept in mind when estimating cardio-
vascular risk in clinical practice.
Hypertension and cardiovascular risk assessment
ssalCnoitadnemmoceR a Levelb
CV risk assessment with the SCORE system
is recommended for hypertensive patients
who are not already at high or very high risk
due to established CVD, renal disease, or
diabetes, a markedly elevated single risk fac-
tor (e.g. cholesterol), or hypertensive
LVH [33,35].
I B
CVD, cardiovascular disease; LVH, left ventricular hypertrophy; SCORE, Systematic
COronary Risk Evaluation.
aClass of recommendation.
bLevel of evidence.
TABLE 7. Correction factors for the Systemic COronary Risk
Evaluation (SCORE) cardiovascular risk estimates in
first-generation immigrants to Europe [35]
Region of origin Multiplication factor
Southern Asia 1.4
Sub-Saharan Africa 1.3
Caribbean 1.3
Western Asia 1.2
Northern Africa 0.9
Eastern Asia 0.7
Southern America 0.7
TABLE 6. Risk modifiers increasing cardiovascular risk estimated by
the Systemic COronary Risk Evaluation (SCORE) system
[35]
Social deprivation, the origin of many causes of CVD
Obesity (measured by BMI) and central obesity (measured by waist
circumference)
Physical inactivity
Psychosocial stress, including vital exhaustion
Family history of premature CVD (occurring at age <55 years in men and
<60 years in women)
Autoimmune and other inflammatory disorders
Major psychiatric disorders
Treatment for infection with human immunodeficiency virus
Atrial fibrillation
Left ventricular hypertrophy
CKD
Obstructive sleep apnoea syndrome
BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease.
2018 ESC/ESH Guidelines for the management of arterial hypertension
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4 BLOOD PRESSUREMEASUREMENT
4.1 Conventional office blood pressure
measurement
Auscultatory or oscillometric semiautomatic or automatic
sphygmomanometers are the preferred method for mea-
suring BP in the doctor’s office. These devices should be
validated according to standardized conditions and proto-
cols [44]. BP should initially be measured in both upper
arms, using an appropriate cuff size for the arm circumfer-
ence. A consistent and significant SBP difference between
arms (i.e. >15mmHg) is associated with an increased
cardiovascular risk [45], most likely due to atheromatous
vascular disease. Where there is a difference in BP between
arms, ideally established by simultaneous measurement,
the arm with the higher BP values should be used for all
subsequent measurements.
In older people, people with diabetes, or people with
other causes of orthostatic hypotension, BP should also be
measured 1 and 3min after standing. Orthostatic hypoten-
sion is defined as a reduction in SBP of at least 20mmHg or
in DBP of at least 10mmHg within 3min of standing, and is
associated with an increased risk of mortality and cardio-
vascular events [46]. Heart rate should also be recorded at
the time of BP measurements because resting heart rate is
an independent predictor of cardiovascular morbid or fatal
events [47], although heart rate is not included in any
cardiovascular risk algorithm. Table 8 summarizes the rec-
ommended procedure for routine office BP measurement.
It is emphasized that office BP is often performed improp-
erly, with inadequate attention to the standardized condi-
tions recommended for a valid measurement of office BP.
Improper measurement of office BP can lead to inaccurate
classification, overestimation of a patient’s true BP, and
unnecessary treatment.
4.2 Unattended office blood pressure
measurement
Automated multiple BP readings in the doctor’s office
improve the reproducibility of BP measurement, and if
the patient is seated alone and unobserved, the ‘white-coat
Hypertension
disease
staging
Other risk factors,
HMOD, or disease
BP (mmHg) grading
High normal
SBP 130–139
DBP 85–89
Grade 1
SBP 140–159
DBP 90–99
Grade 2
SBP 160–179
DBP 100–109
Grade 3
SBP 180
or DBP 110
Stage 1
(uncomplicated)
No other risk
factors
Low risk Low risk Moderate risk High risk
1 or 2 risk factors Low risk Moderate risk
Moderate to
high risk
High risk
3 risk factors
Low to
Moderate risk
Moderate to
high risk
High Risk High risk
Stage 2
(asymptomatic
disease)
HMOD, CKD grade
3, or diabetes
mellitus without
organ damage
Moderate to
high risk
High risk High risk
High to
very high risk
Stage 3
(established
disease)
Established CVD,
CKD grade 4, or
diabetes mellitus
with organ damage
Very high risk Very high risk Very high risk Very high risk
FIGURE 1 Classification of hypertension stages according to blood pressure levels, presence of cardiovascular risk factors, hypertension-mediated organ damage, or
comorbidities. Cardiovascular risk is illustrated for a middle-aged male. The cardiovascular risk does not necessarily correspond to the actual risk at different ages. The use
of the SCORE system is recommended for formal estimation of cardiovascular risk for treatment decisions. BP, blood pressure; CKD, chronic kidney disease; DBP, diastolic
blood pressure; HMOD, hypertension-mediated organ damage; SBP, systolic blood pressure; SCORE, Systematic COronary Risk Evaluation.
TABLE 8. Office blood pressure measurement
Patients should be seated comfortably in a quiet environment for 5min
before beginning BP measurements.
Three BP measurements should be recorded, 1–2min apart, and additional
measurements only if the first two readings differ by >10mmHg. BP is
recorded as the average of the last two BP readings.
Additional measurements may have to be performed in patients with
unstable BP values due to arrhythmias, such as in patents with AF, in who-
m manual auscultatory methods should be used as most automated devic-
es have not been validated for BP measurement in patients with AF.a
Use a standard bladder cuff (12–13 cm wide and 35 cm long) for most
patients, but have larger and smaller cuffs available for larger (arm circu-
mference >32 cm) and thinner arms, respectively.
The cuff should be positioned at the level of the heart, with the back and
arm supported to avoid muscle contraction and isometric exercise-depe-
ndant increases in BP.
When using auscultatory methods, use phase I and V (sudden reduction/
disappearance) Korotkoff sounds to identify SBP and DBP, respectively.
Measure BP in both arms at the first visit to detect possible between-arm
differences. Use the arm with the higher value as the reference.
Measure BP 1min and 3min after standing from a seated position in all
patients at the first measurement to exclude orthostatic hypotension. Ly-
ing and standing BP measurements should also be considered in subseq-
uent visits in older people, people with diabetes, and people with other
conditions in which orthostatic hypotension may frequently occur.
Record heart rate and use pulse palpation to exclude arrhythmia.
AF, atrial fibrillation; BP, blood pressure.
aMost automatic devices are not validated for BP measurement in patients with AF and
will record the highest individual systolic pressure wave form rather than an average of
several cardiac cycles. This will lead to overestimation of BP.
Williams et al.
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effect’ (see Section 4.7.1) can be substantially reduced [48]
or eliminated [49]. Moreover, the BP values are lower than
those obtained by conventional office BPmeasurement and
are similar to, or even less than, those provided by daytime
ambulatory blood pressure monitoring (ABPM) or home
blood pressure monitoring (HBPM) [50]. Use of unattended
office BP measurement in a recent clinical trial [the Systolic
Blood Pressure Intervention Trial (SPRINT)] [51] generated
controversy about its quantitative relationship to conven-
tional office BP measurement (which has been the basis for
all previous epidemiological and clinical trial data); its
feasibility in routine clinical practice has also been ques-
tioned. Presently, the relationship between BP readings
obtained with conventional office BP measurement and
unattended office BP measurement remains unclear, but
available evidence suggests that conventional office SBP
readings may be at least 5–15mmHg higher than SBP levels
obtained by unattended office BPmeasurements [52]. There
is also very limited evidence on the prognostic value of
unattended office BP measurements, that is whether they
guarantee at least the same ability to predict outcomes as
conventional office BP measurements [53].
4.3 Out-of-office blood pressure measurement
Out-of-office BP measurement refers to the use of either
HBPM or ABPM, the latter usually over 24 h. It provides a
larger number of BP measurements than conventional
office BP in conditions that are more representative of daily
life. Recent position papers and practice guidelines provide
comprehensive details for ABPM [54] and HBPM [55], and
are briefly summarized below [54,56].
4.4 Home blood pressure monitoring
Home BP is the average of all BP readings performed with a
semiautomatic, validated BP monitor, for at least 3 days and
preferably for6–7consecutivedaysbeforeeachclinicvisit,with
readings in themorning and the evening, taken in a quiet room
after 5min of rest, with the patient seated with their back and
arm supported. Two measurements should be taken at each
measurement session, performed 1–2min apart [57].
Comparedwith office BP,HBPMvalues are usually lower,
and the diagnostic threshold for hypertension is at least 135/
85mmHg (equivalent to office BP at least 140/90mmHg)
(Table 9)when considering the average of 3–6 days of home
BP values. Compared with office BP, HBPM provides more
reproducible BP data and is more closely related to HMOD,
particularly LVH [58]. Recent meta-analyses of the few avail-
able prospective studies have further indicated that HBPM
better predicts cardiovascular morbidity and mortality than
office BP [59]. There is also evidence that patient self-moni-
toring may have a beneficial effect onmedication adherence
and BP control [60,61], especially when combined with
education and counselling [62]. Telemonitoring and smart-
phone applications may offer additional advantages [63,64],
such as anaid tomemory tomakeBPmeasurements, and as a
convenient way to store and review BP data in a digital diary
and transmit them.We do not recommend the use of apps as
a cuff-independent means of measuring BP.
4.5 Ambulatory blood pressure monitoring
ABPM provides the average of BP readings over a defined
period, usually 24 h. The device is typically programmed to
record BP at 15–30min intervals, and average BP values are
usually provided for daytime, nighttime, and 24 h. A diary of
the patient’s activities and sleep time can also be recorded.
A minimum of 70% usable BP recordings are required for a
valid ABPM measurement session. ABPM values are, on
average, lower than office BP values, and the diagnostic
threshold for hypertension is at least 130/80mmHg over
24 h, at least 135/85mmHg for the daytime average, and at
least 120/70 for the nighttime average (all equivalent to
office BP 140/90mmHg), see Table 9.
ABPM is a better predictor of HMOD than office BP [65].
Furthermore, 24 h ambulatory BP mean has been consis-
tently shown to have a closer relationship with morbid or
fatal events [66–68], and is a more sensitive risk predictor
than office BP of cardiovascular outcomes such as coronary
morbid or fatal events and stroke [68–72].
BP normally decreases during sleep. Although the
degree of nighttime BP dipping has a normal distribution
in a population setting, an arbitrary cut-off has been pro-
posed to define patients as ‘dippers’ if their nocturnal BP
falls by more than 10% of the daytime average BP value;
however, the ‘dipping’ status is often highly variable from
day to day and thus is poorly reproducible [73]. Recognized
reasons for an absence of nocturnal BP dipping are sleep
disturbance, obstructive sleep apnoea, obesity, high salt
intake in salt-sensitive subjects, orthostatic hypotension,
autonomic dysfunction, CKD, diabetic neuropathy, and
old age [54]. Studies that accounted for daytime and night-
time BP in the same statistical model found that nighttime
BP is a stronger predictor of outcomes than daytime BP [54].
The night-to-day ratio is also a significant predictor of
outcome, and patients with a reduced nighttime dip in
BP (i.e. <10% of the daytime average BP or a night-to-
day ratio >0.9) have an increased cardiovascular risk [54].
Moreover, in those in whom there is no nighttime dip in BP
or a higher nighttime than daytime average BP, there is a
substantially increase in risk [74]. Paradoxically, there is also
some evidence of increased risk in patients who have
extreme dipping of their nighttime BP [75], although the
limited prevalence and reproducibility of this phenomenon
makes interpretation of data difficult.
A number of additional indices derived from ABPM record-
ings have some prognostic value, including 24h BP variability
[76], morning BP surge [77] and the ambulatory arterial stiffness
index [78]. However, their incremental predictive value is not
yet clear. Thus, these indices should be regarded as research
tools, with no current indication for routine clinical use.
TABLE 9. Definitions of hypertension according to office,
ambulatory, and home blood pressure levels
Category SBP (mmHg) DBP (mmHg)
Office BPa 140 and/or 90
Ambulatory BP
Daytime (or awake) mean 135 and/or 85
Night-time (or asleep) mean 120 and/or 70
24h mean 130 and/or 80
Home BP mean 135 and/or 85
BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.
aRefers to conventional office BP rather than unattended office BP.
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4.6 Advantages and disadvantages of
ambulatory blood pressure monitoring and
home blood pressure monitoring
A major advantage of both ABPM and HBPM is that they
enable the diagnosis ofwhite-coat andmasked hypertension
(see Section 4.7). The relative advantages and disadvantages
of HBPM and ABPM are shown in Table 10. A particularly
important advantage of HBPM is that it is much cheaper and
thus more available than ABPM. Another is that it provides
multiple measurements over several days or even longer
periods, which is clinically relevant because day-to-day BP
variability may have an independent prognostic value [79].
Unlike ABPM, typical HBPM devices do not provide BP
measurements during routine daily activities and during
sleep, although recent technical advances may allow BP
during sleep to be measured by HBPM. A further consider-
ation is the potential impact of impaired cognition on the
reliability of HBPM measurements and rare instances of
obsessional behaviour, circumstances that may favour the
use of ABPM if out-of-office BP readings are required. In
general, both methods should be regarded as complemen-
tary rather than absolute alternatives.
Despite the advances in out-of-office BP measurement
over the past 50 years, some fundamental questions remain,
the most important of which is whether HBPM-guided or
ABPM-guided therapy results in greater reductions in mor-
bidity and mortality than conventional office BP-guided
treatment, which has been the diagnostic strategy for all
clinical outcome trials.
4.7 White-coat hypertension and masked
hypertension
White-coat hypertension refers to the untreated condition
in which BP is elevated in the office, but is normal when
measured by ABPM, HBPM, or both [80]. Conversely,
‘masked hypertension’ refers to untreated patients in whom
the BP is normal in the office, but is elevated when mea-
sured by HBPM or ABPM [81]. The term ‘true normotension’
is used when both office and out-of-office BP measure-
ments are normal, and ‘sustained hypertension’ is used
when both are abnormal. In white-coat hypertension, the
difference between the higher office and the lower out-of-
office BP is referred to as the ‘white-coat effect’, and is
believed to mainly reflect the pressor response to an alert-
ing reaction elicited by office BP measurements by a doctor
or a nurse [82], although other factors are probably also
involved [83].
Although the terms white-coat and masked hyperten-
sion were originally defined for people who were not
being treated for hypertension, they are now also used
to describe discrepancies between office and out-of-office
BP in patients treated for hypertension, with the terms
masked uncontrolled hypertension (MUCH) (office BP
controlled but home or ambulatory BP elevated) and
white-coat uncontrolled hypertension (WUCH) (office
BP elevated but home or ambulatory BP controlled), com-
pared with sustained uncontrolled hypertension (SUCH)
[84] (both office and home or ambulatory BP are uncon-
trolled).
The white-coat effect is used to describe the difference
between an elevated office BP (treated or untreated) and a
lower home or ambulatory BP in both untreated and
treated patients.
4.7.1 White-coat hypertension
Although the prevalence varies between studies, white-coat
hypertension can account for up to 30–40% of people (and
>50% in the very old) with an elevated office BP. It is more
common with increasing age, in women, and in non-
smokers. Its prevalence is lower in patients with HMOD,
when office BP is based on repeated measurements, or
when a doctor is not involved in the BP measurement. A
significant white-coat effect can be seen at all grades of
hypertension (including resistant hypertension), but the
prevalence of white-coat hypertension is greatest in
grade 1 hypertension.
HMOD is less prevalent in white-coat hypertension
than in sustained hypertension, and recent studies show
that the risk of cardiovascular events associated with
white-coat hypertension is also lower than that in sus-
tained hypertension [68,85,86]. Conversely, compared
with true normotensives, patients with white-coat hyper-
tension have increased adrenergic activity [87], a greater
prevalence of metabolic risk factors, more frequent
asymptomatic cardiac and vascular damage, and a greater
long-term risk of new-onset diabetes and progression to
sustained hypertension and LVH [82]. In addition,
TABLE 10. Comparison of ambulatory blood pressure monitoring and home blood pressure monitoring
ABPM HBPM
Advantages Advantages
Can identify white-coat and masked hypertension Can identify white-coat and masked hypertension
 Stronger prognostic evidence Cheap and widely available
Night-time readings Measurement in a home setting, which may be more relaxed than the doctor’s office
Measurement in real-life settings  Patient engagement in BP measurement
Additional prognostic BP phenotypes  Easily repeated and used over longer periods to assess day-to-day BP variability
Abundant information from a single measurement session,
including short-term BP variability
Disadvantages Disadvantages
 Expensive and sometimes limited availability Only static BP is available
Can be uncomfortable  Potential for measurement error
No nocturnal readingsa
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; HBPM, home blood pressure monitoring.
aTechniques are being developed to enable nocturnal BP measurement with home BP devices.
Williams et al.
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although the out-of-office BP values are, by definition,
normal in white-coat hypertension, they tend to be
higher than those of true normotensive people, which
may explain the increased long-term risk of cardiovascu-
lar events reported in white-coat hypertension by recent
studies after adjustment for demographic and metabolic
risk factors [85,86,88–90]. White-coat hypertension has
also been shown to have a greater cardiovascular risk in
isolated systolic hypertension and older patients [91], and
does not appear to be clinically innocent [68]. The diag-
nosis should be confirmed by repeated office and out-of-
office BP measurements, and should include an extensive
assessment of risk factors and HMOD. Both ABPM and
HBPM are recommended to confirm white-coat hyper-
tension, because the cardiovascular risk appears to be
lower (and close to sustained normotension) in those in
whom both ABPM and HBPM are both normal [82]; for
treatment considerations see Section 8.4.
4.7.2 Masked hypertension
Masked hypertension can be found in approximately 15%
of patients with a normal office BP [17]. The prevalence is
greater in younger people, men, smokers, and those with
higher levels of physical activity, alcohol consumption,
anxiety and job stress [54]. Obesity, diabetes, CKD, family
history of hypertension, and high–normal office BP are
also associated with an increased prevalence of masked
hypertension [17]. Masked hypertension is associated
with dyslipidaemia and dysglycaemia, HMOD [92], adren-
ergic activation, and increased risk of developing diabe-
tes and sustained hypertension [81,93]. Meta-analyses and
recent studies [68] have shown that the risk of cardiovas-
cular events is substantially greater in masked hyperten-
sion compared with normotension, and close to or
greater than that of sustained hypertension [68,93–96].
Masked hypertension has also been found to increase the
risk of cardiovascular and renal events in diabetes, espe-
cially when the BP elevation occurs during the night
[95,97].
4.8 Screening for the detection of hypertension
Hypertension is predominantly an asymptomatic condition
that is best detected by structured population screening
programmes or opportunistic measurement of BP. When
structured population screening programmes have been
undertaken, an alarming number of people (>50%) were
unaware they had hypertension [12,98]. This high rate of
undetected hypertension occurred irrespective of the
income status of the countries studied across the world.
All adults should have their BP recorded in their medical
record and be aware of their BP, and further screening
should be undertaken at regular intervals with the fre-
quency dependent on the BP level. For healthy people
with an optimal office BP (<120/80mmHg), BP should be
remeasured at least every 5 years and more frequently
when opportunities arise. In patients with a normal BP
(120–129/80–84), BP should be remeasured at least every 3
years. Patients with high–normal BP (130–139/85–
89mmHg) should have their BP recorded annually because
of the high rates of progression of high–normal BP to
hypertension. This is true also for people in whom masked
hypertension is detected.
4.9 Confirming the diagnosis of hypertension
BP can be highly variable, thus the diagnosis of hyperten-
sion should not be based on a single set of BP readings at a
single office visit, unless the BP is substantially increased
(e.g. grade 3 hypertension) and there is clear evidence of
HMOD (e.g. hypertensive retinopathy with exudates and
haemorrhages, or LVH, or vascular or renal damage). For
all others (i.e. almost all patients), repeat BPmeasurements
at repeat office visits have been a long-standing strategy to
confirm a persistent elevation in BP, as well as for the
classification of the hypertension status in clinical practice
and RCTs. The number of visits and the time interval
between visits varies according to the severity of the
hypertension, and is inversely related to the severity of
hypertension. Thus, more substantial BP elevation (e.g.
grade 2 or more) requires fewer visits and shorter time
intervals between visits (i.e. a few days or weeks), depend-
ing on the severity of BP elevation and whether there is
evidence of CVD or HMOD. Conversely, in patients with
BP elevation in the grade 1 range, the period of repeat
measurements may extend over a few months, especially
when the patient is at low risk and there is no HMOD.
During this period of BP assessment, cardiovascular risk
assessment and routine screening tests are usually per-
formed (see Section 3).
These Guidelines also support the use of out-of-office
BP measurements (i.e. HBPM and/or ABPM) as an alter-
native strategy to repeated office BP measurements to
confirm the diagnosis of hypertension, when these meas-
urements are logistically and economically feasible
(Fig. 2) [99]. This approach can provide important sup-
plementary clinical information, for example detecting
white-coat hypertension (see Section 4.7.1), which should
be suspected, especially in people with grade 1 hyperten-
sion on office BP measurement and in whom there is no
evidence of HMOD or CVD [100] (Table 11). A particular
challenge is the detection of masked hypertension (see
Section 4.7.2). Masked hypertension is more likely in
people with a BP in the high–normal range in whom
out-of-office BP should be considered to exclude masked
hypertension (see Table 8). Out-of-office BP measure-
ments are also indicated in specific circumstances (see
Section 4.10 and Table 11).
4.10 Clinical indications for out-of-office blood
pressure measurements
Out-of-office BPmeasurements are increasingly used, espe-
cially HBPM but also ABPM, to confirm the diagnosis of
hypertension. Out-of-office BP measurement provides
important complementary information, as discussed above.
The clinical indications for out-of-office BP measurements
are shown in Table 11. HBPM is also increasingly used by
patients to monitor their BP control, which increases their
engagement and may improve their adherence to treatment
and BP control [61,101,102]. It is likely that, with increased
availability and lower cost of these devices, this will become
more commonplace.
2018 ESC/ESH Guidelines for the management of arterial hypertension
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4.11 Blood pressure during exercise and at
high altitude
It is important to recognize that BP increases during
dynamic and static exercise, and that the increase is more
pronounced for SBP than for DBP [103], although only
SBP can be measured reliably with noninvasive methods.
There is currently no consensus on normal BP response
during exercise. The increase in SBP during exercise is
related to preexercise resting BP, age, arterial stiffness
and abdominal obesity, and is somewhat greater in
women than in men and in unfit individuals. There is
some evidence that an excessive rise in BP during exer-
cise predicts the development of hypertension, indepen-
dently from BP at rest [104]. Nevertheless, exercise testing
is not recommended as part of the routine evaluation of
hypertension because of various limitations, including a
lack of standardization of methodology and definitions.
Importantly, except in the presence of very high BP
values (grade 3 hypertension), patients or athletes, with
treated or untreated hypertension should not be discour-
aged from regular exercise, especially aerobic exercise,
which is considered beneficial as part of lifestyle changes
to reduce BP (see Section 7.4.1).
Evidence is available that BP increases with high altitude
exposure, especially above 3000 m and possibly above
2000 m [105]. This is due to a number of factors including
sympathetic activation. Patients with grade 2 hypertension
and increased cardiovascular risk should check their BP
values before and during high altitude (>2500m) exposure.
Patients with grade 1 hypertension may reach very high
altitude (>4000m) with adequate medical therapy; uncon-
trolled severe hypertensive patients (grade 3) should avoid
exposure to very high altitude [105].
4.12 Central aortic pressure
Various techniques allow aortic BP (central BP) to be
derived from peripheral BP measurements using dedicated
algorithms [106,107]. Some studies and meta-analyses have
shown that in hypertensive patients, central BP predicts
cardiovascular events and that there is a differential effect of
antihypertensive drugs on central compared with brachial
BP [108]. The incremental prognostic value of central vs.
conventional clinic BP measurement remains unclear [109].
An exception may be isolated systolic hypertension in the
young, in whom peripheral BP may be disproportionately
elevated relative to a normal central BP. This occurs in a
small fraction of younger people, mainly men with isolated
systolic hypertension, and it remains unclear whether such
patients are at lower risk than suggested by their brachial
office BP [110,111].
TABLE 11. Clinical indications for home blood pressure monitoring
or ambulatory blood pressure monitoring
Conditions in which white-coat hypertension is more common, for example:
Grade I hypertension on office BP measurement
Marked office BP elevation without HMOD
Conditions in which masked hypertension is more common, for example:
High–normal office BP
Normal office BP in individuals with HMOD or at high total
cardiovascular risk
Postural and postprandial hypotension in untreated and treated patients
Evaluation of resistant hypertension
Evaluation of BP control, especially in treated higher-risk patients
Exaggerated BP response to exercise
When there is considerable variability in the office BP
Evaluating symptoms consistent with hypotension during treatment
Specific indications for ABPM rather than HBPM:
Assessment of nocturnal BP values and dipping status (e.g. suspicion of
nocturnal hypertension, such as in sleep apnoea, CKD, diabetes,
endocrine hypertension, or autonomic dysfunction)
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CKD, chronic kidney
disease; HBPM, home blood pressure monitoring; HMOD, hypertension-mediated organ
damage.
FIGURE 2 Screening and diagnosis of hypertension. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; HBPM, home blood pressure monitoring.
Williams et al.
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BP measurement
Recommendations a LevelClass b
Screening programmes for hypertension are
recommended. All adults (18 years or
older) should have their office BP measured
and recorded in their medical file, and be
aware of their BP [12,98].
I B
• Further BP recording is indicated, at least
every 5 years if BP remains optimal.
I C
• Further BP recording is indicated, at least
every 3 years if BP remains normal.
I C
• If BP remains high–normal, further BP
recording, at least annually, is
recommended.
I C
• In older patients (> 50 years), more fre-
quent screening of office BP should be
considered for each BP category because
of the steeper rise in SBP with ageing.
IIa C
It is recommended that office BP should be
measured in both arms at least at the first
visit because a between-arm SBP difference
of > 15 mmHg is suggestive of atheromatous
disease and is associated with an increased
CV risk [45].
I A
If a between-arm difference in BP is
recorded, then it is recommended that all
subsequent BP readings use the arm with
the higher BP reading.
I C
It is recommended that the diagnosis of
hypertension should be based on:
• Repeated office BP measurements on
more than one visit, except when hyper-
tension is severe (e.g. grade 3 and espe-
cially in high-risk patients). At each visit,
three BP measurements should be
recorded, 1–2 min apart, and additional
measurements should be performed if
the first two readings differ by > 10
mmHg. The patient’s BP is the average of
the last two BP readings.
Or
• Out-of-office BP measurement with
ABPM and/or HBPM, provided that
these measurements are logistically and
economically feasible.
C
C
Out-of-office BP (i.e. ABPM or HBPM) is
specifically recommended for a number of
clinical indications, such as identifying white-
coat and masked hypertension, quantifying
the effects of treatment, and identifying pos-
sible causes of side effects [17,54,62,68,72]
(e.g. symptomatic hypotension).
I A
I
I
It is recommended that all hypertensive
patients undergo pulse palpation at rest to
determine heart rate and search for
arrhythmias such as AF [20,47].
I C
Other BP measures and indices (pulse pres-
sure, BP variability, exercise BP, and central
BP) may be considered but are not often
used for routine clinical use at present.
They may provide useful additional informa-
tion in some circumstances and are valuable
tools for research.
IIb C
ABPM, ambulatory blood pressure monitoring; AF, atrial fibrillation; BP, blood pressure;
HBPM, home blood pressure monitoring.
aClass of recommendation.
bLevel of evidence.
5 CLINICAL EVALUATIONAND
ASSESSMENTOF HYPERTENSION-
MEDIATED ORGAN DAMAGE IN
PATIENTSWITH HYPERTENSION
5.1 Clinical evaluation
The purpose of the clinical evaluation is to establish the
diagnosis and grade of hypertension, screen for potential
secondary causes of hypertension, identify factors poten-
tially contributing to the development of hypertension
(lifestyle, concomitant medications or family history);
identify concomitant cardiovascular risk factors (includ-
ing lifestyle and family history); identify concomitant
diseases and establish whether there is evidence of
HMOD or existing cardiovascular, cerebrovascular or
renal disease.
5.2 Medical history
A thorough medical history (Table 12) should address in
particular:
1. Time of the first diagnosis of hypertension, includ-
ing records of any previous medical screening,
hospitalization, etc.
2. Record any current and past BP values
3. Record current and past antihypertensive medications
4. Record other medications
5. Family history of hypertension, CVD, stroke, or
renal disease
6. Lifestyle evaluation, including exercise levels, body
weight changes, diet history, smoking history, alco-
hol use, recreational drug use, sleep history and
impact of any treatments on sexual function
7. History of any concomitant cardiovascular risk
factors
8. Details and symptoms of past and present comor-
bidities
9. Specific history of potential secondary causes of
hypertension (see Section 8.2)
10. History of past pregnancies and oral contraceptive
use
2018 ESC/ESH Guidelines for the management of arterial hypertension
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11. History of menopause and hormone replacement
therapy
12. Use of liquorice
13. Use of drugs that may have a pressor effect
5.3 Physical examination and clinical
investigations
Physical examination provides important indications of
potential causes of secondary hypertension, signs of
comorbidities, and HMOD. Office BP and heart rate
should be measured as summarized in Section 4.
Measurements of office BP on more than one occasion
are usually required to confirm the diagnosis of hyper-
tension unless HBPM or ABPM is used to confirm the
diagnosis (see Section 4).
Details of the requirements for a comprehensive clinical
examination are outlined in Table 13, and this should be
adapted according to the severity of hypertension and
clinical circumstances. Suggested routine clinical investiga-
tions are outlined in Table 14.
5.4 Assessment of hypertension-mediated
organ damage
HMOD refers to structural or functional changes in arteries
or end organs (heart, blood vessels, brain, eyes, and kid-
ney) caused by an elevated BP, and is a marker of preclini-
cal or asymptomatic CVD [112]. HMOD is common in severe
or long-standing hypertension, but can also be found in less
severe hypertension. With wider use of imaging, HMOD is
TABLE 12. Key information to be collected in personal and family medical history
Risk factors
 Family and personal history of hypertension, CVD, stroke, or renal disease
 Family and personal history of associated risk factors (e.g. familial hypercholesterolaemia)
 Smoking history
Dietary history and salt intake
Alcohol consumption
 Lack of physical exercise/sedentary lifestyle
History of erectile dysfunction
 Sleep history, snoring, sleep apnoea (information also from partner)
 Previous hypertension in pregnancy/preeclampsia
History and symptoms of HMOD, CVD, stroke, and renal disease
Brain and eyes: headache, vertigo, syncope, impaired vision, TIA, sensory or motor deficit, stroke, carotid revascularization, cognitive impairment, dementia
(in the elderly)
Heart: chest pain, shortness of breath, oedema, myocardial infarction, coronary revascularization, syncope, history of palpitations, arrhythmias (especially AF),
heart failure
Kidney: thirst, polyuria, nocturia, haematuria, urinary tract infections
 Peripheral arteries: cold extremities, intermittent claudication, pain-free walking distance, pain at rest, peripheral revascularization
 Patient or family history of CKD (e.g. polycystic kidney disease)
History of possible secondary hypertension
Young onset of grade 2 or 3 hypertension (<40 years), or sudden development of hypertension or rapidly worsening BP in older patients
History of renal/urinary tract disease
Recreational drug/substance abuse/concurrent therapies: corticosteroids, nasal vasoconstrictor, chemotherapy, yohimbine, liquorice
Repetitive episodes of sweating, headache, anxiety, or palpitations, suggestive of Phaeochromocytoma
History of spontaneous or diuretic-provoked hypokalaemia, episodes of muscle weakness, and tetany (hyperaldosteronism)
 Symptoms suggestive of thyroid disease or hyperparathyroidism
History of or current pregnancy and oral contraceptive use
History of sleep apnoea
Antihypertensive Drug Treatment
Current/past antihypertensive medication including effectiveness and intolerance to previous medications
Adherence to therapy
AF, atrial fibrillation; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; HMOD, hypertension-mediated organ damage; TIA, transient ischaemic attack.
TABLE 13. Key steps in physical examination
Body habitus
Weight and height measured on a calibrated scale, with calculation
of BMI
Waist circumference
Signs of HMOD
Neurological examination and cognitive status
 Fundoscopic examination for hypertensive retinopathy
 Palpation and auscultation of heart and carotid arteries
 Palpation of peripheral arteries
Comparison of BP in both arms (at least once)
Secondary hypertension
 Skin inspection: cafe-au-lait patches of neurofibromatosis
(phaeochromocytoma)
Kidney palpation for signs of renal enlargement in polycystic kidney disease
Auscultation of heart and renal arteries for murmurs or bruits indicative
of aortic coarctation, or renovascular hypertension
Comparison of radial with femoral pulse: to detect radio-femoral delay
in aortic coarctation
 Signs of Cushing’s disease or acromegaly
 Signs of thyroid disease
BMI, body mass index; BP, blood pressure; HMOD, hypertension-mediated organ damage.
TABLE 14. Routine workup for evaluation of hypertensive patients
Routine laboratory tests
Haemoglobin and/or haematocrit
Fasting blood glucose and glycated HbA1c
Blood lipids: total cholesterol, LDL cholesterol, HDL cholesterol
Blood triglycerides
Blood potassium and sodium
Blood uric acid
Blood creatinine and eGFR
Blood liver function tests
Urine analysis: microscopic examination; urinary protein by dipstick test or,
ideally, albumin:creatinine ratio
12-lead ECG
eGFR, estimated glomerular filtration rate; HbA1c, haemoglobin A1c.
Williams et al.
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becoming increasingly apparent in asymptomatic patients
[43]. Cardiovascular risk increases with the presence of
HMOD, and more so when damage affects multiple organs
[16,113,114]. Some types of HMOD can be reversed by
antihypertensive treatment, especially when used early,
but with long-standing hypertension, HMOD may become
irreversible despite improved BP control [115,116]. Never-
theless, BP-lowering treatment is still important as it may
delay the further progression of HMOD and will reduce the
elevated cardiovascular risk of these patients [116].
Although poor technical provision and cost may limit the
search for HMOD in some countries, it is recommended that
basic screening for HMOD is performed in all hypertensive
patients and more detailed assessment is performed when
the presence of HMOD might influence treatment deci-
sions. The various investigations to establish HMOD are
shown in Table 15.
5.4.1 Using hypertension-mediated organ damage
to help stratify risk in hypertensive patients
As discussed in Section 3, hypertensive patients with
documented CVD, diabetes, CKD, grade 3 hypertension,
or marked cholesterol elevation (e.g. familial hypercho-
lesterolaemia) are already at high or very high cardiovas-
cular risk (10% risk of a fatal event). Thus, the presence
of HMOD is unlikely to influence treatment, as these
patients should already receive lifestyle interventions,
BP-lowering medications, statins, and in some
cases antiplatelet therapy, to reduce their risk [35] (see
Section 9).
The main advantage of detecting HMOD is that it may
reclassify a patient’s SCORE risk assessment from low to
moderate or frommoderate to high risk [117]. The specific
impact of HMOD [114] with regard to the reclassification
of risk estimation according to the SCORE system has not
been clearly defined. The SCORE system already takes
account of the grade of hypertension as SBP is included in
the risk calculation. Moreover, CKD and the presence of
vascular disease on imaging are already specified as high
or very high risk (Table 5). Conditioning of the risk score
by the presence of HMOD will be most important in
middle-aged patients with hypertension, many of whom
will be at moderate-risk and at higher risk if HMOD is
detected. Moreover, a risk-conditioning effect of HMOD
will also be important in younger hypertensive patients
who are invariably classified as low risk according to the
SCORE system. In addition, detecting HMOD in younger
patients with grade 1 hypertension provides unequivocal
evidence of hypertension-mediated damage and indi-
cates a clear need for BP-lowering treatment in patients
who may be reluctant to be treated. For the same reason,
the presence of HMOD in a patient with high–normal BP
would also provide a rationale to consider BP-lowering
treatment.
Another important consideration is whether the pres-
ence of a specific manifestation of HMOD (e.g. LVH or
CKD) might influence the selection of drug treatment for
hypertension. This was considered important in the
previous guidelines [17], but is now considered less
important. In patients more likely to have HMOD (i.e.
those with high grade 1 or grade 2–3 hypertension), we
now recommend initial treatment with a combination of
two drugs, usually an angiotensin-converting enzyme
(ACE) inhibitor or angiotensin receptor blocker (ARB) in
combination with a calcium channel blocker (CCB) or
thiazide-type diuretic, which would be the optimal
treatment for all manifestations of HMOD (see
Section 7).
TABLE 15. Assessment of hypertension-mediated organ damage
Basic screening tests for HMOD Indication and interpretation
12-lead ECG Screen for LVH and other possible cardiac abnormalities, and to document heart rate and cardiac rhythm
Urine albumin:creatinine ratio To detect elevations in albumin excretion indicative of possible renal disease
Blood creatinine and eGFR To detect possible renal disease
Fundoscopy To detect hypertensive retinopathy, especially in patients with grade 2 or 3 hypertension
More detailed screening for HMOD
Echocardiography To evaluate cardiac structure and function, when this information will influence treatment decisions
Carotid ultrasound To determine the presence of carotid plaque or stenosis, particularly in patients with cerebrovascular
disease or vascular disease elsewhere
Abdominal ultrasound and Doppler studies To evaluate renal size and structure (e.g. scarring) and exclude renal tract obstruction as possible
underlying causes of CKD and hypertension
Evaluate abdominal aorta for evidence of aneurysmal dilatation and vascular disease
Examine adrenal glands for evidence of adenoma or phaeochromocytoma (CT or MRI preferred for
detailed examination); see section 8.2 regarding screening for secondary hypertension
Renal artery Doppler studies to screen for the presence of renovascular disease, especially in the
presence of asymmetric renal size
PWV An index of aortic stiffness and underlying arteriosclerosis
ABI Screen for evidence of LEAD
Cognitive function testing To evaluate cognition in patients with symptoms suggestive of cognitive impairment
Brain imaging To evaluate the presence of ischaemic or haemorrhagic brain injury, especially in patients with a history
of cerebrovascular disease or cognitive decline
ABI, ankle-brachial index; CKD, chronic kidney disease; CT, computed tomography; eGFR, estimated glomerular filtration rate; HMOD, hypertension-mediated organ damage; LEAD,
lower extremity artery disease; LVH, left ventricular hypertrophy; MRI, magnetic resonance imaging; PWV, pulse wave velocity.
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5.5 Characteristics of hypertension-mediated
organ damage
5.5.1 The heart in hypertension
Chronically increased left ventricular workload in
hypertensive patients can result in LVH, impaired left
ventricular relaxation, left atrial enlargement, an
increased risk of arrhythmias, especially AF, and an
increased risk of heart failure with preserved ejection
fraction (HFpEF) and heart failure with reduced ejection
fraction (HFrEF).
5.5.1.1 Electrocardiogram
A 12-lead ECG should be part of the routine assessment
in all hypertensive patients. The ECG is not a particularly
sensitive method of detecting LVH and its sensitivity
varies according to body weight. ECG LVH provides
independent prognostic information, even after adjusting
for other cardiovascular risk factors and echocardio-
graphic left ventricular mass [118]. In addition to LVH,
the presence of a ‘strain pattern’ on an ECG is associated
with increased risk [119]. The prevalence of ECG LVH
increases with the severity of hypertension [120]. The
most commonly used criteria to define ECG LVH are
shown in Table 16.
The ECG cannot exclude LVH because it has poor
sensitivity. When detailed information on cardiac struc-
ture and function will influence treatment decisions,
echocardiography is recommended. When LVH is present
on the ECG, it can be used to detect changes in LVH
during follow-up in untreated and treated patients
[121,122].
5.5.1.2 Transthoracic echocardiography in
hypertension
Echocardiographic LVH is a potent predictor of mortality in
both hypertensive patients and the general population
[123,124], and regression of echocardiographic LVH due
to treatment of hypertension predicts an improved progno-
sis [125]. Two-dimensional transthoracic echocardiography
(TTE) also provides information about left ventricular
geometry, left atrial volume, aortic root dimensions, left
ventricular systolic and diastolic function, pump perfor-
mance, and output impedance [123,126,127]. Whether addi-
tional parameters other than evidence of increased left
ventricular mass and left atrial dilatation are useful to help
stratify cardiovascular risk is uncertain [123,126,128]. The
partition values recommended for the definition of LVH by
echocardiography are shown in Table 17.
Three-dimensional TTE is a more reliable method for
quantitative analysis [129], specifically for left ventricular
mass [130], volumes, and ejection fraction, and has superior
reproducibility to two-dimensional TTE but much less
prognostic validation [131]. More detailed information on
the use of echocardiography to assess the hypertensive
heart is available [43]. Cardiac magnetic resonance is the
gold standard for cardiac anatomical and functional quan-
tification [132–134].
Abnormal left ventricular geometry in hypertensive
patients is frequently associated with diastolic dysfunction
[127,135], which can be further evaluated by a combination
of transmitral flow and tissue Doppler studies [136]. Left
atrial size is also frequently increased in hypertensive
patients and is associated with adverse cardiovascular
events [128,137] and incident AF [138], and is related to
diastolic dysfunction [139,140]. During the diagnostic
workup for secondary hypertension, a suprasternal view
should also be performed for the identification of aortic
coarctation [141].
5.5.2 The blood vessels in hypertension
5.5.2.1 Carotid artery
Carotid intima–media thickness (IMT) quantified by carotid
ultrasound, and/or the presence of plaques, predicts car-
diovascular risk [42,142]. This holds true both for the IMT
value at the carotid bifurcations (reflecting primarily ath-
erosclerosis) and for the IMT value at the level of the
common carotid artery (reflecting primarily hypertension-
TABLE 16. The most commonly used simple criteria and recognized
cut-off points for definitions of electrocardiogram left
ventricular hypertrophy
ECG voltage criteria Criteria for LVH
SV1þRV5 (Sokolow–Lyon criterion) >35mm
R wave in aVL 11mm
SV3þRaVL (Cornell voltage)a >28mm (men)
>20mm (women)
Cornell duration productb >2440mmms
LVH, left ventricular hypertrophy.
aSum of limb and precordial lead voltage.
bProduct of Cornell voltageQRS duration (mmms).
TABLE 17. Echocardiographic definitions of left ventricular hypertrophy, concentric geometry, left ventricular chamber size, and left atrial
dilatation
Parameter Measure Abnormality threshold
LVH Left ventricular mass/height2.7 (g/m2.7) >50 (men)
>47 (women)
LVHa Left ventricular mass/BSA (g/m2) >115 (men)
>95 (women)
Left ventricular concentric geometry RWT 0.43
Left ventricular chamber size Left ventricular end-diastolic diameter/height (cm/m) >3.4 (men)
>3.3 (women)
Left atrial size (elliptical) Left atrial volume/height2 (ml/m2) >18.5 (men)
>16.5 (women)
BSA, body surface area; LVH, left ventricular hypertrophy; RWT, relative wall thickness.
aBSA normalization may be used in normal weight patients.
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related hypertrophy). A carotid IMT more than 0.9mm is
considered abnormal [143], but the upper limit of normality
varies with age. The presence of a plaque can be identified
by an IMT at least 1.5mm, or by a focal increase in thickness
of 0.5mm or 50% of the surrounding carotid IMT value
[144]. Stenotic carotid plaques have a strong predictive
value for both stroke and myocardial infarction, indepen-
dent of traditional cardiovascular risk factors [42,142], and
confer superior prognostic accuracy for future myocardial
infarction comparedwith IMT [145]. The presence of carotid
plaques will automatically reclassify patients from interme-
diate to high risk [146,147]; however, routine carotid imag-
ing is not recommended unless clinically indicated (i.e.
presence of carotid bruit, previous transient ischemic attack
(TIA) or cerebrovascular disease, or as part of the assess-
ment of patients with evidence of vascular disease).
5.5.2.2 Pulse wave velocity
Large artery stiffening is themost important pathophysiolog-
ical determinant of isolated systolic hypertension and age-
dependent increase in pulse pressure [148]. Carotid-femoral
pulsewavevelocity (PWV) is thegold standard formeasuring
large artery stiffness [149]. Reference values for PWV are
available in healthy populations and patients at increased
cardiovascular risk [150]. A PWVmore than 10m/s is consid-
ereda conservative estimateof significant alterationsof aortic
function in middle-aged hypertensive patients [149]. The
additive value of PWV above and beyond traditional risk
factors, including SCOREand the Framingham risk score, has
been suggested by several studies [151]. However, routine
use of PWV measurement is not practical and is not recom-
mended for routine practice.
5.5.2.3 Ankle–brachial index
Ankle-brachial index (ABI) may be measured either with
automated devices, or with a continuous wave Doppler
unit and a BP sphygmomanometer. A low ABI (i.e. <0.9)
indicates lower extremity artery disease (LEAD), is usually
indicative of advanced atherosclerosis [152], and has pre-
dictive value for cardiovascular events [153], being associ-
ated with an almost two-fold greater 10-year cardiovascular
mortality and major coronary event rate, compared with the
overall rate in each Framingham category [153]. Even
asymptomatic LEAD, detected by a low ABI, is associated
in men with a high incidence of cardiovascular morbid and
fatal events, approaching 20% in 10 years [153,154]. Routine
use of ABI is not recommended in hypertensive patients,
but should be considered in patients with symptoms or
signs of LEAD, or in moderate-risk patients in whom a
positive test would reclassify the patient as high-risk.
5.5.3 The kidney in hypertension
Hypertension is the second most important cause of CKD
after diabetes. Hypertension may also be the presenting
feature of asymptomatic primary renal disease. An alter-
ation of renal function is most commonly detected by an
increase in serum creatinine. This is an insensitive marker of
renal impairment because a major reduction in renal func-
tion is needed before serum creatinine rises. Furthermore,
BP reduction by antihypertensive treatment often leads
to an acute increase in serum creatinine by as much as
20–30%, especially with renin–angiotensin system (RAS)
blockers, which has a functional basis and does not usually
reflect manifest renal injury, but the long-term clinical
significance is unclear [155,156]. The diagnosis of hyper-
tension-induced renal damage is based on the finding of
reduced renal function and/or the detection of albuminuria.
CKD is classified according to estimated glomerular filtra-
tion rate (eGFR), calculated by the 2009 CKD-Epidemiology
Collaboration formula [157].
The albumin:creatinine ratio (ACR) is measured from
a spot urine sample (preferably early morning urine),
and is the preferred method to quantify urinary albumin
excretion. A progressive reduction in eGFR and increased
albuminuria indicate progressive loss of renal function, and
are both independent and additive predictors of increased
cardiovascular risk and progression of renal disease [158].
Serum creatinine, eGFR and ACR should be documented
in all hypertensive patients, and if CKD is diagnosed,
repeated at least annually [159]. One negative urinary
dipstick test does not rule out albuminuria, in contrast to
a normal ACR [160].
5.5.4 Hypertensive retinopathy
The prognostic significance of hypertensive retinopathy by
fundoscopy has been well documented [161]. Detection of
retinal haemorrhages,microaneurysms, hard exudates, cotton
wool spots, and papilloedema is highly reproducible, indi-
cates severe hypertensive retinopathy, and is highly predictive
of mortality [161,162]. In contrast, evidence of arteriolar nar-
rowing, either focal or general, and arteriovenous nicking at
early stages of hypertensive retinopathy have less predictive
value [163], and limited interobserver and intraobserver repro-
ducibility, even with experienced observers [164]. Fundo-
scopy should be performed in patients with grade 2 or 3
hypertensionor hypertensivepatientswith diabetes, inwhom
significant retinopathy is more likely. Fundoscopy may be
considered in other hypertensive patients. The increasing
emergence of new techniques to visualize the fundus through
smartphone technologies should increase the feasibility of
more routine fundoscopy [165].
5.5.5 The brain in hypertension
Hypertension increases the prevalence of brain damage, of
which transient ischaemic attack (TIA) and stroke are themost
dramatic acute clinical manifestations. In the asymptomatic
phase, brain damage can be detected by MRI as white matter
hyperintensities, silentmicroinfarcts, (most of which are small
and deep, i.e. lacunar infarctions), microbleeds and brain
atrophy [166,167]. White matter hyperintensities and silent
infarcts are associated with an increased risk of stroke and
cognitive decline due to degenerative and vascular dementia
[166–169]. Availability and cost do not permit the widespread
use of brain MRI for the evaluation of hypertensive patients,
butwhitematterhyperintensity andsilentbrain infarcts should
be sought in all hypertensive patients with neurological dis-
turbances, cognitive decline, and, particularly, memory loss
[168,169]. A family history of cerebral haemorrhage at middle
age and early-onset dementia should prompt MRI. Cognitive
impairment in older patients is, at least in part, hypertension-
related, andcognitive evaluation tests should be considered in
2018 ESC/ESH Guidelines for the management of arterial hypertension
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the clinical assessment of hypertensive patients with a history
suggestive of early cognitive impairment. The Mini-Mental
State Examination has been the most widely used method in
clinical trials, but is now being superseded by more sophisti-
cated cognitive tests that are more suitable for routine clinic
visits [170].
5.6 Hypertension-mediated organ damage
regression and cardiovascular risk reduction
with antihypertensive treatment
As discussed above, HMOD assessment may play a role in
stratifying the risk of patients with hypertension. In post-
hoc analyses, BP treatment-induced regression of some
(but not all) manifestations of asymptomatic HMOD, as a
consequence of treatment, is associated with a reduction in
cardiovascular risk, thereby providing additional informa-
tion on the effectiveness of treatment in individual patients
[16,104,171]. This has been best illustrated for the treatment-
induced regression of LVH measured by either ECG or
echocardiography [125,172,173]. A reduced incidence of
cardiovascular events and slower progression of renal
disease has been reported with a treatment-induced reduc-
tion in urinary protein excretion in both diabetic and
nondiabetic patients, especially for microalbuminuria
[174], but results are discordant [175–179]. There is also
evidence that treatment-induced changes in eGFR predict
cardiovascular events [180] and progression to end-stage
renal disease [181,182]. Two meta-analyses [183,184] failed
to document any predictive value of treatment-induced
reductions in carotid IMT for cardiovascular events. Evi-
dence on the predictive power of treatment-induced
changes on other measures of HMOD (PWV and ABI)
are either limited or absent. Regression of HMOD might
not be possible even when BP is controlled, particularly
when HMOD is advanced, because some of the changes
become irreversible.
The information available on the sensitivity and timing of
changes in HMOD during antihypertensive treatment is
summarized in Table 18. If, when, and how often the
assessment of HMOD should be performed has not
been validated in follow-up studies.HMODcanalso develop
during the course of antihypertensive treatment [185], and
this may be accompanied by increased risk [186–188].
5.7 When to refer a patient with hypertension
for hospital-based care
Hypertension is a very common condition and most
patients with hypertension, in most healthcare systems,
will be managed in the primary care setting. However,
there are circumstances in which a referral for routine
hospital-based evaluation and treatment may be required,
keeping in mind that in some instances out-of-office or
office-based care of hypertensive patients depends on the
healthcare organization of a given country:
1. Patients in whom secondary hypertension is sus-
pected (see Section 8.2)
2. Younger patients (<40 years) with grade 2 or more
severe hypertension in whom secondary hyperten-
sion should be excluded
3. Patients with treatment-resistant hypertension (see
Section 8.1)
4. Patients in whom more detailed assessment of
HMOD would influence treatment decisions
5. Patients with sudden onset of hypertension when BP
has previously been normal
6. Other clinical circumstances in which the referring
doctor feels more specialist evaluation is required.
There are also rarer circumstances in which a patient
with hypertension should be referred to hospital for emer-
gency care, which will often require inpatient care (see
Section 8.3).
TABLE 18. Sensitivity to detect treatment-induced changes, reproducibility and operator independence, time to changes, and prognostic
value of changes provided by markers of hypertension-mediated organ damage
CMR, cardiac magnetic resonance; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HMOD, hypertension-mediated organ damage; IMT, intima–media thickness;
LVH, left ventricular hypertrophy; PWV, pulse wave velocity.
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Clinical evaluation and HMOD assessment
Recommendations Classa Levelb
Heart
12-lead ECG is recommended for all hypertensive patients [120]. I B
Echocardiography:
• Is recommended in hypertensive patients when there are ECG abnormalities or signs or symptoms of LV
dysfunction [42,134].
I B
• May be considered when the detection of LVH may influence treatment decisions [42,134]. IIb B
Blood vessels
Ultrasound examination of the carotid arteries:
•  Is recommended in patients with stroke or TIA [134]
I B
• May be considered for the detection of asymptomatic atherosclerotic plaques or carotid stenosis in patients with
documented vascular disease elsewhere [42]. IIb B
Measurement of PWV may be considered for measuring arterial stiffness [109,189]. IIb B
Measurement of ABI may be considered for the detection of advanced LEAD [153,190]. IIb B
Kidney
Measurement of serum creatinine and eGFR is recommended in all hypertensive patients [180]. I B
Measurement of urine albumin:creatinine ratio is recommended in all hypertensive patients [43,180]. I B
Renal ultrasound and Doppler examination should be considered in patients with impaired renal function, albuminuria,
or for suspected secondary hypertension. IIa C
Fundoscopy
Is recommended in patients with grades 2 or 3 hypertension and all hypertensive patients with diabetes. I C
May be considered in other hypertensive patients. IIb C
Brain
In hypertensive patients with neurological symptoms and/or cognitive decline, brain MRI or CT should be considered for
detecting brain infarctions, microbleeds, and white matter lesions [168,169]. IIa B
ABI, ankle-brachial index; CKD, chronic kidney disease; CT, computed tomography; eGFR, estimated glomerular filtration rate; HMOD, hypertension-mediated organ damage; LEAD,
lower extremity artery disease; LVH, left ventricular hypertrophy; MRI, magnetic resonance imaging; PWV, pulse wave velocity.
aClass of recommendation.
bLevel of evidence.
6 GENETICS ANDHYPERTENSION
A positive family history is a frequent feature in hyper-
tensive patients, with the heritability estimated to vary
between 35 and 50% in most studies [191,192]. However,
hypertension is a highly heterogeneous disorder with a
multifactorial aetiology. Several genome-wide association
studies and their meta-analyses have identified 120 loci
that are associated with BP regulation, but together these
only explain about 3.5% of the trait variance [193]. Several
rare, monogenic forms of hypertension have been
described such as glucocorticoid-remediable aldosteron-
ism, Liddle’s syndrome, and others, where a single gene
mutation fully explains the pathogenesis of hypertension
and dictates the best treatment modality [194–196]. There
are also inherited forms of phaeochromocytoma and
paraganglioma, which are also rare causes of hyperten-
sion [197–200]. Outside of specialist clinics evaluating
patients for these rare causes of secondary hypertension,
there is no role for genetic testing in hypertension in
routine clinical care.
Genetic testing and hypertension
Recommendations a LevelClass b
Genetic testing should be considered in spe-
cialist centres for patients suspected to have
rare monogenic causes of secondary hyper-
tension or for those with
phaeochromocytoma [198].
IIa B
Routine genetic testing for hypertensive
patients is not recommended. III C
aClass of recommendation.
bLevel of evidence.
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7 TREATMENTOF HYPERTENSION
7.1 Beneficial effects of blood pressure-
lowering therapy in hypertension
There are two well established strategies to lower BP:
lifestyle interventions and drug treatment. Device-based
therapy is also emerging, but is not yet proven as an
effective treatment option. Lifestyle interventions can
undoubtedly lower BP and in some cases cardiovascular
risk (see Section 7.4.1), but most patients with hyperten-
sion will also require drug treatment. The drug treatment
of hypertension is founded on very solid evidence,
underpinned by the largest number of outcome-based
RCTs in clinical medicine. Meta-analyses of RCTs includ-
ing several hundred thousand patients have shown that a
10mmHg reduction in SBP or a 5mmHg reduction in
DBP is associated with significant reductions in all major
cardiovascular events by 20%, all-cause mortality by 10–
15%, stroke by 35%, coronary events by 20%, and heart
failure by 40% [2,8]. These relative risk reductions are
consistent, irrespective of baseline BP within the hyper-
tensive range, the level of cardiovascular risk, comorbid-
ities (e.g. diabetes and CKD), age, sex, and ethnicity
[2,201].
Relative outcome reductions calculated by two recent
meta-analyses are similar to those provided by the original
meta-analysis of the effects of BP lowering on outcomes in
1994 [202]. Thus, the benefits of antihypertensive treatment
have not been attenuated by the widespread concomitant
prescription of lipid-lowering and antiplatelet therapies in
contemporary medicine.
Another important objective of antihypertensive therapy
is to reduce the development of CKD; however, the slow rate
of decline in renal function in most hypertensive patients
makes thedemonstrationofpotentialbenefits ofBP lowering
difficult. Consequently, the protective effect of BP reduction
on kidney function can be less obvious and has been
restricted to patients with diabetes or CKD, in whom there
is a faster rate of disease progression [203]. Some, but not all,
RCTs have also shown a protective effective of BP lowering
on the progression of CKD towards end-stage renal disease
in both diabetic and nondiabetic nephropathy [2].
The recommendations that follow are based on outcome
evidence from RCTs; however, it must be acknowledged
that RCTs based on clinical outcomes have limitations, the
most important of which are that the data are largely limited
to older and high-risk patients, preferentially recruited to
increase statistical power, and over a relatively short dura-
tion of follow-up, rarely beyond 5 years. This means that
recommendations for life-long treatment for younger and
lower risk patients are necessarily based on considerable
extrapolation. Big data, now being collected by national
health system registries, health insurance companies, and
prolonged observational follow-up of RCTs, are becoming
an important source of long-term information on the effects
of chronic treatment [204], which adds to that provided by
observational studies over several decades [205–207]. Such
evidence suggests that the benefit of continued treatment is
maintained over decades [206].
7.2 When to initiate antihypertensive
treatment
7.2.1 Recommendations in previous guidelines
All guidelines agree that patients with grade 2 or 3
hypertension should receive antihypertensive drug
treatment alongside lifestyle interventions [208]. Guide-
lines are also consistent in recommending that patients
with grade 1 hypertension and high cardiovascular risk
or HMOD should be treated with BP-lowering drugs.
There has been less consistency about whether BP-
lowering drugs should be offered to patients with grade
1 hypertension and low–moderate cardiovascular risk
or grade 1 hypertension in older patients (>60 years), or
the need for BP-lowering drug treatment in patients with
high–normal BP levels [17,209,210]. This uncertainty
relates to the fact that low-risk patients with high–
normal BP or grade 1 hypertension have rarely been
included in RCTs, and that in older patients, RCTs have
invariably recruited patients with at least grade 2 hyper-
tension. New analyses and RCT data have become
available in these important areas and are discussed
below.
7.2.2 Drug treatment for patients with grade 1
hypertension at low-moderate cardiovascular risk
Recent meta-analyses show significant treatment-induced
reductions in cardiovascular events and mortality in
patients with grade 1 hypertension [8,201,211]. However,
the first of these analyses included a substantial number
of patients who had grade 1 hypertension despite exist-
ing treatment, and were therefore likely to have had
initial BPs above the grade 1 range. Furthermore, many
of the patients had diabetes and were therefore at high
cardiovascular risk [211]. The second meta-analysis, lim-
ited to RCTs in patients with grade 1 hypertension and
low–moderate-risk (five RCTs, 8974 patients), demon-
strated a significant reduction in all major cardiovascular
events by BP-lowering drug treatment [combined stroke
and coronary artery disease (CAD) reduced by 34%, and
all-cause mortality by 19% for an SBP reduction of
7mmHg] [8]. A third analysis demonstrated a benefit of
BP lowering in reducing death and CVD in patients with
a baselineBP140/90mmHgorhigher, but notwhenbaseline
BP was lower [201]. These findings have been supported by
the results of a subgroup analysis of the Heart Outcomes
Prevention Evaluation (HOPE)-3 trial, showing a significant
27% reduction in major cardiovascular outcomes in patients
at intermediate cardiovascular risk and baseline SBP values
in the grade 1 hypertensive range [i.e. >143.5mmHg (mean
154mmHg)] when SBP was lowered by drug treatment by a
mean of 6mmHg [212].
Based on these new data, this Task Force now
recommends that lifestyle advice should be accompa-
nied by BP-lowering drug treatment in patients with
grade 1 hypertension at low–moderate cardiovascular
risk.
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7.2.3 Initiation of blood pressure-lowering drug
treatment in older people with grade 1
hypertension
Discussion about the treatment of ‘the elderly’ or ‘older’
people has been complicated by the various definitions of
older age used in RCTs. For example, older was defined as
more than 60 years in the earliest trials, then as 65, 70 and
finally 75 [51] or 80 years [213] in later trials. Chronological
age is often a poor surrogate for biological age, with
consideration of frailty and independence influencing
the likely tolerability of BP-lowering medications. For
the purposes of this guideline, the ‘old’ are defined as at
least 65 years and the ‘very old’ as at least 80 years. The
previous Guidelines [17] noted that all available evidence
on cardiovascular event reduction by BP lowering in older
patients was obtained in patients whose baseline SBP was
at least 160mmHg, and there is strong evidence that these
patients should be offered BP-lowering drug treatment
[210,214].
Undoubtedly, there are RCTs showing outcome bene-
fits with BP-lowering treatment in older patients whose
baseline BP was in a lower SBP range, but these patients
were often on background antihypertensive treatment,
thus they cannot be defined as having true grade 1
hypertension. This is also the case for the data recently
published from the SPRINT trial, which included a cohort
of patients older than 75 years, in whom more intense BP
lowering reduced the risk of major cardiovascular events
and mortality [51,215]. However, in most RCTs showing a
protective effect of BP-lowering treatment in patients
with an untreated baseline BP in the grade 1 hyperten-
sion range, older patients were well represented. This
was further supported by the recent HOPE-3 trial, which
showed beneficial effects of BP lowering on cardiovas-
cular outcomes in patients, many with grade 1 hyperten-
sion (SBP >143mmHg and mean BP¼ 154mmHg),
whose mean age was 66 years, and in whom only 22%
had prior treatment of hypertension [212].
The evidence supports the recommendation that older
patients (>65 years, including patients over 80 years)
should be offered BP-lowering treatment if their SBP is at
least 160mmHg. There is also justification to now rec-
ommend BP-lowering treatment for old patients (aged
>65 but not >80 years) at a lower BP (i.e. grade 1
hypertension; SBP¼ 140–159mmHg) [201]. BP-lowering
drugs should not be withdrawn on the basis of age alone.
It is well established that BP-lowering treatment with-
drawal leads to a marked increase in cardiovascular risk.
This was exemplified in older patients by a recent sub-
group analysis of the Hypertension in the Very Elderly
Trial (HYVET) [213], reporting that in patients aged at
least 80 years, cardiovascular risk reduction was greatest
in those who continued treatment rather than in those
whose treatment was discontinued [216]. As stated above,
all of the above recommendations relate to relatively fit
and independent older patients, because physically and
mentally frail and institutionalized patients have been
excluded in most RCTs of patients with hypertension
[214]. Further details of the treatment of hypertension
in older patients and very old patients is provided in
Section 8.8.
7.2.4 Initiation of blood pressure-lowering drug
treatment in patients with high-normal blood
pressure
The previous (2013) Guidelines [17] recommended not
to initiate antihypertensive treatment in people with
high–normal BP and low–moderate cardiovascular risk.
This recommendation is further supported by new evi-
dence:
1. In all RCTs (including SPRINT) [51] andmeta-analyses
[2] that have reported reduced major outcomes by
lowering ‘baseline’ BP in the high–normal range, the
‘baseline’ BP was commonly measured on a back-
ground of antihypertensive treatment. Therefore,
these studies do not provide evidence to support
treatment initiation in patients without hypertension
[8].
2. The HOPE-3 trial [212], in which only 22% of the
patients at intermediate cardiovascular risk had back-
ground antihypertensive treatment, showed that BP-
lowering treatment did not reduce the risk of major
cardiovascular events in patients with baseline SBP
values in the high–normal range.
3. Ameta-analysis of 13 RCTs or RCT subgroups (involv-
ing 21 128 individuals) in patients at low–moderate
cardiovascular risk and untreated baseline BP in the
high–normal and normal range, showed no effect of
BP-lowering treatment on any cardiovascular out-
comes [217].
4. Another recent analysis, including patients with
high–normal BP, concluded that primary preventive
BP lowering was associated with reduced risk for
death and incident CVD if baseline SBP was
140mmHg or higher, but at lower BP levels [i.e.
high–normal BP (<140/90mmHg)], treatment was
not associated with any benefit in primary prevention
[201].
5. The situation may be different in very high-risk
patients with a high–normal BP and established
CVD. In a meta-analysis of 10 RCTs or RCT subgroups
that also included individuals at high or very high
cardiovascular risk, mostly with previous CVD and
untreated high–normal and normal BP (n¼ 26 863),
BP-lowering drug treatment, achieving an SBP reduc-
tion of 4mmHg, reduced the risk of stroke but not any
other cardiovascular events [217]. In another analysis
of trials including people with previous CAD and a
mean baseline SBP of 138mmHg, treatment was
associated with reduced risk for major cardiovascular
events (relative risk 0.90; 95% confidence interval
0.84–0.97), but was not associated with an increased
survival (relative risk 0.98; 95% confidence interval
0.89–1.07) [201]. Thus, the benefit for treating people
with high–normal BP appears marginal and, if pres-
ent, appears to be restricted to those at very high
cardiovascular risk and established CVD, especially
CAD.
We recommend that patients with high–normal BP and
low–moderate cardiovascular risk should be offered life-
style advice, because this reduces their risk of progressing
2018 ESC/ESH Guidelines for the management of arterial hypertension
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to established hypertension and may further reduce
their cardiovascular risk. These patients should not be
offered BP-lowering drug treatment. Nevertheless,
based on the data from the HOPE-3 trial, drug treatment
may be considered in these patients if their BP is close to
the hypertension diagnostic threshold of 140/90mmHg,
after a prolonged attempt to control BP with lifestyle
changes.
BP-lowering drugs may be considered for patients with
high–normal BP and established CVD, especially CAD. In
these patients, monotherapy may be sufficient.
7.2.5 Should blood pressure-lowering drug
treatment be initiated on the basis of blood
pressure values or the level of total cardiovascular
risk?
Two recent meta-analyses of RCTs [8,218] have shown
that when BP-lowering data are stratified according to
cardiovascular risk, the relative risk reductions do not
differ across the various risk strata; not surprisingly, the
absolute risk reduction is greater with increasing baseline
cardiovascular risk. These data have been taken as sup-
port for the hypothesis that BP-lowering treatment should
be based on cardiovascular risk and target those at great-
est cardiovascular risk, irrespective of their BP [218].
However, it has recently been made that whereas patients
at high or very high cardiovascular risk exhibit the great-
est absolute reduction in cardiovascular outcomes with
BP-lowering treatment, they also have the highest resid-
ual risk, which means failure of treatment to exert full
protection [8]. It is the opinion of this Task Force that
these data support earlier treatment of patients with SBP
or DBP values more than 140/90mmHg when their
cardiovascular risk is still low–moderate, to prevent
the accumulation of HMOD and a high incidence of late
treatment failure (residual risk), which would otherwise
occur if treatment was delayed by a purely cardiovascular
risk-based approach. The most effective strategy to
reduce risk is to prevent the development of high car-
diovascular-risk situations with earlier intervention. The
assessment of cardiovascular risk is at the core of the
treatment strategy recommended by these Guidelines
because of the frequent coexistence of multiple cardio-
vascular risk factors in hypertensive patients, and to
inform the use of concomitant medications (e.g. statins,
antiplatelet therapies, etc., see Section 9) to reduce car-
diovascular risk. We conclude that, in general, the deci-
sion to use BP-lowering treatment should not be based
solely on the level of cardiovascular risk because even in
patients at the highest risk (with established CVD), when
baseline BP is below 140/90mmHg, the benefits of BP-
lowering treatment are at best marginal and most evident
in patients with CAD at the upper end of the high–
normal BP range [201].
7.2.6 Initiation of blood pressure-lowering drug
treatment
In patients with grade 2 or 3 hypertension, it is recom-
mended that BP-lowering drug treatment should be initi-
ated alongside lifestyle interventions. In patients with grade
1 hypertension at high risk or with HMOD, drug treatment
should also be initiated simultaneously with lifestyle
interventions. In lower-risk patients with grade 1 hyperten-
sion, BP-lowering drug treatment should be initiated after
3–6 months if BP is not controlled by lifestyle interventions
alone (Fig. 3). Recommended BP thresholds for the
initiation of antihypertensive drug treatment are shown
in Table 19.
FIGURE 3 Initiation of blood pressure-lowering treatment (lifestyle changes and medication) at different initial office blood pressure levels. BP, blood pressure; CAD,
coronary artery disease; CVD, cardiovascular disease; HMOD, hypertension-mediated organ damage.
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Initiation of hypertension treatment according to office BP
Recommendations Classa Levelb
Prompt initiation of BP-lowering drug treatment is recommended in patients with grade 2 or 3 hypertension at any level of CV
risk, simultaneous with the initiation of lifestyle changes [2,8].
I A
In patients with grade 1 hypertension:
Lifestyle interventions are recommended to determine if this will normalize BP [219].
II B
In patients with grade 1 hypertension at low–moderate-risk and without evidence of HMOD, BP-lowering drug treatment is
recommended if the patient remains hypertensive after a period of lifestyle interventionc [211,212].
I A
In patients with grade 1 hypertension and at high risk or with evidence of HMOD, prompt initiation of drug treatment is rec-
ommended simultaneously with lifestyle interventions [211,212].
I A
In fit older patients with hypertension (even if aged > 80 years), BP-lowering drug treatment and lifestyle intervention are rec-
ommended when SBP is >_ 160 mmHg [210,220,221].
I A
BP-lowering drug treatment and lifestyle intervention are recommended for fit older patients (> 65 years but not > 80 years)
when SBP is in the grade 1 range (140–159 mmHg), provided that treatment is well tolerated [212].
I A
Antihypertensive treatment may also be considered in frail older patients if tolerated [215]. IIb B
Withdrawal of BP-lowering drug treatment on the basis of age, even when patients attain an age of >_ 80 years, is not recom-
mended, provided that treatment is well tolerated [213].
III A
In patients with high–normal BP (130–139/85–89 mmHg):
Lifestyle changes are recommended [17,35].
Drug treatment may be considered when their cardiovascular risk is very high due to established CVD, especially CAD [217].
I A
IIb A
BP, blood pressure; CAD, coronary artery disease; CVD, cardiovascular disease; HMOD, hypertension-mediated organ damage.
aClass of recommendation.
bLevel of evidence.
cIn patients with grade 1 hypertension and at low–moderate-risk, drug treatment may be preceded by a prolonged period of lifestyle intervention to determine if this approach will
normalize BP. The duration of the lifestyle intervention alone will depend on the level of BP within the grade 1 range, that is the likelihood of achieving BP control with lifestyle
intervention alone, and the opportunities for significant lifestyle change in individual patients.
7.3 Blood pressure treatment targets
7.3.1 New evidence on SBP and diastolic blood
pressure treatment targets
The 2013 ESH/ESC hypertension Guidelines [17] recom-
mended an office BP treatment target of <140/90mmHg,
regardless of the number of comorbidities and level of
cardiovascular risk. The Guidelines specifically stated that
evidence from RCTs, meta-analyses, and post-hoc analy-
sis of large-scale RCTs all showed no obvious incremental
benefit of lowering BP to less than 130/80mmHg. Since
then, new information has emerged from post-hoc anal-
yses of large outcome trials in patients at high cardiovas-
cular risk [222–224], registries in patients with coronary
disease, and, more importantly, new RCTs and meta-
analyses of all available RCT evidence. In the post-hoc
RCT analyses and registry data, compared with a target
SBP of between 130 and 139mmHg, lowering SBP to less
than 130mmHg was, in general, associated with no
further benefit on major cardiovascular events, except
perhaps for further reductions in the risk of stroke. A
consistent finding was that reducing SBP to less than
120mmHg increased the incidence of cardiovascular
events and death.
A recent RCT relevant to the issue of target BP is SPRINT,
which compared two different SBP targets (<140 or
<120mmHg) in more than 9000 patients at high cardio-
vascular risk, but excluded patients with diabetes or previ-
ous stroke. More intensive BP-lowering treatment
(achieved SBP 121 vs. 136mmHg) was associated with a
25% reduction in major cardiovascular events and a 27%
reduction in all-cause death (but no significant reduction in
stroke or myocardial infarction) [51]. This outcome
unquestionably provides strong support for the beneficial
effects of more vs. less intensive BP-lowering treatment
strategies in higher risk patients. However, this RCT does
not clarify the optimal BP target because the method used
for office BP measurement in SPRINT (unattended auto-
matic measurement) had not been used in any previous
RCTs that provide the evidence base for the treatment of
hypertension [225]. This is because unattended automated
office BP measurement results in lower BP values, relative
to conventional office BPmeasurement, due to the absence
of the white-coat effect [52,54]. Thus, it has been suggested
that the BP values reported in SPRINT may correspond to
conventional office SBPs in the 130–140 and 140–
150mmHg ranges in the more vs. less intensive BP-lower-
ing groups, respectively.
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Some new information on SBP and DBP targets for drug
treatment has been provided by two recent, large meta-
analyses of RCTs of BP lowering. In the first of these meta-
analyses, achieved SBP was stratified according to three
SBP target ranges (149–140, 139–130 and <130mmHg)
[226]. Lowering SBP to less than 140mmHg reduced the
relative risk of all major cardiovascular outcomes (includ-
ing mortality); similar benefits were seen when SBP was
lowered to less than 130mmHg (average 126mmHg).
Importantly, the latter was also true when the achieved
SBP in the comparator group was 130–139mmHg. Stratifi-
cation of RCTs for achieved DBP, to either 89–80 or less
than 80mmHg, also showed a reduction in all types of
cardiovascular outcomes compared with higher DBP val-
ues [226].
The second meta-analysis, which also included the
SPRINT trial [2], noted that every 10mmHg reduction in
SBP reduced the rate of major cardiovascular events and
death for baseline SBP values more than 160mmHg to
baseline values between 130 and 139mmHg, implying
benefit at achieved SBP values of less than 130mmHg.
Furthermore, a benefit of a 10mmHg reduction in SBP
was also reported for patients with a baseline SBP of less
than 130mmHg, thereby achieving values less than
120mmHg. However, there were far fewer patients in these
subgroups, and this last set of data will have been heavily
influenced by the unusually low BP values in the SPRINT
trial, due to the method of BP measurement (see above).
Importantly, this analysis showed consistent benefit from
intensive BP lowering in patients at all levels of risk,
including those with and without existing CVD, stroke,
diabetes and CKD.
Finally, in the first meta-analysis [226], the incremental
benefit of BP lowering on events progressively decreased as
the target BP was lowered. Furthermore, an additional
meta-analysis by the same group found that permanent
treatment discontinuation because of treatment-related
adverse effects was significantly higher in those targeted
to lower BP values [227]. Therefore, advocating more
intensive BP-lowering targets for all has to be viewed in
the context of an increased risk of treatment discontinua-
tion due to adverse events, which might offset, in part or
completely, the limited incremental reduction in
cardiovascular risk.
Whilst considering BP targets, it is important to acknowl-
edge that less than 50% of patients treated for hypertension
currently achieve a target office SBP of less than 140mmHg
[11,12]. This is a major missed opportunity for CVD preven-
tion in millions of people across the world.
This Task Force recommends that when BP-lowering
drugs are used, the first objective should be to lower BP to
<140/90mmHg in all patients. Provided that the treatment
is well tolerated, treated BP values should be targeted to
130/80mmHg or lower in most patients, although in some
groups the evidence is less compelling. In older patients
(>65 years), SBP should be targeted to between 130 and
140mmHg, and DPB to less than 80mmHg. Treated SBP
should not be targeted to less than 120mmHg.
Importantly, we specify a target range because the lower
safety boundary assumes greater importance when BP is
targeted to lower levels. Furthermore, in general, when SBP
is lowered to less than 120mmHg in patients included in
RCTs (i.e. older and higher-risk patients, often with comor-
bidities and CVD), the risk of harm appears to increase and
outweigh the benefits [222].
7.3.2 Blood pressure targets in specific subgroups
of hypertensive patients
7.3.2.1 Diabetes mellitus
RCTs in type 1 diabetes mellitus demonstrate that BP-
lowering treatment has a renoprotective effect [228], but
because these patients tend to be younger, previous RCTs
have had inadequate power to study cardiovascular out-
comes and to establish optimal BP targets.
In contrast, there have been many BP-lowering treat-
ment RCTs, either exclusively dedicated to patients with
type 2 diabetes or hypertension trials that have included a
large cohort of patients with type 2 diabetes [2]. Most
of these RCTs have shown that BP lowering to less than
140/85mmHg is beneficial in patients with type 2 diabetes
and hypertension. However, the results have been less
clear about whether a lower BP target is associated with
further benefits. The evidence can be summarized as
follows:
1. A large RCT in patients with type 2 diabetes has shown
that an achieved SBP of less than 135mmHg, compared
with 140mmHg, was associatedwith a significant reduc-
tion in cardiovascular and all-cause mortality [229].
2. Evidence from another large RCT in patients with
type 2 diabetes showed that, compared with patients
with an on-treatment SBP of 135mmHg, reducing
SBP to 121mmHg did not reduce cardiovascular
TABLE 19. Summary of office blood pressure thresholds for treatment
Office SBP treatment threshold (mmHg)
Age group Hypertension þ Diabetes þ CKD þ CAD þ Stroke/TIA
Office DBP treatment
threshold (mmHg)
18–65 years 140 140 140 140a 140a 90
65–79 years 140 140 140 140a 140a 90
80 years 160 160 160 160 160 90
Office DBP treatment threshold (mmHg) 90 90 90 90 90
BP, blood pressure; CAD, coronary artery disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; SBP, systolic blood pressure; TIA, transient ischaemic attack.
aTreatment may be considered in these very high-risk patients with high–normal SBP (i.e. SBP 130–140mmHg).
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morbidity and mortality or all-cause death, but sub-
stantially reduced the risk of stroke [230].
3. Although one recent meta-analysis concluded that
most of the benefit associated with BP lowering was
obtained at higher BP targets (i.e. <150mmHg but
not <140mmHg) [231], other large meta-analyses
have confirmed that in type 2 diabetes, lowering
SBP to <140mmHg is associated with reductions in
all major cardiovascular events [1,232–234].
4. Two of the meta-analyses concluded that the overall
benefit of lowering BP in patients with type 2 diabetes
(unlike patients without type 2 diabetes) largely dis-
appears when SBP is lowered to less than 130/
80mmHg [1,235], except for the continuing incre-
mental benefit on stroke.
5. Similar evidence for stroke benefit from lower
achieved SBP has also been reported from post-
hoc analysis of diabetic patients in the ONTARGET
(Ongoing Telmisartan Alone and in combination with
Ramipril Global Endpoint Trial) study. In addition,
reanalysis of the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) [230] trial in type 2
diabetes, after removing the interaction from the
intensive glucose-lowering arm and thereby limiting
the analysis to BP-lowering effects, showed an overall
reduction in cardiovascular events with intensive SBP
lowering to less than 130mmHg [236].
6. Further recent analysis of the ACCORD trial has
shown that reducing SBP to less than 120mmHg
was associated with increased risk of major cardio-
vascular events [236].
7. With regard toDBP, earlier evidence suggested a benefit
on major cardiovascular events when DBPwas lowered
to less than 85mmHg [237,238]. More recently, in the
Action in Diabetes and Vascular Disease: Preterax and
Diamicron – MRControlled Evaluation (ADVANCE) trial
[229], the benefits on cardiovascular outcomes were
observed at diastolic pressures of 75mmHg. This is
consistent with evidence from the meta-analyses cited
above, that it is safe and effective to lower DBP to less
than 80mmHg in patients with type 2 diabetes.
In summary, in patients with diabetes receiving BP-
lowering drugs, it is recommended that office BP should
be targeted to an SBP of 130mmHg [229], and lower if
tolerated. In older patients (aged65 years) the SBP target
range should be 130–140mmHg [213] if tolerated. SBP
should not be lowered to less than 120mmHg and DBP
should be lowered to less than 80mmHg. Attention should
also be given to the consistency of BP control, because
visit-to-visit BP variability is associated with increased
cardiovascular and renal disease risk. Furthermore, cardio-
vascular protection has been found to be greater when BP
control is accompanied by fewer visit-to-visit BP variations
[239–241].
7.3.2.2 Older patients
The definition of ‘older’ is complex. As populations age,
there is increasingly wide variation between a patient’s
chronological age and their functional status, ranging
from fit, active, and independent, through to frail and
dependent. The anticipated benefits vs. potential harm
of BP treatment in older patients will be influenced by
the patient’s ability to tolerate treatment and their health
and functional status. For the purposes of these Guide-
lines, ‘older’ patients are defined as those aged at least
65 years.
In the 2013 ESH/ESC hypertension Guidelines, the
target SBP for older hypertensive patients was set at
140–150mmHg because this was the range of systolic
values achieved by major outcome trials demonstrating
a beneficial effect of antihypertensive treatment in these
patients. A similar SBP target was suggested by the
HYVET trial, in which treating to an SBP target of less
than 150mmHg (achieving a mean SBP of 144mmHg) in
the very old (>80 years) demonstrated significant reduc-
tions in mortality, fatal stroke, and heart failure, with the
caveat that the ‘very old’ patients in this study were
active and independent [213]. More recent evidence
supports a lower SBP target for older patients (65
years):
1. The SPRINT trial included a high proportion of
patients over the age of 75 years (n¼ 2636) and
demonstrated that more intensive BP-lowering treat-
ment (mean achieved BP¼ 124/62mmHg) signifi-
cantly reduced the risk of major cardiovascular
events, heart failure, and all-cause death (all by
>30%) compared with standard treatment (mean
achieved BP¼ 135/67mmHg) [215]. It has been noted
above that the BP measurement technique used in
SPRINT generated lower values than those provided
by the conventional office BPmeasurement [225,242].
Consequently, the SBP of 124mmHg achieved in the
intensively treated older patients in the SPRINT trial
most probably reflects a conventional office SBP
range of 130–139mmHg.
2. Although HYVET and most other RCTs in older
patients have recruited relatively fit and indepen-
dent patients, the SPRINT study also suggested
that there are benefits of more intensive treatment
being extended to older patients who are at the
frailer end of the spectrum of patients meeting
the recruitment criteria, with reduced gait speed
[215].
Based on the new data, the targets suggested by the
previous Guidelines now appear too conservative for many
old and very old patients, especially those who are active
and independent. Consequently, we recommend that in
older patients treated for hypertension, BP should be
lowered to less than 140/80mmHg, but not below an
SBP of 130mmHg. Importantly, the impact of BP-lowering
on the well being of the patient should be closely moni-
tored, because the increased risk of adverse events (e.g.
injurious falls) with lower BP values could be more pro-
nounced in older patients in the real-life setting than in the
closely monitored conditions of RCTs. Further details on the
approach to treatment of the frail older patient are dis-
cussed in Section 8.8.
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7.3.2.3 Office vs. home and ambulatory blood
pressure targets
No outcome-based RCT has used ABPM or HBPM to guide
the treatment of hypertension. Thus, ABPM and HBPM BP
targets are based on extrapolation from observational data
rather than on outcome trials. Although we do not provide
formal ABPM or HBPM BP targets for treated patients, it
should be noted that:
1. In population studies, the difference between office
and out-of-office BP levels decreases as office BP
decreases, to a point of around 115–120/70mmHg, at
which office and 24 h ABPM mean BP values are
usually similar [54].
2. This convergence has also been confirmed in treated
patients [243] in whom the difference between office
BP and ambulatory BP values diminishes and
becomes negligible at an SBP of approximately
120mmHg.
3. In treated patients, a target office SBP of 130mmHg
might therefore correspond to a slightly lower mean
24h SBP, that is approximately 125mmHg.
4. Although there are no available data, the home
SBP target, to be equivalent to an office SBP target
of 130mmHg, might also be lower than
130mmHg.
Office BP treatment targets in hypertensive patients
BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure;
SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
cLess evidence is available for this target in low–moderate-risk patients.
7.4 Treatment of hypertension
7.4.1 Lifestyle changes
Healthy lifestyle choices can prevent or delay the onset of
hypertension and can reduce cardiovascular risk [17,35]. Effec-
tive lifestyle changes may be sufficient to delay or prevent the
need for drug therapy in patients with grade 1 hypertension.
They can also augment the effects of BP-lowering therapy, but
they should never delay the initiation of drug therapy in
patients with HMOD or at a high level of cardiovascular risk.
A major drawback of lifestyle modification is the poor persis-
tence over time [245,246]. The recommended lifestyle mea-
sures that have been shown to reduce BP are salt restriction,
moderation of alcohol consumption, high consumption of
vegetables and fruits, weight reduction and maintaining an
ideal body weight, and regular physical activity [17]. In addi-
tion, tobacco smoking has an acute prolonged pressor effect
that may raise daytime ambulatory BP, but smoking cessation
and other lifestylemeasures are also important beyondBP (i.e.
for CVD and cancer prevention) [35].
7.4.2 Dietary sodium restriction
There is evidence of a causal relationship between sodium
intake and BP, and excessive sodium consumption (>5 g
sodium per day, e.g. one small teaspoon of salt per day) has
been shown to have a pressor effect and be associated with
an increased prevalence of hypertension and the rise in SBP
with age [247]. Conversely, sodium restriction has been
shown to have a BP-lowering effect in many trials. A recent
meta-analysis of these trials showed that a reduction of 1.75 g
sodium per day (4.4 g salt per day) was associated with a
mean 4.2/2.1mmHg reduction in SBP/DBP, with a more
pronouncedeffect (5.4/2.8mmHg) inpeoplewithhyper-
tension [248]. The beneficial effect of a reduced sodium
intake on BP tends to diminish with time, in part due to
poor dietary persistence. The BP-lowering effect of sodium
restriction is greater in black people, in older patients, and in
patients with diabetes, metabolic syndrome, or CKD [249]. In
people with treated hypertension, effective sodium restric-
tion may reduce the number or dose of BP-lowering drugs
that are necessary to control BP [250,251].
The effect of reduced dietary sodium on cardiovascular
events remains unclear [252–255]. Prospective cohort studies
have reported an overall increased risk of mortality and
cardiovascular events on high sodium intake. However, they
also reported that reducing sodium intake below a certain
level (about 3 g of sodium per day) further reduced BP, but
paradoxically was associated with an increased risk of all-
cause and cardiovascular mortalities in both the general
population and in hypertensive people, suggesting a J-curve
phenomenon [256]. The mechanism of this apparent
increased risk at low sodium intake is not well understood
and might be confounded by reverse causality. There is no
evidence from epidemiological studies that very low sodium
intakemay cause harm [257]. Although a few trials andmeta-
analyses suggest that reducing salt intake from high to
moderate is accompanied by a lower risk of cardiovascular
events [254,255,258], to date, no prospective RCT has pro-
vided definitive evidence about the optimal sodium intake to
minimize cardiovascular events and mortality. Increased
potassium intake is associated with BP reduction and may
Recommendations a LevelClass b
It is recommended that the first objective of
treatment should be to lower BP to < 140/
90 mmHg in all patients and, provided that
the treatment is well tolerated, treated BP
values should be targeted to 130/80 mmHg
or lower in most patients [2,8].
I A
In patients < 65 years receiving BP-lowering
drugs, it is recommended that SBP should
be lowered to a BP range of 120–129
mmHg in most patients [2,215,229].c
I A
In older patients (aged >_ 65 years) receiving
BP-lowering drugs:
• It is recommended that SBP should be
targeted to a BP range of 130–139
mmHg [2,235,244].
I A
• Close monitoring of adverse effects is
recommended.
I C
• These BP targets are recommended for patients
at any level of cardiovascular risk and in patients
with and without established CVD [2,8].
I A
A DBP target of < 80 mmHg should be consid-
ered for all hypertensive patients, independent
of the level of risk and comorbidities [226,235].
IIa B
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have a protective effect, thereby modifying the association
between sodium intake, BP and CVD [259].
Globally, usual sodium intake is between 3.5 and 5.5 g/
day (which corresponds to 9–12 g of salt per day), with
marked differences between countries and even between
regions within countries. We recommend sodium intake to
be limited to approximately 2.0 g/day (equivalent to
approximately 5.0 g salt per day) in the general population
and to try to achieve this goal in all hypertensive patients.
Effective salt reduction is not easy and there is often poor
appreciation of which foods contain high salt levels. Advice
should be given to avoid added salt and high-salt foods. A
reduction in population salt intake remains a public health
priority but requires a combined effort between the food
industry, governments, and the public in general, as 80% of
salt consumption involves hidden salt in processed foods.
7.4.3 Moderation of alcohol consumption
There is a long-established positive linear association
between alcohol consumption, BP, the prevalence of
hypertension and CVD risk. Binge drinking can have a
strong pressor effect [17]. The Prevention and Treatment
of Hypertension Study (PATHS) investigated the effects of
alcohol reduction on BP; the intervention group had a
modest 1.2/0.7mmHg lower BP than the control group
at the end of the 6-month period [260]. A Mendelian
randomization meta-analysis of 56 epidemiological studies
suggested that reduction of alcohol consumption, even for
light–moderate drinkers, might be beneficial for cardiovas-
cular health [261]. Hypertensive men who drink alcohol
should be advised to limit their consumption to 14 and
women to 8 units per week (1 unit is equal to 125ml of wine
or 250ml of beer). Alcohol-free days during the week and
avoidance of binge drinking [35] are also advised.
7.4.4 Other dietary changes
Hypertensive patients should be advised to eat a healthy
balanced diet containing vegetables, legumes, fresh fruits,
low-fat dairy products, whole grains, fish, and unsaturated
fatty acids (especially olive oil), and to have a low consump-
tion of red meat and saturated fatty acids [262–264]. The
Mediterranean diet includes many of these nutrients and
foods, with a moderate consumption of alcohol (mostly wine
withmeals). Anumberof studies andmeta-analyses [262–265]
have shown that the Mediterranean diet is associated with a
reduction in cardiovascular events and all-cause mortality. An
RCT in high-risk individuals on the Mediterranean diet over 5
years showed a 29% cardiovascular risk reduction compared
with a low-fat control diet, and a 39% reduction in stroke [265].
TheMediterranean diet also significantly reduced ambulatory
BP, blood glucose, and lipid levels [266]. The diet should be
accompanied by other lifestyle changes such as physical
exercise and weight loss [35].
With regard to coffee consumption, caffeine has been
shown to have an acute pressor effect [267]. Nevertheless,
coffee consumption is associated with cardiovascular ben-
efits, as highlighted by a recent systematic review of pro-
spective cohort studies including more than 1 million
participants and 36 352 cardiovascular events [267]. More-
over, green or black tea consumption may also have a small
but significant BP-lowering effect [268,269].
Regular consumption of sugar-sweetened soft drinks has
been associated with overweight, metabolic syndrome,
type 2 diabetes, and higher cardiovascular risk. The con-
sumption of these drinks should be discouraged [35].
Thus, adopting a healthy and balanced diet may assist in
BP reduction and also reduce cardiovascular risk.
7.4.5 Weight reduction
Excessive weight gain is associated with hypertension, and
reducing weight towards an ideal body weight decreases
BP [270]. In a meta-analysis, the mean SBP and DBP
reductions associated with an average weight loss of
5.1 kg were 4.4 and 3.6mmHg, respectively [271]. Both
overweight and obesity are associated with an increased
risk of cardiovascular death and all-cause mortality. Weight
reduction is recommended in overweight and obese hyper-
tensive patients for control of metabolic risk factors, but
weight stabilizationmay be a reasonable goal for many. The
Prospective Studies Collaboration [272] concluded that
mortality was lowest at a BMI of approximately 22.5–
25 kg/m2, whereas a more recent meta-analysis concluded
that mortality was lowest in subjects with overweight
[273,274]. Although the optimal BMI is unclear, mainte-
nance of a healthy body weight (BMI of approximately
20–25 kg/m2 in people <60 years of age; higher in older
patients) and waist circumference (<94 cm for men and
<80 cm for women) is recommended for nonhypertensive
individuals to prevent hypertension, and for hypertensive
patients to reduce BP [35]. Weight loss can also improve the
efficacy of antihypertensive medications and the cardiovas-
cular risk profile. Weight loss should employ a multidisci-
plinary approach that includes dietary advice, regular
exercise, and motivational counselling [35,275]. Further-
more, short-term results are often not maintained over
the long-term. Weight loss can also be promoted by anti-
obesity drugs and, to a greater degree, bariatric surgery,
which appears to decrease cardiovascular risk in severely
obese patients. Further details are available in a recent
document of the ESH and the European Association for
the Study of Obesity [276].
7.4.6 Regular physical activity
Physical activity induces an acute rise in BP, especially SBP,
followed by a short-lived decline in BP below baseline.
Epidemiological studies suggest that regular aerobic physi-
cal activity may be beneficial for both the prevention and
treatment of hypertension, and to lower cardiovascular risk
and mortality. A meta-analysis of RCTs, which rely on self-
reported exercise and are by necessity unblinded, has
shown that aerobic endurance training, dynamic resistance
training and isometric training reduce resting SBP and DBP
by 3.5/2.5, 1.8/3.2 and 10.9/6.2mmHg, respectively, in
general populations [277]. Endurance training, but not other
types of training, reduces BP more in hypertensive partic-
ipants (8.3/5.2mmHg). Regular physical activity of lower
intensity and duration lowers BP less than moderate-inten-
sity or high-intensity training, but is associated with at least
a 15% decrease in mortality in cohort studies [278,279].
This evidence suggests that hypertensive patients should
be advised to participate in at least 30min of moderate-
intensity dynamic aerobic exercise (walking, jogging,
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cycling or swimming) on 5–7 days/week. Performance of
resistance exercises on 2–3 days/week can also be advised.
For additional benefit in healthy adults, a gradual increase
in aerobic physical activity to 300min a week of moderate
intensity or 150min a week of vigorous-intensity aerobic
physical activity, or an equivalent combination thereof, is
recommended [35]. The impact of isometric exercises on BP
and cardiovascular risk is less well established [280].
7.4.7 Smoking cessation
Smoking is a major risk factor for CVD and cancer. Although
the rate of smoking is declining in most European countries,
especially in men, it is still common inmany regions and age
groups, and overall the prevalence remains high at 20–35%
in Europe [281]. There is also evidence suggesting ill-health
effects of passive smoking [282]. Studies using ABPM have
shown that both normotensive subjects anduntreated hyper-
tensive smokers present higher daily BP values than non-
smokers [283]. No chronic effect of smoking has been
reported for officeBP [284],which is not loweredby smoking
cessation. Smoking is second only to BP in contributing risk
to the global burden of disease, and smoking cessation is
probably the single most effective lifestyle measure for the
prevention of CVD, including stroke, myocardial infarction,
and PAD [285,286]. Therefore, the history of tobacco use
should be established at each patient visit and hypertensive
smokers should be counselled regarding smoking cessation.
Brief advice from a physician has a small but significant
effect of 1–3% over and above the unassisted 12-month quit
rate [287]. This can be improved by the use of pharmaco-
logical measures, with varenicline and combination nico-
tine replacement therapy being superior to bupropion or
single nicotine replacement therapy [288]. In comparison
with placebo, nicotine replacement therapy or treatment
with buproprion doubles the chance of quitting, while
varenicline or combination nicotine replacement therapy
triples the chance of quitting. Combining behavioural sup-
port with pharmacotherapy increases the chance of success
by 70–100% compared with brief advice alone [289].
Lifestyle interventions for patients with hypertension or high-normal BP
Recommendations a LevelClass b
Salt restriction to < 5 g per day is
recommended [248,250,255,258].
I A
It is recommended to restrict alcohol con-
sumption to:
• Less than 14 units per week for men.
• Less than 8 units per week for women [35].
I A
It is recommended to avoid binge drinking. III C
Increased consumption of vegetables, fresh
fruits, fish, nuts, and unsaturated fatty acids
(olive oil); low consumption of red meat;
and consumption of low-fat dairy products
are recommended [262,265].
I A
Body-weight control is indicated to avoid
obesity (BMI > 30 kg/m2 or waist circumfer-
ence >102 cm in men and > 88 cm in
women), as is aiming at healthy BMI (about
20–25 kg/m 2)  and waist circumference val-
ues (< 94 cm in men and < 80 cm in women)
to reduce BP and cardiovascular risk 
[262,271,273,290].
I A
Regular aerobic exercise (e.g. at least 30
min of moderate dynamic exercise on 5–7
days per week) is recommended
[262,278,279].
I A
Smoking cessation, supportive care, and
referral to smoking cessation programs are
recommended [286,288,291].
I B
BMI, body mass index; BP, blood pressure.
aClass of recommendation.
bLevel of evidence mostly based on the effect on BP and/or cardiovascular risk profile.
TABLE 20. Compelling and possible contraindications to the use of specific antihypertensive drugs
Contraindications
Drug Compelling Possible
Diuretics (thiazides/thiazide-like,
e.g. chlorthalidone and indapamide)
Gout Metabolic syndrome
Glucose intolerance
 Pregnancy
Hypercalcaemia
Hypokalaemia
Beta-blockers Asthma
Any high-grade sinoatrial or atrioventricular block
 Bradycardia (heart rate <60 beats/min)
Metabolic syndrome
Glucose intolerance
Athletes and physically active patients
Calcium antagonists (dihydropyridines)  Tachyarrhythmia
Heart failure (HFrEF, class III or IV)
 Preexisting severe leg oedema
Calcium antagonists (verapamil, diltiazem) Any high-grade sinoatrial or atrioventricular block
 Severe left ventricular dysfunction
(left ventricular ejection fraction <40%)
 Bradycardia (heart rate <60 beats/min)
Constipation
ACE inhibitors  Pregnancy
 Previous angioneurotic oedema
Hyperkalaemia (potassium >5.5mmol/l)
 Bilateral renal artery stenosis
Women of child-bearing potential
without reliable contraception
ARBs  Pregnancy
Hyperkalaemia (potassium >5.5mmol/l)
 Bilateral renal artery stenosis
Women of child-bearing potential
without reliable contraception
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; HFrEF, heart failure with reduced ejection fraction.
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7.5 Pharmacological therapy for hypertension
7.5.1 Drugs for the treatment of hypertension
Most patientswill require drug therapy in addition to lifestyle
measures to achieve optimal BP control. In the previous
Guidelines, five major drug classes were recommended for
the treatment of hypertension: ACE inhibitors, ARBs, beta-
blockers, CCBs, and diuretics (thiazides and thiazide-like
diuretics such as chlorthalidone and indapamide), based on:
proven ability to reduce BP; evidence from placebo-con-
trolled studies that they reduce cardiovascular events; and
evidence of broad equivalence on overall cardiovascular
morbidity and mortality, with the conclusion that benefit
from their use predominantly derives from BP lowering.
These conclusions have since been confirmed by recent
meta-analyses [1,2,217,292]. These meta-analyses have
reported cause-specific differences on outcomes between
some drugs (e.g. less stroke prevention with beta-blockers,
and less heart failure prevention with CCBs); however,
overall, major cardiovascular outcomes and mortality were
similar with treatment based on initial therapy with all five
major classes of treatment. These Guidelines thus recom-
mend that the same five major classes of drugs should form
the basis of antihypertensive therapy. There are compelling
orpossible contraindications for each class of drug (Table 20)
and preferential use of some drugs for some conditions, as
discussed below. There is also evidence that there are differ-
ences in the persistence and discontinuation rates of the
major drug classes [293,294].
Other classes of drugs have been less widely studied in
event-based RCTs or are known to be associated with a
higher risk of adverse effects [e.g. alpha-blockers, centrally
acting agents, and mineralocorticoid receptor antagonists
(MRAs)]. These are useful additions to the antihypertensive
armamentarium in patients whose BP cannot be controlled
by proven combinations of the aforementioned major
drug classes.
7.5.1.1 Blockers of the renin-angiotensin system
(angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers)
Both ACE inhibitors and ARBs are among the most widely
used classes of antihypertensive drugs. They have similar
effectiveness [295,296] as each other and other major drug
classes on major cardiovascular events and mortality out-
comes [2,292]. ARBs are associated with significantly lower
treatment discontinuation rates for adverse events than
those of all other antihypertensive therapies [297], and
similar rates to placebo [294]. ACE inhibitors and ARBs
should not be combined for the treatment of hypertension
because there is no added benefit on outcomes and an
excess of renal adverse events [298,299]. Dual combination
of RAS blockers also led to the premature cessation of
another trial due to adverse events [291], when a renin
inhibitor, aliskiren, was combined with either an ACE
inhibitor or an ARB in people with diabetes. This result
halted further research into the clinical utility of aliskiren for
BP treatment.
Both ACE inhibitors and ARBs reduce albuminuria more
than other BP-lowering drugs and are effective at delaying
the progression of diabetic and nondiabetic CKD [217]. A
recent meta-analysis shows that RAS blockers are the only
antihypertensive agents for which evidence is available of a
reduced risk of end-stage renal disease [217].
ACE inhibitors and ARBs also appear effective in pre-
venting or regressing HMOD, such as LVH and small artery
remodelling, for an equivalent reduction in BP [292]. Both
drugs reduce incident AF, which may be related to
improved left ventricular function and more effective left
ventricular structural regression [292]. ACE inhibitors and
ARBs are also indicated postmyocardial infarction and in
patients with chronic HFrEF, which are frequent compli-
cations of hypertension.
ACE inhibitors are associated with a small increased risk
of angioneurotic oedema, especially in people of black
African origin and, in such patients, when RAS blockers are
used, an ARB may be preferred.
7.5.1.2 Calcium channel blockers
CCBs are widely used for the treatment of hypertension and
have similar effectiveness as other major drug classes on BP,
major cardiovascular events, and mortality outcomes
[2,292]. CCBs have a greater effect on stroke reduction than
expected for the BP reduction achieved, but may also be
less effective at preventing HFrEF [2,292]. However, in
antihypertensive treatment trials, emergent heart failure is
the event considered. Though clinically a very relevant
event, it is a difficult endpoint to quantify precisely, either
because symptoms and signs are relatively nonspecific or
because oedema due to CCBs may result in misdiagnosis.
Comparison with diuretics may also be difficult because
fluid loss may mask signs and symptoms of incipient heart
failure rather than preventing it. CCBs have also been
compared with other antihypertensive agents in HMOD-
based trials, and are reported to bemore effective than beta-
blockers in slowing the progression of carotid atheroscle-
rosis, and in reducing LVH and proteinuria [17].
CCBs are a heterogeneous class of agents. Most RCTs
demonstrating the benefits of CCBs on outcomes have used
dihydropyridines (especially amlodipine). A smaller num-
ber of RCTs have compared nondihydropyridines (verapa-
mil and diltiazem) with other drugs, and meta-analyses
evaluating the two subclasses (vs. other drugs) have not
shown substantial differences in effectiveness [292].
7.5.1.3 Thiazide/thiazide-like diuretics (e.g.
chlorthalidone and indapamide)
Diuretics have remained the cornerstone of antihyperten-
sive treatment since their introduction in the 1960s. Their
effectiveness in preventing all types of cardiovascular mor-
bidities and mortality has been confirmed in RCTs and
meta-analyses [300]. Diuretics also appear to be more
effective than other drug classes in preventing heart failure
[292]. There has been debate about whether thiazide-like
diuretics such as chlorthalidone and indapamide should be
given preference over classical thiazide diuretics (e.g.
hydrochlorothiazide and bendrofluazide), but their superi-
ority on outcomes has never been tested in head-to-head
RCTs. Chlorthalidone and indapamide have been used in a
number of RCTs showing cardiovascular benefits, and these
2018 ESC/ESH Guidelines for the management of arterial hypertension
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agents are more potent per milligram than hydrochlorothi-
azide in lowering BP, with a longer duration of action
compared with hydrochlorothiazide and no evidence of
a greater incidence of side effects [301]. Lower dose thia-
zide-like diuretics (typical of modern antihypertensive
treatment regimens) also have more evidence from RCTs
demonstrating reductions in cardiovascular events and
mortality, when compared with lower dose thiazide diu-
retics [302]. That said, hydrochlorothiazide, alone or in
combination with a potassium-sparing agent, has also been
used in BP-lowering RCTs, with positive results [303]. A
recent meta-analysis of placebo-controlled studies based
on thiazides, chlorthalidone and indapamide reported sim-
ilar effects on cardiovascular outcomes of the three types of
diuretics [300]. Therefore, in the absence of evidence from
direct comparator trials and recognizing that many of the
approved single-pill combinations (SPCs) are based on
hydrochlorothiazide (see below), we recommend that thia-
zides, chlorthalidone, and indapamide can all be consid-
ered suitable antihypertensive agents. Both thiazide and
thiazide-like diuretics can reduce serum potassium and
have a side effect profile that is less favourable than RAS
blockers, which may account for their association with a
higher rate of treatment discontinuation [293,300]. They
also exhibit dysmetabolic effects that increase insulin resis-
tance and the risk of new-onset diabetes. Potassium may
attenuate these effects [304], and a recent study has shown
that the adverse effect of thiazides on glucose metabolism
may be reduced by the addition of a potassium-sparing
diuretic [305]. Both thiazides and thiazide-like agents are
less effective antihypertensive agents in patients with a
reduced GFR (eGFR <45ml/min) and become ineffective
when the eGFR is less than 30ml/min. In such circum-
stances, loop diuretics such as furosemide (or torasemide)
should replace thiazides and thiazide-like diuretics to
achieve an antihypertensive effect.
7.5.1.4 Beta-blockers
RCTs and meta-analyses demonstrate that when compared
with placebo, beta-blockers significantly reduce the risk of
stroke, heart failure, and major cardiovascular events in
hypertensive patients [300]. When compared with other BP-
lowering drugs, beta-blockers are usually equivalent in
preventing major cardiovascular events, except for less
effective prevention of stroke, which has been a consistent
finding [1,2,217]. It is possible that the difference originated
from small differences in achieved BP (including central
SBP [108] between different drug treatments), to which
cerebrovascular events may be especially sensitive. RCTs
based on HMOD have also indicated that beta-blockers are
somewhat less effective than RAS blockers and CCBs in
preventing or regressing LVH, carotid IMT, aortic stiffness,
and small artery remodelling [17]. In addition, a mortality
benefit in postmyocardial infarction is uncertain in patients
without left ventricular dysfunction [306]. Beta-blockers, as
well as diuretics, and particularly their combination, are
also associated with increased risk of new-onset diabetes in
predisposed subjects (mostly those with the metabolic
syndrome). They also exhibit a somewhat less favourable
side effect profile than that of RAS blockers, with a higher
rate of treatment discontinuation when assessed in real-life
conditions [293].
Beta-blockers have been shown to be particularly useful
for the treatment of hypertension in specific situations such
as symptomatic angina, for heart rate control, postmyocar-
dial infarction, HFrEF, and as an alternative to ACE inhib-
itors or ARBs in younger hypertensive women planning
pregnancy or of child-bearing potential.
Finally, beta-blockers are not a homogeneous class. In
recent years, the use of vasodilating beta-blockers – such as
labetalol, nebivolol, celiprolol, and carvedilol – has
increased. Studies on nebivolol have shown that it has
more favourable effects on central BP, aortic stiffness,
endothelial dysfunction, and so on. It has no adverse effect
on the risk of new-onset diabetes and a more favourable
side effect profile than classical beta-blockers [307,308],
including less adverse effects on sexual function. Bisopro-
lol, carvedilol and nebivolol have been shown to improve
outcomes in RCTs in heart failure [136]; however, there are
no RCTs reporting patient outcomes with these beta-block-
ers in hypertensive patients.
7.5.1.5 Other antihypertensive drugs
Centrally active drugs were widely used in the earliest
decades of antihypertensive treatment when other treat-
ments were not available, but are less frequently used now,
principally because of their poorer tolerability relative to
the newer major classes of drugs. The alpha-blocker dox-
azosin was effective in the Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT) as third-line therapy (with no
increase in the risk of heart failure) [309], and was more
effective than placebo but less effective than spironolactone
at lowering BP in resistant hypertension in the Prevention
And Treatment of Hypertension With Algorithm-based
therapY-2 (PATHWAY-2) study [310]. Alpha-blockers may
also be required in specific indications (e.g. the treatment of
symptomatic prostatic hypertrophy). Antihypertensive
drugs, other than themajor classes already discussed above,
are no longer recommended for the routine treatment of
hypertension, and are primarily reserved for add-on ther-
apy in rare cases of drug-resistant hypertension where all
other treatment options have failed.
7.5.2 Drug treatment strategy for hypertension
Guidelines have generated a variety of different strategies to
initiate and escalate BP-lowering medication to improve BP
control rates. In previous Guidelines, the emphasis was on
initial use of different monotherapies, increasing their dose,
or substituting for another monotherapy. However, increas-
ing the dose of monotherapy produces little additional BP
lowering and may increase the risk of adverse effects, while
switching from one monotherapy to another is frustrating,
time consuming, and often ineffective. For these reasons,
more recent Guidelines have increasingly focused on the
stepped-care approach, initiating treatment with different
monotherapies and then sequentially adding other drugs
until BP control is achieved. Despite this, BP control rates
have remained poor worldwide. As shown by recent obser-
vations, irrespective of the world region, whether high-
income or low-income economies, or the level of sophisti-
cation of healthcare provision, only 40% of patients with
Williams et al.
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hypertension are treated; of these, only 35% are controlled
to a BP of less than 140/90mmHg [12]. This failure to
achieve BP control in most hypertensive patients, despite
numerous iterations of previous Guidelines, suggests that
these treatment strategies are not working and that a
different approach is needed. This Task Force believes that
one of the most important issues to address in these Guide-
lines is ‘how do we improve BP control in treated patients?’.
This has become an even more pressing matter because,
based on new evidence, current Guidelines are recom-
mending more stringent BP targets (on-treatment values
of 130/80mmHg in the general population and 140/
90mmHg in older hypertensive people), which will make
the achievement of BP control even more challenging.
Several reasons need to be considered to identify why
the current treatment strategy has failed to achieve better BP
control rates:
1. Efficacy of pharmacological therapies. Are the
best available treatments, in whatever combination,
incapable of controlling BP in most patients? The
evidence from RCTs demonstrating that BP control
can be achieved in most recruited patients, and that
no more than 5–10% of these patients exhibit resis-
tance to the selected treatment regimen, suggests that
ineffective drug therapy is not the source of
the problem.
2. Physician or treatment inertia. (i.e. failure to
adequately uptitrate treatment). Evidence suggests
that inertia [311] contributes to suboptimal BP control,
with many patients remaining on monotherapy and/
or suboptimal doses, despite inadequate BP control
[12].
3. Patient adherence to treatment. Evidence is accu-
mulating that adherence is a much more important
factor than previously recognized. Studies using urine
or blood assays for the presence or absence of
medication have shown that adherence to treatment
is low. This is supported by studies in the general
population in which adherence to treatment, based
on prescription refilling, was <50% of the treatment
in half of the patients [312]. Poor adherence has also
been shown to be associated with increased cardio-
vascular risk in various studies [313] (see Section 10).
4. Insufficient use of combination treatment. BP is
a multiregulated variable depending on many com-
pensating pathways. Consequently, combinations of
drugs, working through different mechanisms, are
required to reduce BP in most people with hyperten-
sion. Thus, monotherapy is likely to be inadequate
therapy inmost patients. Indeed, almost all patients in
RCTs have required combinations of drugs to control
their BP [314].
5. Complexity of current treatment strategies.
There is also evidence that adherence to treatment
is adversely affected by the complexity of the pre-
scribed treatment regimen. In a recent study, adher-
ence to treatment was strongly influenced by the
number of pills that a patient was prescribed for
the treatment of hypertension [315]. Nonadherence
was usually less than 10% with a single pill, rising to
20%with two pills, 40%with three pills, and very high
rates of partial or complete nonadherence in patients
receiving five or more pills [315].
The above considerations suggest that the most effective
evidence-based treatment strategy to improve BP control is
one that: encourages the use of combination treatment in
most patients, especially in the context of lower BP targets;
enables the use of SPC therapy for most patients, to improve
adherence to treatment; and follows a treatment algorithm
that is simple, applies to all patients, and is pragmatic, with
the use of SPC therapy as initial therapy for most patients,
except those with BP in the high–normal range and in frail
older patients (see below).
7.5.2.1 Drug combinations for hypertension
treatment
Among the large number of RCTs of antihypertensive
therapy, only a few have directly compared different
two-drug combinations, with systematic use of the two
combinations in both arms. In other trials, treatment was
initiated using monotherapy in either arm and another drug
(and sometimes more than one drug) was added, usually in
a nonrandomized fashion, according to a prespecified
treatment algorithm. In a few trials, the design precluded
the use of what might be considered optimal combinations
becausemultiple monotherapies were being evaluated [e.g.
the Antihypertensive and Lipid-Lowering Treatment to Pre-
vent Heart Attack Trial (ALLHAT), where the add-on ther-
apy to either a diuretic, CCB, ACE inhibitor, or alpha-
blocker was a beta-blocker, clonidine, or reserpine] [316].
With this caveat, Table 21 shows that a variety of drug
combinations have been used in at least one active arm of
placebo-controlled trials and have been associated with
significant benefit on major cardiovascular events. In trials
comparing different regimens (Table 22), all combinations
have been used in a larger or smaller proportion of patients,
without major differences in benefits. The only exceptions
are two trials in which a large proportion of the patients
received either an ARB–diuretic combination [317] or CCB–
ACE inhibitor combination [318], with both regimens being
superior to a beta-blocker–diuretic combination in reduc-
ing cardiovascular outcomes. However, in six other trials
(with seven comparisons), beta-blockers followed by diu-
retics or diuretics followed by beta-blockers were not
associated with a significantly different risk of any cardio-
vascular outcome [233,234,316,319–321], and the beta-
blocker diuretic combination was significantly more effec-
tive than placebo in three trials [322–324]. It should be
mentioned that the beta-blocker–diuretic combination may
result in more cases of new-onset diabetes in susceptible
individuals compared with other combinations [325]. A
rarely used combination of thiazide and potassium-sparing
diuretic (amiloride) has also been shown to be equivalent to
CCB-based treatment [310,326], and was recently reported
to be associated with fewer metabolic adverse effects
compared with thiazide alone (less hypokalaemia and
glucose intolerance) [305].
Three outcome trials directly compared two different
combinations, each involving a combination of a RAS
blocker (ACE inhibitor or ARB) and a CCB with other
combinations. In the Avoiding Cardiovascular Events
2018 ESC/ESH Guidelines for the management of arterial hypertension
Journal of Hypertension www.jhypertension.com 1987
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 22. Major drug combinations used in trials of antihypertensive treatment in a stepped approach or as a randomized combination
(combinations vs. other combinations)
Trial Comparator Type of patients SBP difference (mmHg) Outcomes [change in relative risk (%)]
ACE inhibitor and diuretic combination
CAPPP [335] BB þ diuretic Hypertensive þ3 þ5% cardiovascular events (NS)
ACCOMPLISH [327] ACE inhibitor þ CCB Hypertensive with risk factors þ1 þ21% cardiovascular events (P <0.001)
ARB and diuretic combination
LIFE [317] BB þ diuretic Hypertensive with LVH –1 –26% stroke (P <0.001)
CCB and diuretic combination
ELSA [336] BB þ diuretic Hypertensive 0 NS difference in cardiovascular events
CONVINCE [233] BB þ diuretic Hypertensive with risk factors 0 NS difference in cardiovascular events
VALUE [337] ARB þ diuretic High-risk hypertensive –2.2 –3% cardiovascular events (P¼NS)
COPE [338] CCB þ BB Hypertensive þ0.7 NS difference in cardiovascular events or stroke
ACE inhibitor and CCB combination
NORDIL [339] BB þ diuretic Hypertensive þ3 NS difference in cardiovascular events
INVEST [340] BB þ diuretic Hypertensive with CAD 0 NS difference in cardiovascular events
ASCOT [318] BB þ diuretic Hypertensive with risk factors –3 –16% cardiovascular events (P <0.001)
ACCOMPLISH [327] ACE inhibitor þ diuretic Hypertensive with risk factors –1 –21% cardiovascular events (P <0.001)
Beta-blocker and diuretic combination
CAPPP [335] ACE inhibitor þ diuretic Hypertensive –3 –5% cardiovascular events (P¼NS)
LIFE [317] ARB þ diuretic Hypertensive with LVH þ1 þ26% stroke (P <0.001)
ALLHAT [316] ACE inhibitor þ BB Hypertensive with risk factors –2 NS difference in cardiovascular events
ALLHAT [316] CCB þ BB Hypertensive with risk factors –1 NS difference in cardiovascular events
CONVINCE [233] CCB þ diuretic Hypertensive with risk factors 0 NS difference in cardiovascular events
NORDIL [339] ACE inhibitor þ CCB Hypertensive –3 NS difference in cardiovascular events
INVEST [340] ACE inhibitor þ CCB Hypertensive with CAD 0 NS difference in cardiovascular events
ASCOT [318] ACE inhibitor þ CCB Hypertensive with risk factors þ3 þ16% cardiovascular events (P < 0.001)
Beta-blocker and CCB combination
COPE [329] ARB þ CCB Hypertensive þ0.8 NS difference in cardiovascular events or stroke
ARB and CCB combination
COPE [329] CCB þ diuretic Hypertensive –0.7 NS difference in cardiovascular events or stroke
COPE [329] CCB þ BB Hypertensive –0.8 NS difference in cardiovascular events or stroke
COLM [328] ARB þ diuretic Older hypertensive 0 NS difference in cardiovascular events
ACCOMPLISH, Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension; ACE, angiotensin-converting enzyme; ALLHAT,
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ARB, angiotensin receptor blocker; ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; BB, beta-blocker;
CAD, coronary artery disease; CAPPP, Captopril Prevention Project; CCB, calcium channel blocker; COLM, Combination of OLMesartan and a calcium channel blocker or diuretic in
Japanese elderly hypertensive patients; CONVINCE, Controlled Onset Verapamil Investigation of Cardiovascular End Points; COPE, Combination Therapy of Hypertension to Prevent
Cardiovascular Events; ELSA, European Lacidipine Study on Atherosclerosis; INVEST, International Verapamil-Trandolapril Study; LIFE, Losartan Intervention For Endpoint reduction in
hypertension; LVH, left ventricular hypertrophy; NORDIL, Nordic Diltiazem; NS, non-significant; SBP, systolic blood pressure; VALUE, Valsartan Antihypertensive Long-term Use Evaluation.
TABLE 21. Major drug combinations used in trials of antihypertensive treatment in a stepped approach or as a randomized combination
(combinations vs. placebo or monotherapy)
Trial Comparator Type of patients
SBP difference
(mmHg)
Outcomes
[change in relative risk (%)]
ACE inhibitor and diuretic combination
PROGRESS [27] Placebo Previous stroke or TIA –9 –28% strokes (P <0.001)
ADVANCE [229] Placebo Diabetes –5.6 –9% micro/macrovascular events (P¼0.04)
HYVET [220] Placebo Hypertensive; 80 years –15 –34% cardiovascular events (P <0.001)
ARB and diuretic combination
SCOPE [330] Diuretic þ placebo Hypertensive; 70 years –3.2 –28% nonfatal strokes (P¼0.04)
CCB and diuretic combination
FEVER [331] Diuretic þ placebo Hypertensive –4 –27% cardiovascular events (P <0.001)
ACE inhibitor and CCB combination
Syst-Eur [332] Placebo Older with ISH –10 –31% cardiovascular events (P <0.001)
Syst-China [333] Placebo Older with ISH –9 –37% cardiovascular events (P <0.004)
Beta-blocker and diuretic combination
Coope and Warrender [322] Placebo Older hypertensive –18 –42% strokes (P <0.03)
SHEP [323] Placebo Older with ISH –13 –36% strokes (P <0.001)
STOP-H [324] Placebo Older hypertensive –23 –40% cardiovascular events (P¼0.003)
STOP-H 2 [334] ACE inhibitor or conventional
antihypertensive
Hypertensive 0 NS difference in cardiovascular events
Combination of two RAS blockers/ACE inhibitor R ARB or RAS blocker R renin inhibitor)
ONTARGET [299] ACE inhibitor or ARB High-risk patients More renal events
ALTITUDE [291] ACE inhibitor or ARB High-risk diabetic patients More renal events
ACE, angiotensin-converting enzyme; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and Diamicron – MR Controlled Evaluation; ALTITUDE, Aliskiren Trial in Type 2
Diabetes Using Cardiovascular and Renal Disease Endpoints; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; FEVER, Felodipine Event Reduction; HYVET, Hypertension
in the Very Elderly Trial; ISH, isolated systolic hypertension; NS, non-significant; ONTARGET, Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint trial;
PROGRESS, perindopril protection against recurrent stroke study; RAS, renin-angiotensin system; SBP, systolic blood pressure; SCOPE, Study on Cognition and Prognosis in the Elderly;
SHEP, Systolic Hypertension in the Elderly Program; STOP-H, Swedish Trial in Old Patients with Hypertension; Syst-China, Systolic Hypertension in China; Syst-Eur, Systolic Hypertension in
Europe; TIA, transient ischaemic attack.
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Through Combination Therapy in Patients Living With
Systolic Hypertension (ACCOMPLISH) trial, the ACE inhibi-
tor–CCB combination was superior to the same ACE inhib-
itor in combination with a thiazide diuretic at preventing
major cardiovascular outcomes, despite no apparent BP
difference between the two arms [327]. This finding was not
confirmed in the Combination of OLMesartan and a CCB
or diuretic in Japanese older hypertensive patients
(COLM)[328] and Combination Therapy of Hypertension
to Prevent Cardiovascular Events (COPE) trials [329], which
reported no significant differences in cardiovascular events
when a RAS blocker-CCB combination was compared with
a RAS blocker–thiazide diuretic combination, but both of
these trials had insufficient statistical power.
Based on the results of outcome RCTs and recent meta-
analyses, and evidence of BP-lowering effectiveness, all
five major drug classes can, in principle, be combined with
one another, except for ACE inhibitors and ARBs, whose
concomitant use may lead to no additional benefit but
increased adverse effects and is thus discouraged. We
recommend that the treatment of hypertension should be
preferentially based on combinations of an ACE inhibitor or
ARB with a CCB and/or a thiazide/thiazide-like diuretic.
These combinations are nowwidely available in a single pill
and in a range of doses, facilitating simplification of treat-
ment, flexible prescribing, and uptitration from lower to
higher doses. Combination therapy that includes an ACE
inhibitor or ARB with either a CCB or thiazide/thiazide-like
diuretic are complementary because both CCBs or diuretics
activate the RAS, which will be counteracted by their
combination with an ACE inhibitor or ARB. These combi-
nations will also limit potential adverse effects associated
with diuretic or CCB monotherapy, reducing the risk of
hypokalaemia due to diuretics and reducing the prevalence
of peripheral oedema due to CCBs. These combinations
also ensure that the RAS is inhibited as part of the treatment
strategy, which is an important consideration for many
patient groups (e.g. diabetes, LVH, proteinuria).
Other combinations, such as CCB þ diuretic, also have
evidence from RCTs supporting their use [233,329]. These
are much less widely available as SPCs and do not include
blockade of the RAS, which may be desirable in many
patient groups.
Beta-blockers in combination should be preferentially
used when there is a specific clinical indication for their use
(e.g. in patients with symptomatic angina, for patients
requiring heart rate control, postmyocardial infarction,
chronic HFrEF, and as an alternative to ACE inhibitors or
ARBs in younger hypertensive women planning pregnancy
or of child-bearing potential). SPCs of beta-blockers with an
ACE inhibitor, CCB, or diuretic are available.
7.5.2.2 Rationale for initial two-drug combination
therapy for most patients
As discussed above and with the emphasis in these Guide-
lines on achieving a BP target in most patients of less than
130/80mmHg, the majority of patients will require combi-
nation therapy. Initial combination therapy is invariably
more effective at BP lowering than monotherapy, indeed
even low-dose combination therapy is usually more effec-
tive than maximal dose monotherapy [341]. Furthermore,
the combination of medications targeting multiple mecha-
nisms, such as blocking the RAS as well as inducing vaso-
dilatation and/or diuresis, reduces the heterogeneity of the
BP response to initial treatment and provides a steeper dose
response than is observed with escalating doses of mono-
therapy [342]. Finally, two-drug combinations as initial
therapy have been shown to be safe and well tolerated,
with no or only a small increase in the risk of hypotensive
episodes [341], even when given to patients with grade 1
hypertension [343], in which adverse events leading to
treatment discontinuation are infrequent [294].
Although no RCT has compared major cardiovascular
outcomes between initial combination therapy and mono-
therapy, observational evidence suggests that the time
taken to achieve BP control is an important determinant
of clinical outcomes, especially in higher risk patients, with
a shorter time to control associated with lower risk [344].
Furthermore, there is evidence from the more general
hypertensive population that, compared with patients on
initial monotherapy, those who start treatment with a two-
drug combination exhibit more frequent BP control after 1
year [341,345]. This is probably because initial combination
treatment is associated with a better long-term adherence to
the prescribed treatment regimen [346] and because initial
two-drug administration prevents therapeutic inertia (i.e.
reluctance or failure to upgrade treatment from one to more
drugs when BP is uncontrolled) [347]. Studies from very
large hypertension cohorts in usual care have shown that
initial combination treatment results in reduced treatment
discontinuation and a lower risk of cardiovascular events
than initial monotherapy followed by the traditional
stepped-care approach [312,346]. The usual-care settings
for these studies may be especially relevant to study the true
impact of treatment strategies on adherence and therapeu-
tic inertia, because this can be difficult to replicate in a
conventional RCT in which the motivation of the clinical
staff and patients, and the monitoring of treatment, are very
different from usual care. In this regard, the outcome of
these real-life studies of the impact of initial combination
therapy on adherence, BP control, and cardiovascular out-
comes may be especially relevant [348].
A consideration in the current Guidelines was to persist
with the current stepped-care approach to BP treatment,
which has been interpreted as recommending monother-
apy as initial therapy for most patients, reflecting current
practice. In fact, the previous Guidelines did acknowledge
the possibility of initial combination therapy for patients
with grade 2 or 3 hypertension, or patients at high or very
high risk. In other words, initial monotherapy was only
recommended for grade 1 hypertension and low-risk or
moderate-risk patients. Thus, in reality, the shift in empha-
sis in this new guidance is subtle. However, normalizing the
concept of initiating therapy with a two-drug combination
for most patients with hypertension is likely to have a major
effect on clinical practice and the speed and quality of BP
control. We acknowledge that some low-risk or moderate-
risk patients with grade 1 hypertension may achieve their
BP target with monotherapy, but this is unlikely in patients
with an initial SBP more than 150mmHg who would
require a BP reduction of at least 20mmHg. Moreover,
the possibility of starting with a low-dose combination of
2018 ESC/ESH Guidelines for the management of arterial hypertension
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two antihypertensive drugs, even in grade 1 hypertensive
patients with low–moderate-risk, is supported by the
reduction of cardiovascular events obtained by combina-
tion therapy in the upper tertile (grade 1 hypertension) in
the HOPE-3 trial [212]. In patients with high–normal BP and
a high cardiovascular risk or in frail older patients, treatment
initiation with monotherapy may be appropriate in the
former because only a small BP reduction may be required
to achieve the BP target, and in the latter because in older
patients baroreflex sensitivity is frequently impaired and the
risk of hypotension is greater.
7.5.2.3 Uptitration of treatment to three-drug
combination therapy
Studies suggest that two-drug combination therapy will
control BP in approximately two-thirds of patients [341].
For patients whose BP is not controlled by two-drug com-
bination therapy, the logical option is to increase treatment
to three-drug combination therapy: usually a RAS blocker, a
CCB, and a diuretic. Studies suggest that a three-drug
combination should control BP in more than 80% of
patients [349,350]. This rate of BP control is much greater
than the current rate of BP control across Europe in treated
hypertensive patients. We do not recommend three-drug
combinations as initial therapy.
7.5.2.4 Rationale for single-pill combination therapy
as usual therapy for hypertension
The 2013 ESH/ESC Guidelines [17] favoured the use of
combinations of two antihypertensive drugs in a single pill,
because reducing the number of pills to be taken daily
improves adherence and increases the rate of BP control
[346,351]. This recommendation is endorsed by the current
Guidelines. It is further supported by data from recent
studies using various methods to assess adherence to
treatment, including the quantification of antihypertensive
drugs in urine and blood [352,353], and estimates such as
pill counting or prescription refills, which, although indi-
rect, allow the measurement of adherence on a prolonged
basis, thereby accounting for its time-variable nature
[347,354]. These studies have unequivocally shown a direct
inverse relationship between the number of pills and the
likelihood of adherence. This approach is now facilitated by
the availability of several SPCs with a range of dosages,
which eliminates the often-stated disadvantage of SPC
therapy (i.e. the inability to increase the dose of one drug
independently of the other). It is also convenient that the
most widely available SPCs mirror the major drug class
combinations recommended by these Guidelines. The
major advantage of an SPC as the usual therapeutic
approach for hypertension is that patients can progress
from 1, 2, or 3 drug treatments while remaining on a simple
treatment regimen with a single pill throughout, increasing
the likelihood of adherence to therapy and achieving BP
control. Such an approach has the potential to double BP
control rates in treated patients from the present low level
of 40%. Although, at present, the availability of two-drug
SPCs is largely limited to a RAS blocker with either a CCB or
diuretic, it would be desirable to see the development of an
expanded range of low-cost SPCs in different drug formu-
lations, tailored to different clinical requirements.
Polypills have also emerged as SPCs (i.e. a fixed-dose
combination of one or more antihypertensive agents with a
statin and low-dose aspirin), with the rationale that hyper-
tensive patients are often at sufficient cardiovascular risk to
benefit from statin therapy. Studies of bioequivalence sug-
gest that when combined in the polypill, different agents
maintain all or most of their expected effect [355]. Further-
more, studies performed in the setting of secondary preven-
tion, particularly in patients with a previous myocardial
infarction, have shown that use of the polypill is accompa-
nied by a better adherence to treatment compared with
separate medications [356]. The ESC Guidelines for the
management of myocardial infarction suggest that the use
of the polypill may be considered to improve long-term
adherence to prescribed therapy (class IIb, level B) [353].
No data are available for primary prevention in patients with
hypertension. Nevertheless, the advantage of treatment sim-
plification and adherence suggests that use of the polypill
may be considered in patients with hypertension as substi-
tution therapy, when the need and effectiveness of each
polypill component has been previously established by their
administration in separate tablets [355].
7.5.2.5 Further uptitration of antihypertensive
therapy
When BP remains uncontrolled with three-drug combina-
tion therapy, the patient is classified as having resistant
hypertension, assuming that secondary causes of hyperten-
sion and poor adherence to treatment have been excluded,
and that the elevation in BP has been confirmed by
repeated office BP measurement, ABPM, or HBPM (see
Section 8.1). Such patients should be considered for spe-
cialist evaluation. Additional treatment options include the
addition of low-dose spironolactone (25–50mg daily)[310]
or another additional diuretic therapy [higher-dose amilor-
ide 10–20mg daily [357], higher dose thiazide or thiazide-
like diuretics, loop diuretics in patients with significant
renal impairment (eGFR <45ml/min/m2), beta-blockers,
alpha-blockers, centrally acting agents (e.g. clonidine), or,
rarely, minoxidil] (see Section 8.1).
7.5.3 The drug treatment algorithm for
hypertension
Reflecting on the evidence above, and recognizing the
urgent need to address the factors contributing to the poor
control of BP in treated hypertensive patients (see Section
7.5.1), this drug treatment algorithm has been developed to
provide a simple and pragmatic treatment recommendation
for the treatment of hypertension, based on a few key
recommendations:
1. The initiation of treatment in most patients with an
SPC comprising two drugs, to improve the speed,
efficiency, and predictability of BP control.
2. Preferred two-drug combinations are a RAS blocker
with a CCB or a diuretic. A beta-blocker in combina-
tion with a diuretic or any drug from the other major
classes is an alternative when there is a specific
indication for a beta-blocker, for example angina,
postmyocardial infarction, heart failure, or heart
rate control.
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3. Use monotherapy for low-risk patients with stage 1
hypertensionwhose SBP is<150mmHg, very high-risk
patients with high–normal BP, or frail older patients.
4. The use of a three-drug SPC comprising a RAS
blocker, a CCB, and a diuretic if BP is not controlled
by a two-drug SPC.
5. The addition of spironolactone for the treatment of
resistant hypertension, unless contraindicated (see
Section 8.1.4).
6. The use of other classes of antihypertensive drugs in
the rare circumstances in which BP is not controlled
by the above treatments.
7. Information on availability and recommended doses
of individual drugs, as well as SPCs and free combi-
nations, can be found in national formularies.
This treatment algorithm focuses on the five major
classes of drugs: ACE inhibitors, ARBs, CCBs, thiazide or
thiazide-like diuretics, and beta-blockers. The algorithm
recommends initial therapy for most patients with a two
drug-combination, ideally as an SPC. Variations from the
core drug treatment algorithm for uncomplicated hyperten-
sion shown in Figure 4 are specified in Figures 5–8.
Recommended BP target ranges for treated hypertension
are shown in Table 23.
The drug treatment strategy for patients with hyperten-
sion should be based on the algorithm shown (Figures 4–
8), unless there are contraindications to these drugs (Table
20), or concomitant conditions or diseases are present that
require specific modification of the drugs, as outlined in the
recommendations below.
7.6 Device-based hypertension treatment
Various device-based therapies have emerged, principally
targeted at the treatment of resistant hypertension. These
are discussed below.
7.6.1 Carotid baroreceptor stimulation (pacemaker
and stent)
Carotid baroreceptor stimulation or baroreflex amplifica-
tion therapy – externally via an implantable pulse generator
or internally via an implantable device designed to increase
the strain on the carotid bulb – can lower BP in patients
with resistant hypertension. An RCT with the first genera-
tion of an implantable pulse generator showed sustained
BP-lowering efficacy (and sympathetic nervous system
inhibition), but with some concerns about procedural
and longer-term safety [358]. A second-generation unilateral
device has been developed to improve safety and sustained
efficacy. A propensity score-matched comparison of the
first-generation and second-generation systems revealed
that BP at 12 months post-implantation was similar, with
a better safety profile for the second-generation device
[359]. However, no RCT is currently available with this
second-generation device. Another consideration is that
implantation is costly and requires a complex surgical
intervention. This has led to the development of an endo-
vascular carotid baroreflex amplification device using a
dedicated stent-like device designed to stretch the carotid
bulb and increase baroreflex stimulation. Preliminary data
in humans have shown evidence of BP-lowering efficacy of
this new approach [360], but data from ongoing RCTs are
needed to definitively understand its longer-term efficacy
and safety.
Drug treatment strategy for hypertension
Recommendations Classa Levelb
Among all antihypertensive drugs, ACE inhibitors, ARBs, beta-blockers, CCBs, and diuretics (thiazides and thiazide-like
drugs such as chlorthalidone and indapamide) have demonstrated effective reduction of BP and cardiovascular events in
RCTs, and thus are indicated as the basis of antihypertensive treatment strategies [2].
I A
Combination treatment is recommended for most hypertensive patients as initial therapy. Preferred combinations should
comprise a RAS blocker (either an ACE inhibitor or an ARB) with a CCB or diuretic. Other combinations of the five major
classes can be used [233,318,327,329,341–345].
I A
It is recommended that beta-blockers are combined with any of the other major drug classes when there
are specific clinical situations, e.g. angina, post-myocardial infarction, heart failure, or heart rate control [300,341].
I A
It is recommended to initiate an antihypertensive treatment with a two-drug combination, preferably in an SPC.
Exceptions are frail older patients and those at low risk and with grade 1 hypertension (particularly if SBP is
< 150 mmHg) [342,346,351].
I B
It is recommended that if BP is not controlledc with a two-drug combination, treatment should be increased to a
three-drug combination, usually a RAS blocker with a CCB and a thiazide/thiazide-like diuretic, preferably
as an SPC [349,350].
I A
It is recommended that if BP is not controlledcwith a three-drug combination, treatment should be increased by the addition
of spironolactone or, if not tolerated, other diuretics such as amiloride or higher doses of other diuretics, a beta-blocker, or
an alpha-blocker [310].
I B
The combination of two RAS blockers is not recommended [291,298,299]. III A
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; RAS, renin-angiotensin system; RCT, randomized controlled
trial; SBP, systolic blood pressure; SPC, single-pill combination.
aClass of recommendation.
bLevel of evidence.
cAdherence should be checked.
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7.6.2 Renal denervation
The rationale for renal denervation lays with the impor-
tance of sympathetic nervous system influences on renal
vascular resistance, renin release and sodium reabsorption
[361], the increased sympathetic tone to the kidney and
other organs in hypertensive patients [361], and the pressor
effect of renal afferent fibres documented in experimental
animals [362]. Catheter-based renal denervation using
radiofrequency, ultrasound, or perivascular injection of
neurotoxic agents such as alcohol has been introduced
as a minimally invasive treatment option for patients with
resistant hypertension [363]. However, the clinical evidence
in support of renal denervation as an effective BP-lowering
technique is conflicting. Several observational studies and
national and international registries [364] support the BP-
lowering efficacy of renal denervation originally reported in
the Symplicity HTN-1 and HTN-2 trials [365]. A reduction in
sympathetic activity following renal denervation has also
Initial therapy
Dual combination
Step 2
Triple combination
Step 3
Triple combination +
spironolactone or 
other drug
Beta-blockers
Consider beta-blockers at any treatment step, when there is a specific 
indication for their use, e.g. heart failure, angina, post-MI, atrial fibrillation, 
or younger women with, or planning, pregnancy
Consider monotherapy in
low risk grade 1 hypertension
(systolic BP <150mmHg), or in
very old ( 80 years) or frailer patients
Consider referral to a specialist centre
for further investigation
1 Pill ACEi or ARB + CCB or diuretic
ACEi or ARB + CCB + diuretic
Resistant hypertension
Add spironolactone (25–50 mg o.d.)
or other diuretic, alpha-blocker or beta-blocker
2 Pills
1 Pill
FIGURE 4 Core drug treatment strategy for uncomplicated hypertension. The core algorithm is also appropriate for most patients with HMOD, cerebrovascular
disease, diabetes, or PAD. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; HMOD, hypertension-mediated
organ damage; MI, myocardial infarction; o.d., once daily; PAD, peripheral artery disease.
Initial therapy
Dual combination
Step 2
Triple combination
Step 3
Triple combination +
spironolactone or 
other drug
very old ( 80 years) or frailer patients
Consider initiating therapy 
when systolic BP is 
130 mmHg in these very 
high risk patients with 
established CVD
Consider referral to a specialist centre
for further investigation
1 Pill ACEi or ARB + beta-blocker or CCB 
or CCB + diuretic or beta-blocker
or beta-blocker + diuretic
Triple combination of above
Resistant hypertension
Add spironolactone (25–50 mg o.d.)
or other diuretic, alpha-blocker or beta-blocker
2 Pills
1 Pill
Consider monotherapy in low risk
grade 1 hypertension
(systolic BP <150mmHg), or in
FIGURE 5 Drug treatment strategy for hypertension and coronary artery disease. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; o.d., once daily.
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been observed [366]. However, two RCTs with a sham
procedure control [367,368] failed to document the superi-
ority of renal denervation compared with the sham proce-
dure in reducing BP, but did confirm the safety of the
procedure. Another RCT, the Renal Denervation for Hyper-
tension (DENERHTN) trial [369], showed the superiority of
renal denervation in combination with optimized pharma-
cotherapy compared with pharmacotherapy alone. The
PRAGUE-15 study [370] documented similar effects
between renal denervation and optimized pharmacother-
apy (mainly by adding spironolactone) with respect to BP-
lowering efficacy; however, the latter was associated with
more side effects and high discontinuation rates. Beyond
resistant hypertension, interim data in the first 80 patients
treated with renal denervation but with no background
antihypertensive therapy showed a modest effect of renal
denervation vs. sham control on 24 h ambulatory BP after 3
months [366]. This study is ongoing.
Evaluating the efficacy of renal denervation has been
challenging because theprocedure needs to be applied to a
population with a high probability of BP response. This is
complicated by the complex pathophysiology of hyper-
tension, the lack of clinically applicable measures of sym-
pathetic activity, the absence of predictors of the long-term
BP response following renal denervation, and the absence
of reliable markers of procedural success to immediately
establish whether denervation has been achieved [371].
There is evidence indicating that isolated systolic hyper-
tension, characterized by increased aortic stiffness, is asso-
ciated with a limited response to renal denervation
[372,373] and baroreceptor stimulation (see above). Except
for rare problems related to the catheterization procedure
FIGURE 6 Drug treatment strategy for hypertension and chronic kidney disease. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; o.d., once daily. aCKD
is defined as an eGFR <60ml/min/1.72m2 with or without proteinuria. bUse loop diuretics when eGFR is <30ml/min/1.72m2, because thiazide/thiazide-like diuretics are
much less effective/ineffective when eGFR is reduced to this level. cCaution: risk of hyperkalaemia with spironolactone, especially when eGFR is <45ml/min/1.72m2 or
baseline Kþ 4.5mmol/l.
FIGURE 7 Drug treatment strategy for hypertension and hear failure with reduced ejection fraction. Do not use nondihydropyridine CCBs (e.g. verapamil or
diltiazem). ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; ESC, European Society of Cardiology; HFrEF,
heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist. aConsider an angiotensin receptor/neprilysin inhibitor instead of ACEi or ARB per
ESC Heart Failure Guidelines [136]. bDiuretic refers to thiazide/thiazide-like diuretic. Consider a loop diuretic as an alternative in patients with oedema. cMRA (spironolac-
tone or eplerenone).
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(access site complications, vessel dissection, etc.), no
major complications or deterioration of renal function have
been reported.
Major uncertainties remain as to the clinical role of
renal denervation outside of clinical studies, which
should be performed in carefully selected patients at
specialist hypertension centres and by experienced
operators.
7.6.3 Creation of an arteriovenous fistula
The central iliac arteriovenous anastomosis creates a
fixed-calibre (4mm) conduit between the external iliac
artery and vein using a stent-like nitinol device (ROX
arteriovenous coupler) [374,375]. Device deployment
can be verified and is reversible, resulting in the diversion
of arterial blood (0.8–1 l/min) into the venous circuit with
immediate, verifiable reductions in BP [374,375]. The BP-
lowering effect of arteriovenous anastomosis was first
observed in a study of patients with chronic obstructive
pulmonary disease (COPD), in whom a moderate
improvement in the 6min walking test was shown [376].
In the ROX CONTROL HTN trial, patients with resistant
hypertension were randomized to receive either standard
care or insertion of an arteriovenous coupler in combina-
tion with standard care [377]. At 6 months, office and
ambulatory BP were significantly reduced in the coupler
group compared with the control group. Some important
safety aspects need to be considered. Ipsilateral venous
stenosis, which needed venoplasty and/or stenting,
occurred in 29% of patients. There were no reports of
right heart failure or high-output cardiac failure after
device implantation over the short-term, but longer follow-
up is clearly needed [377,378].
7.6.4 Other devices
The carotid body is located at the bifurcation of the com-
mon carotid. It is innervated by nerve fibres from the vagus
nerve through the cervical ganglion and the carotid sinus
nerve [379]. Stimulation of the carotid body drives sympa-
thetic tone, resulting in an increase in BP and minute
Initial therapy
Dual combination
Step 2
Triple combination
Add oral anticoagulation when indicated according to the CHA2DS2-VASc score, unless contraindicated.
Routine combination of beta-blockers with non-dihydropyridine CCBs (e.g. verapamil or diltiazem) is not recommended due to a potential
marked reduction in heart rate.
ACEi or ARB + beta-blocker
or non-DHP CCBa,
or beta-blocker + CCB
ACEi or ARB + beta-blocker
+ DHP CCB or diuretic
or beta-blocker + DHP CCB + diuretic
a
FIGURE 8 Drug treatment strategy for hypertension and atrial fibrillation. ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin
receptor blocker; CCB, calcium channel blocker; CHA2DS2-VASc, Cardiac failure, Hypertension, Age 75 (Doubled), Diabetes, Stroke (Doubled) – Vascular disease, Age
65–74 and Sex category (Female); DHP, dihydropyridine.
TABLE 23. Office blood pressure treatment target range
Office SBP treatment target ranges (mmHg)
Age group Hypertension þ Diabetes þ CKD þ CAD þ Strokea/TIA
Office DBP
treatment
target range
(mmHg)
18–65 years Target to 130
or lower if tolerated
Not <120
Target to 130
or lower if tolerated
Not <120
Target to <140 to 130
if tolerated
Target to 130
or lower if tolerated
Not <120
Target to 130
or lower if tolerated
Not <120
70–79
65–79 yearsb Target to 130–139
if tolerated
Target to 130–139
if tolerated
Target to 130–139
if tolerated
Target to 130–139
if tolerated
Target to 130–139
if tolerated
70–79
80 yearsb Target to 130–139
if tolerated
Target to 130–139
if tolerated
Target to 130–139
if tolerated
Target to 130–139
if tolerated
Target to 130–139
if tolerated
70–79
Office DBP
treatment
target range
(mmHg)
70–79 70–79 70–79 70–79 70–79
CAD, coronary artery disease; CKD, chronic kidney disease (includes diabetic and nondiabetic CKD); DBP, diastolic blood pressure; SBP, systolic blood pressure; TIA, transient ischaemic
attack.
aRefers to patients with previous stroke and does not refer to blood pressure targets immediately after acute stroke.
bTreatment decisions and blood pressure targets may need to be modified in older patients who are frail and independent.
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Device-based therapies for hypertension
ssalCnoitadnemmoceR a Levelb
Use of device-based therapies is not recom-
mended for the routine treatment of hyperten-
sion, unless in the context of clinical studies
and RCTs, until further evidence regarding their
safety and efficacy becomes available [367,368].
III B
RCT, randomized controlled trial.
aClass of recommendation.
bLevel of evidence.
ventilation. Surgical resection of the carotid body is associ-
ated with reductions in BP [380] and sympathetic overac-
tivity in patients with heart failure [381]. Devices for
endovascular carotid body modification by ultrasound-
guided ablation have been developed and are currently
under investigation.
In summary, device-based therapy for hypertension is a
fast-moving field. Further sham-controlled studies are
needed before device-based therapies can be recom-
mended for the routine treatment of hypertension outside
of the framework of clinical trials.
8 HYPERTENSION IN SPECIFIC
CIRCUMSTANCES
8.1 Resistant hypertension
8.1.1 Definition of resistant hypertension
Hypertension is defined as resistant to treatment when
the recommended treatment strategy fails to lower office
SBP and DBP values to less than 140mmHg and/or less
than 90mmHg, respectively, and the inadequate control
of BP is confirmed by ABPM or HBPM in patients whose
adherence to therapy has been confirmed. The recom-
mended treatment strategy should include appropriate
lifestyle measures and treatment with optimal or best-
tolerated doses of three or more drugs, which should
include a diuretic, typically an ACE inhibitor or an ARB,
and a CCB. Pseudo-resistant hypertension (see below)
and secondary causes of hypertension should also have
been excluded (see Section 8.2).
Prevalence studies of resistant hypertension have been
limited by variation in the definition used, and reported
prevalence rates range from 5 to 30% in patients with treated
hypertension. After applying a strict definition (see above)
and having excluded causes of pseudo-resistant hyperten-
sion (see Section 8.1.2), the true prevalence of resistant
hypertension is likely to be less than 10% of treated patients.
Patients with resistant hypertension are at higher risk of
HMOD, CKD and premature cardiovascular events [382].
8.1.2 Pseudo-resistant hypertension
Several possible causes of pseudo-resistant hypertension
should be evaluated and ruled out before concluding that
the patient has resistant hypertension:
1. Poor adherence to prescribed medicines is a
frequent cause of pseudo-resistant hypertension,
occurring in at least 50% of patients assessed
by therapeutic drug monitoring, and is directly
related to the number of tablets prescribed [315]
(see Section 10).
2. White-coat phenomenon (in which office BP is
elevated but BP is controlled at ABPM or HBPM) is
not uncommon in these patients, hence the recom-
mendation to confirm office hypertension with
ABPM or HBPM before confirming the diagnosis of
resistant hypertension.
3. Poor office BP measurement technique, includ-
ing the use of cuffs that are too small relative to the
arm circumference, can result in a spurious elevation
of BP.
4. Marked brachial artery calcification, especially in
older patients with heavily calcified arteries.
5. Clinician inertia, resulting in inadequate doses
or irrational combinations of BP-lowering drug
therapies.
Other causes of resistant hypertension
1. Lifestyle factors, such as obesity or large gains in
weight, excessive alcohol consumption, and high
sodium intake.
2. Intake of vasopressor or sodium-retaining substan-
ces, drugs prescribed for conditions other than
hypertension, some herbal remedies, or recreational
drug use (cocaine, anabolic steroids, etc.) (see
Table 24).
3. Obstructive sleep apnoea (usually, but not invariably,
associated with obesity).
4. Undetected secondary forms of hypertension (see
Section 8.2).
5. Advanced HMOD, particularly CKD or large-artery
stiffening.
Resistant hypertension is associated with older age
(especially >75 years), male sex, black African origin,
higher initial BP at diagnosis of hypertension, highest BP
ever reached during the patient’s lifetime, frequent outpa-
tient visits, obesity, diabetes, atherosclerotic disease and
HMOD, CKD, and a Framingham 10¼year coronary risk
score more than 20% [383,384].
8.1.3 Diagnostic approach to resistant hypertension
Diagnosis of resistant hypertension requires detailed infor-
mation about:
1. The patient’s history, including lifestyle characteris-
tics, alcohol and dietary sodium intake, interfering
drugs or substances, and sleep history.
2. The nature and dosing of the antihypertensive
treatment.
3. A physical examination, with a particular focus on
determining the presence of HMOD and signs of
secondary hypertension.
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4. Confirmation of treatment resistance by out-of-office
BP measurements (i.e. ABPM or HBPM).
5. Laboratory tests to detect electrolyte abnormalities
(hypokalaemia), associated risk factors (diabetes),
organ damage (advanced renal dysfunction), and
secondary hypertension.
6. Confirmation of adherence to BP-lowering
therapy.
Patients should be screened for a secondary cause of
hypertension, especially primary aldosteronism [386] or
atherosclerotic renal artery stenosis, particularly in older
patients or patients with CKD. Poor adherence to treatment
should be considered, but its identification may be chal-
lenging in routine clinical practice [387]. Some methods are
easy to use but of limited value (e.g. standardized ques-
tionnaires), whereas others, such as drug screening of urine
or blood, show considerable promise but are not yet widely
available [388]. Other methods include the measurement of
BP after directly observed treatment intake [389], which has
been used in clinical trials [390] but may be more difficult to
implement in routine clinical practice.
8.1.4 Treatment of resistant hypertension
Effective treatment combines lifestyle changes (especially
the reduction of sodium intake), discontinuation of inter-
fering substances, and the sequential addition of antihyper-
tensive drugs to the initial triple therapy. Ultimately,
replacing all current drugs by a simpler treatment regimen
using SPC treatment is recommended to reduce pill burden
and improve adherence to treatment. The optimal drug
treatment of resistant hypertension has been poorly stud-
ied. The most effective strategy seems to be additional
diuretic treatment to decrease volume overload, together
with the restriction of salt intake, particularly in patients
with CKD. BP control may be improved by increasing the
dose of the existing diuretic or by switching to a more
potent thiazide-like diuretic (chlorthalidone or indapa-
mide). A loop diuretic should replace thiazides/thiazide-
like diuretics if the eGFR is less than 30ml/min. Although
resistant hypertension may show a BP reduction if the
existing diuretic dose is further increased, most patients
require the administration of additional drugs. There is
growing evidence to suggest that the fourth-line treatment
should involve a blockade of the biological effects of
aldosterone through the use of MRAs [391] (spironolactone
up to 50mg/day), as shown in the PATHWAY 2 study [357]
and supported by other studies and their meta-analysis
[392–394]. Not all patients will be able to tolerate spirono-
lactone due to antiandrogenic side effects resulting in breast
tenderness or gynaecomastia (in 6%), impotence in men,
and menstrual irregularities in women. Moreover, the effi-
cacy and safety of spironolactone for the treatment of
resistant hypertension has not yet been established in
patients with significant renal impairment. As such, the
use of spironolactone for resistant hypertension should
usually be restricted to patients with an eGFR at least
45ml/min and a plasma potassium concentration of
4.5mmol/l. Moreover, electrolytes and eGFR should be
monitored soon after initiation and at least annually there-
after. On theoretical grounds, alternative additional diuretic
therapy to spironolactone (when it is not tolerated due to
androgen-like side effects) could include the MRA epler-
enone (50–100mg/day). Amiloride (10–20mg/day) has
recently been shown to be as effective as spironolactone
25–50mg daily) in reducing BP in the PATHWAY2 study
[357]. It is emphasized that the same cautions about the
use of these agents should be considered in patients
with reduced eGFR and baseline potassium levels more
than 4.5mmol/l. The PATHWAY-2 study also evaluated
bisoprolol (5–10mg/day) or doxazosin modified release
(4–8mg/day) as alternatives to spironolactone. Neither was
as effective as spironolactone, but they did reduce BP
significantly vs. placebo when added to background treat-
ment in resistant hypertension [310]. Thus, bisoprolol and
doxazosin have an evidence base for the treatment of
resistant hypertension when spironolactone is contraindi-
cated or not tolerated. Direct vasodilators, such as hydral-
azine or minoxidil, are infrequently used because they may
cause severe fluid retention and tachycardia.
New BP-lowering drugs (nitric oxide donors, vasopres-
sin antagonists, aldosterone synthase inhibitors, neutral
endopeptidase inhibitors, and endothelin antagonists) are
all under investigation [388].
TABLE 24. Resistant hypertension characteristics, secondary causes, and contributing factors (adapted from reference [385])
Characteristics of patients
with resistant hypertension
Causes of secondary resistant
hypertension
Drugs and substances that may
cause raised BP
Demographics
Older age (especially >75 years)
Obesity
More common in black people
 Excess dietary sodium intake
High baseline BP and chronicity
of uncontrolled hypertension
More common causes
 Primary hyperaldosteronism
Atherosclerotic renovascular disease
 Sleep apnoea
CKD
Prescribed drugs
Oral contraceptives
 Sympathomimetic agents (e.g. decongestants in proprietary cold remedies)
Nonsteroidal anti-inflammatory drugs
Cyclosporin
 Erythropoietin
 Steroids (e.g. prednisolone and hydrocortisone)
 Some cancer therapies
Concomitant disease
HMOD: LVH and/or CKD
Diabetes
Atherosclerotic vascular disease
Aortic stiffening and isolated
systolic hypertension
Uncommon causes
 Phaeochromocytoma
 Fibromuscular dysplasia
Aortic coarctation
Cushing’s disease
Hyperparathyroidism
Nonprescription drugs
Recreational drugs (e.g. cocaine, amphetamines, and anabolic steroids)
 Excessive liquorice ingestion
Herbal remedies (e.g. ephedra and ma huang)
BP, blood pressure; CKD, chronic kidney disease; HMOD, hypertension-mediated organ damage; LVH, left ventricular hypertrophy.
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Resistant hypertension
Recommendations a LevelClass b
It is recommended that hypertension be
defined as resistant to treatment (i.e. resist-
ant hypertension) when:
• Optimal doses (or best-tolerated doses) of
an appropriate therapeutic strategy, which
should include a diuretic (typically an ACE
inhibitor or an ARB with a CCB and a thia-
zide/thiazide-type diuretic), fails to lower
clinic SBP and DBP values to < 140 mmHg
and/or < 90 mmHg, respectively; and
• The inadequate control of BP has been
confirmed by ABPM or HBPM; and
• After exclusion of various causes of
pseudo-resistant hypertension (espe-
cially poor medication adherence) and
secondary hypertension.
I C
Recommended treatment of resistant
hypertension is:
• Reinforcement of lifestyle measures,
especially sodium restriction [395].
• Addition of low-dose spironolactonec to
existing treatment [310,392,394].
• Or the addition of further diuretic ther-
apy if intolerant to spironolactone, with
either eplerenone,c amiloride,c a higher-
dose thiazide/thiazide-like diuretic, or a
loop diuretic [357].d
• Or the addition of bisoprolol or
doxazosin [310].
I B
ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme;
ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker;
DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; SBP, systolic
blood pressure.
aClass of recommendation.
bLevel of evidence.
cWhen spironolactone is not tolerated, replace with amiloride or eplerenone. The use of
these drugs should be restricted to patients with an estimated glomerular filtration rate
45ml/min and a plasma potassium concentration of 4.5mmol/l, because of the risk
of hyperkalaemia.
dA loop diuretic should replace thiazides/thiazide-like diuretics if the estimated
glomerular filtration rate is <30ml/min.
8.2 Secondary hypertension
Secondary hypertension is hypertension due to an identifi-
able cause, which may be treatable with an intervention
specific to the cause. A high index of suspicion and early
detection of secondary causes of hypertension are impor-
tant because interventions may be curative, especially in
younger patients [e.g. corrective surgery for aortic coarcta-
tion, renal angioplasty in younger patients with renal artery
fibromuscular dysplasia, reversal of an endocrine cause of
hypertension (e.g. by removal of an adrenal adenoma), or
drug treatment of a monogenic disorder affecting a specific
drug-sensitive ion channel (e.g. selective use of amiloride in
Liddle’s syndrome)]. Interventions that treat the cause of
secondary hypertension later in life are less likely to be
curative (i.e. remove the need for antihypertensive medi-
cation) because longstanding hypertension results in vas-
cular and other organ damage that sustains the elevated BP,
but intervention is still important because it will often result
in much better BP control with less medication.
The prevalence of secondary hypertension is reported to
be 5–15% [396] of people with hypertension. Screening all
hypertensive patients for secondary hypertension is not
feasible or cost-effective; however, there are some general
patient characteristics that suggest those more likely to have
secondary hypertension and in whom screening should be
considered after confirming that BP is elevated with ABPM
(Table 25).
It is beyond the scope of these Guidelines to describe the
detailed clinical management of specific causes of second-
ary hypertension. However, the commoner causes of sec-
ondary hypertension, clinical history, and screening tests
are described in Table 26, and the typical age distribution
of these causes of secondary hypertension is shown in
Table 27. Review of these tables demonstrates that most
screening can be undertaken with blood and urine tests,
abdominal ultrasound, and echocardiography. Referral to a
specialist centre is recommended for additional investiga-
tions to confirm a suspected diagnosis of secondary hyper-
tension and for clinical management. Other causes of
secondary hypertension due to drugs and substances,
and rarer monogenic causes, are described below and
are summarized in Tables 28 and 29.
8.2.1 Drugs and other substances that may cause
secondary hypertension
Medications and other substances may cause a sufficient
increase in BP to raise the suspicion of secondary hyper-
tension [397] (Table 28). Consequently, a careful drug
history is important when considering a diagnosis of sec-
ondary hypertension. Moreover, other commonly used
drugs such as nonsteroidal anti-inflammatory drugs or
glucocorticoids can antagonize the BP-lowering effect of
antihypertensive medications in patients treated for hyper-
tension and may contribute to a loss of BP control.
8.2.2 Genetic causes of secondary hypertension
Genetic causes of secondary hypertension are usually due
to single-gene disorders (see Section 6) [194,195]. They are
rare but important causes of secondary hypertension
because identifying the cause can point to a specific drug
TABLE 25. Patient characteristics that should raise the suspicion of
secondary hypertension
Characteristic
Younger patients (<40 years) with grade 2 hypertension or onset of
any grade of hypertension in childhood
Acute worsening hypertension in patients with previously documented
chronically stable normotension
 Resistant hypertension (see section 8.1)
 Severe (grade 3) hypertension or a hypertension emergency (see
section 8.3)
 Presence of extensive HMOD
Clinical or biochemical features suggestive of endocrine causes of
hypertension or CKD
Clinical features suggestive of obstructive sleep apnoea
 Symptoms suggestive of phaeochromocytoma or family history of
phaeochromocytoma
CKD, chronic kidney disease; HMOD, hypertension-mediated organ damage.
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treatment (Table 29) [194,195]. Common features of these
genetic disorders are that they usually present with hyper-
tension in children, adolescents, or young adults, and most
monogenic disorders induce hypertension by increasing
the renal tubular reabsorption of sodium. Thus, they are
usually associated with a suppressed plasma renin concen-
tration (PRC) or plasma renin activity (PRA), which is
unusual in younger patients and especially those treated
with antihypertensive medications (e.g. RAS blockers,
CCBs, or diuretics), that would be expected to increase
PRC or PRA. Thus, the finding of a suppressed PRC or PRA,
especially while taking these drugs, should raise the suspi-
cion of secondary hypertension due a salt-retaining state.
Importantly, beta-blockers in particular, but also nonsteroi-
dal anti-inflammatory drugs, alpha-methyl dopa, or cloni-
dine, suppress PRC and PRA. These drugs should be
TABLE 26. Common causes of secondary hypertension
Cause
Prevalence in
hypertensive
patients Suggestive symptoms and signs Screening Investigations
Obstructive sleep apnoea 5–10% Snoring; obesity (can be present in non obese);
morning headache; daytime somnolence
Epworth score and ambulatory polygraphy
Renal parenchymal disease 2–10% Mostly asymptomatic; diabetes; haematuria,
proteinuria, nocturia; anaemia, renal mass in
adult polycystic CKD
Plasma creatinine and electrolytes, eGFR; urine
dipstick for blood and protein, urinary albu-
min:creatinine ratio; renal ultrasound
Renovascular disease
Atherosclerotic renovascular
disease
Fibromuscular dysplasia
1–10% Older; widespread atherosclerosis (especially
PAD); diabetes; smoking; recurrent flash pul-
monary oedema; abdominal bruit
Younger; more common in women; abdominal
bruit
Duplex renal artery Doppler or CT angiography
or MR angiography
Endocrine causes
Primary Aldosteronism 5–15% Mostly asymptomatic; muscle weakness (rare) Plasma aldosterone and renin, and aldosterone:
renin ratio; hypokalaemia (in a minority):
note hypokalaemia can depress aldosterone
levels
Phaeochromocytoma <1% Episodic symptoms (the 5 ‘Ps’): paroxysmal
hypertension, pounding headache, perspira-
tion, palpitations, and pallor; labile BP; BP sur-
ges precipitated by drugs (e.g. beta-blockers,
metoclopramide, sympathomimetics, opioids,
and tricyclic antidepressants)
Plasma or 24 h urinary fractionated
metanephrines
Cushing’s syndrome <1% Moon face, central obesity, skin atrophy, striae
and bruising; diabetes; chronic steroid use
24 h urinary-free cortisol
Thyroid disease
(hyperthyroidism or
hypothyroidism)
1–2% Signs and symptoms of hyperthyroidism or
hypothyroidism
Thyroid function tests
Hyperparathyroidism <1% Hypercalcaemia, hypophosphataemia Parathyroid hormone, Ca2þ
Other causes
Coarctation of the aorta <1% Usually detected in children or adolescence;
different BP (20/10mmHg) between upper–
lower extremities and/or between right–left
arm and delayed radial-femoral femoral
pulsation; low ABI interscapular ejection
murmur; rib notching on chest X-ray
Echocardiogram
ABI, ankle-brachial index; BP, blood pressure; CKD, chronic kidney disease; CT, computed tomography; eGFR, estimated glomerular filtration rate; MR, magnetic resonance; PAD,
peripheral artery disease.
TABLE 27. Incidence and typical causes of secondary hypertension according to age
Age group Per cent with underlying cause Typical causes
Young children (<12 years) 70–85 Renal parenchymal disease
Coarctation of the aorta
Monogenic disorders
Adolescents (12–18 years) 10–15 Renal parenchymal disease
Coarctation of the aorta
Monogenic disorders
Young adults (19–40 years) 5–10 Renal parenchymal disease
 Fibromuscular dysplasia (especially in women)
Undiagnosed monogenic disorders
Middle-aged adults (41–65 years) 5–15  Primary aldosteronism
Obstructive sleep apnoea
Cushing’s syndrome
 Phaeochromocytoma
Renal parenchymal disease
Atherosclerotic renovascular disease
Older adults (>65 years) 5–10 Atherosclerotic renovascular disease
Renal parenchymal disease
 Thyroid disease
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discontinued (if clinically feasible) for at least 2 weeks
before measuring PRC or PRA.
8.3 Hypertension urgencies and emergencies
Hypertension emergencies are situations in which severe
hypertension (grade 3) is associated with acute HMOD,
which is often life-threatening and requires immediate but
careful intervention to lower BP, usually with intravenous
(i.v.) therapy [398]. The rate andmagnitude of an increase in
BPmay be at least as important as the absolute level of BP in
determining the magnitude of organ injury [399]. Typical
presentations of a hypertension emergency are:
1. Patients withmalignant hypertension, character-
ized by severe hypertension (usually grade 3) associ-
ated with funduscopic changes (flame haemorrhages
and/or papilloedema), microangiopathy, and dis-
seminated intravascular coagulation, and can be asso-
ciated with encephalopathy (in about 15% of cases)
[400], acute heart failure, and acute deterioration in
renal function. The hallmark of this condition is small
artery fibrinoid necrosis in the kidney, retina, and
brain. The term ‘malignant’ reflects the very poor
prognosis for this condition if untreated [401–404].
2. Patients with severe hypertension associated
with other clinical conditions who are likely to
require an urgent reduction of BP, for example acute
aortic dissection, acute myocardial ischaemia, or
acute heart failure.
3. Patients with sudden severe hypertension due
to phaeochromocytoma, associated with organ
damage.
4. Pregnant women with severe hypertension or
preeclampsia (see Section 8.9.1).
The most common emergency symptoms will depend of
the organs affected but may include headache, visual dis-
turbances, chest pain, dyspnoea, dizziness, and other neu-
rological deficits. In patients with hypertensive
encephalopathy, the presence of somnolence, lethargy,
tonic clonic seizures and cortical blindness may precede
a loss of consciousness; however, focal neurological lesions
are rare and should raise the suspicion of stroke.
Acute stroke, especially intracerebral haemorrhage,
when associated with severe hypertension has often been
termed a hypertension emergency, but a more cautious
approach is now recommended for acute BP lowering in
the emergency setting of acute stroke (see Section 8.15).
The term ‘hypertension urgency’ has also been used to
describe severe hypertension in patients presenting to the
emergency department in whom there is no clinical evi-
dence of acute HMOD [405]. Whilst these patients require
BP reduction, they do not usually require admission to
hospital, and BP reduction is best achieved with oral
medication according to the drug treatment algorithm pre-
sented in Figure 4. However, these patients will require
urgent outpatient review to ensure that their BP is coming
under control.
Acute and severe increases in BP can sometimes be
precipitated by ingestion of sympathomimetics such as
meta-amphetamine or cocaine. This can result in a hyper-
tension emergency when there is evidence of acute HMOD.
It is emphasized that many patients in an emergency
department with acute pain or distress may experience an
acute elevation in BP that will be restored to normal when
TABLE 28. Medications and other substances that may increase blood pressure [397]
Medication/substance
Oral contraceptive pill Especially oestrogen containing; cause hypertension in 5% of women, usually mild but can be severe
Diet pills For example, phenylpropanolamine and sibutramine
Nasal decongestants For example, phenylephrine hydrochloride and naphazoline hydrochloride
Stimulant drugs Amphetamine, cocaine, and ecstasy; these substances usually cause acute rather than chronic hypertension
Liquorice Chronic excessive liquorice use mimics hyperaldosteronism by stimulating the mineralocorticoid receptor and inhibiting
cortisol metabolism
Immunosuppressive medications For example, cyclosporin A (tacrolimus has less effect on BP and rapamycin has almost no effect on BP) and steroids
(e.g. corticosteroids and hydrocortisone)
Antiangiogenic cancer therapies Antiangiogenic drugs such as VEGF inhibitors (e.g. bevacizumab), tyrosine kinase inhibitors (e.g. sunitinib), and sorafenib
have been reported to increase BP
Other drugs and substances
that may raise BP
Anabolic steroids, erythropoietin, nonsteroidal anti-inflammatory drugs, and herbal remedies (e.g. ephedra and ma huang)
BP, blood pressure; VEGF, vascular endothelial growth factor.
TABLE 29. Rare genetic causes of secondary hypertension
Condition Phenotype Mechanism and effect
Liddle syndrome Hypokalaemia, metabolic alkalosis, low PRA or PRC, low PAC Increased renal tubular ENaC activity: responds to treatment
with amiloride
Apparent mineralocorticoid
excess
Hypokalaemia, metabolic alkalosis, low PRA or PRC, low PAC Decreased 11b-dehydrogenase isoenzyme 2
Gordon syndrome Hyperkalaemia, metabolic acidosis, low PRA or PRC, low PAC Overactivity of sodium chloride co-transporter
Geller syndrome Pregnancy-exacerbated hypertension, low PRA or PRC, low PAC Agonist effect of progesterone on the mineralocorticoid receptor
Glucocorticoid remediable
hypertension
Hypokalaemia, metabolic alkalosis, low PRC or PRA,
and increased PAC
Chimeric CYP11b1 to CYP11b2 gene: response to treatment
with glucocorticoids
ENaC, epithelial sodium channel; PAC, plasma aldosterone concentration; PRA, plasma renin activity; PRC, plasma renin concentration.
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the pain and distress are relieved, rather than requiring any
specific intervention to lower BP.
For patients with a suspected hypertension emergency, a
diagnostic workup is shown in Table 30.
8.3.1 Acute management of hypertensive
emergencies
Apart from acute BP lowering in stroke, there are no RCTs
evaluating different treatment strategies for hypertensive
emergencies. The key considerations in defining the treat-
ment strategy are:
1. Establishing the target organs that are affected,
whether they require any specific interventions other
than BP lowering, andwhether there is a precipitating
cause for the acute rise in BP that might affect the
treatment plan (e.g. pregnancy);
2. The recommended timescale and magnitude of BP
lowering required for safe BP reduction;
3. The type of BP-lowering treatment required. With
regard to drug treatment, in a hypertension emer-
gency, i.v. treatment with a drug with a short half-life
is ideal to allow careful titration of the BP response to
treatment in a higher dependency clinical area with
facilities for continuous haemodynamic monitoring.
Recommended drug treatments for specific hyperten-
sion emergencies [398,406] are shown in Table 31 and an
expanded range of possible drug choices [398] is shown in
Table 32. Rapid uncontrolled BP lowering is not recom-
mended as this can lead to complications [397].
Although i.v. drug administration is recommended for
most hypertension emergencies, oral therapy with ACE
inhibitors, ARBs, or beta-blockers is sometimes very effec-
tive in malignant hypertension because the renin system is
activated by renal ischaemia. However, low initial doses
should be used because these patients can be very sensitive
to these agents and treatment should take place in hospital.
Further comprehensive details on the clinical management
of hypertension emergencies are available [398].
8.3.2 Prognosis and follow-up
The survival of patients with hypertension emergencies has
improved dramatically over past decades [407], but these
patients remain at high risk [408,409] and should be
screened for secondary hypertension (see Section 8.2).
After discharge from hospital, when BP has reached a safe
and stable level on oral therapy, we recommend frequent,
at least monthly, visits in a specialized setting until the
optimal target BP is achieved and long-term specialist
follow-up thereafter.
8.4 White-coat hypertension
As discussed in Section 4, white-coat hypertension is
defined as an elevated office BP despite a normal out-of-
office BP. White-coat hypertension may be present in many
people with an increased office BP, with a maximum in
grade 1 hypertension, and very old people (>50%). Com-
pared with normotensive people, white-coat hypertension
is associated with an increased prevalence of dysmetabolic
risk factors and asymptomatic organ damage. It is also
associated with a greater risk of developing type 2 diabetes
and sustained hypertension, as well as an overall increased
risk of cardiovascular events [68,410–412]. It is recom-
mended that people with white-coat hypertension should
have an accurate assessment of their cardiovascular risk
profile, including a search for HMOD. Office and out-of-
office BP (both home and ambulatory BP) should be
measured frequently, for example no less than every 2
years. Treatment should consider lifestyle changes to
reduce the elevated cardiovascular risk [85,86,89].
TABLE 31. Hypertensive emergencies requiring immediate blood pressure lowering with intravenous drug therapy
Clinical presentation Timeline and target for BP reduction First-line treatment Alternative
Malignant hypertension with or without
acute renal failure
Several hours
Reduce MAP by 20–25%
Labetalol
Nicardipine
Nitroprusside
Urapidil
Hypertensive encephalopathy Immediately reduce MAP by 20–25% Labetalol, nicardipine Nitroprusside
Acute coronary event Immediately reduce SBP to <140mmHg Nitroglycerine, labetalol Urapidil
Acute cardiogenic pulmonary oedema Immediately reduce SBP to <140mmHg Nitroprusside or nitroglycerine
(with loop diuretic)
Urapidil (with loop diuretic)
Acute aortic dissection Immediately reduce SBP to <120mmHg
AND heart rate to <60 bpm
Esmolol and nitroprusside or nitroglycerine
or nicardipine
Labetalol OR metoprolol
Eclampsia and severe pre
eclampsia/HELLP
Immediately reduce SBP to <160mmHg
AND DBP to <105mmHg
Labetalol or nicardipine and
magnesium sulfate
Consider delivery
BP, blood pressure; bpm, beats/min; DBP, diastolic blood pressure; HELLP, haemolysis, elevated liver enzymes, and low platelets; i.v., intravenous; MAP, mean arterial pressure; SBP,
systolic blood pressure.
TABLE 30. Diagnostic workup for patients with a suspected
hypertension emergency
Common tests for all potential causes
 Fundoscopy is a critical part of the diagnostic workup
12-lead ECG
Haemoglobin, platelet count, fibrinogen
Creatinine, eGFR, electrolytes, LDH, haptoglobin
Urine albumin:creatinine ratio, urine microscopy for red cells,
leucocytes, casts
 Pregnancy test in women of child-bearing age
Specific tests by indication
 Troponin, CK-MB (in suspected cardiac involvement, e.g. acute chest
pain or acute heart failure) and NT-proBNP
Chest X-ray (fluid overload)
 Echocardiography (aortic dissection, heart failure, or ischaemia)
CT angiography of thorax and/or abdomen in suspected acute aortic
disease (e.g. aortic dissection)
CT or MRI brain (nervous system involvement)
Renal ultrasound (renal impairment or suspected renal artery stenosis)
Urine drug screen (suspected methamphetamine or cocaine use)
CK-MB, creatinine kinase-muscle/brain; CT, computed tomography; ECG,
electrocardiogram; eGFR, estimated glomerular filtration rate; LDH, lactate
dehydrogenase; NT-proBNP, N-terminal pro-B natriuretic peptide.
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Whether or not patients with white-coat hypertension
should receive antihypertensive drugs is unresolved. In
white-coat hypertension, antihypertensive drugs have been
shown to effectively and persistently lower office BP, with
no concomitant reduction (indeed, even a small increase)
of ambulatory BP values [413,414]. Whether these BP
changes lead to cardiovascular protection has not been
investigated with adequately powered outcome studies and
remains unknown. However, it should be considered that
people with white-coat hypertension have inevitably been
well represented in trials documenting the protective effect
of antihypertensive drugs [415], particularly those address-
ing conditions in which white-coat hypertension is more
common, such as grade 1 hypertension or hypertension in
older patients. In a recent subanalysis of the HYVET trial of
the very old with hypertension, white-coat hypertension
was reported to account for 55% of the trial population
[416]. Thus, antihypertensive drug treatment cannot defini-
tively be excluded for patients with white-coat hyperten-
sion and may be considered, in particular, in white-coat
hypertensive people with a higher cardiovascular risk pro-
file, such as those with HMOD, an uncertain out-of-office
BP normality pattern (i.e. ambulatory but not home BP
normality or vice versa), or a persistent office BP elevation
at repeated visits [417–420]. No cardiovascular risk excess
has been reported in patients in whom white-coat hyper-
tension results from treatment-dependant normalization of
out-of-office BP only [418,421]. Thus, whether this condi-
tion benefits from an uptitration of the existing drug treat-
ment regimen (to also achieve office BP normalization)
remains to be determined.
8.5 Masked hypertension
As reported in Section 4.7.2, masked hypertension is
defined in people whose BP is normal in the office but
elevated on out-of-office BP measurements. Such people
usually have dysmetabolic risk factors and asymptomatic
organ damage, which are substantially more frequent than
in people who are truly normotensive [93,410–412,422].
The challenge is how to diagnose masked hypertension,
because most hypertension screening programmes use
office BP measurement, which is normal in these people.
Masked hypertension is commoner in younger rather than
older individuals, and in those with an office BP in the
borderline hypertension range (i.e. 130–139/80–
89mmHg). It is uncommon in people whose office BP is
less than 130/80mmHg. Masked hypertension is associated
with progression to sustained office hypertension,
increased frequency of developing type 2 diabetes, and
the presence of HMOD. The long-term risk of fatal and
nonfatal cardiovascular events approaches that of patients
with sustained hypertension [68,81,93,95,423]. Patients with
masked hypertension should have an accurate initial assess-
ment of their cardiovascular risk profile. Cardiovascular risk
factors (including organ damage and ideally both home and
ambulatory BP) should then be periodically monitored.
Factors contributing to the out-of-office BP elevation
(e.g. smoking) should be discouraged and lifestyle inter-
ventions implemented to improve out-of-office BP levels.
The impact of antihypertensive drug treatment on cardio-
vascular outcomes in people with masked hypertension has
never been studied. Nevertheless, treatment with BP-low-
ering medication should be considered because these
patients are at high cardiovascular risk, often have HMOD,
and the adverse prognostic importance of out-of-office BP
elevations has been well documented [68,74].
8.6 Masked uncontrolled hypertension
MUCH occurs in some treated patients in whom the office
BP appears controlled to recommended BP targets, but BP
TABLE 32. Drug types, doses, and characteristics for treatment of hypertension emergencies
Drug
Onset of
action
Duration of
action Dose Contraindications
Adverse
effects
Esmolol 1–2min 10–30min 0.5–1mg/kg i.v. bolus; 50–300mg/kg/min i.v.
infusion
Second or third-degree AV block, systolic
heart failure, asthma, bradycardia
Bradycardia
Metoprolol 1–2min 5–8 h 2.5–5mg i.v. bolus over 2 minutes; may repeat
every 5 minutes to a maximum dose of 15mg
Second or third-degree AV block, systolic
heart failure, asthma, bradycardia
Bradycardia
Labetalol 5–10min 3–6 h 0.25–0.5mg/kg i.v. bolus; 2–4mg/min i.v. infusion
until goal BP is reached, thereafter 5–20mg/h
Second or third-degree AV block; systolic
heart failure, asthma, bradycardia
Bronchoconstriction,
foetal bradycardia
Fenoldopam 5–15min 30–60min 0.1mg/kg/min i.v. infusion, increase every
15min with 0.05 to 0.1mg/kg/min
increments until goal BP is reached
Caution in glaucoma
Clevidipine 2–3min 5–15min 2mg/h i.v. infusion, increase every 2min with
2mg/h until goal BP
Headache, reflex
tachycardia
Nicardipine 5–15min 30–40min 5–15mg/h i.v. infusion, starting dose 5mg/h,
increase every 15–30min with 2.5mg until
goal BP, thereafter decrease to 3mg/h
Liver failure Headache, reflex
tachycardia
Nitroglycerine 1–5min 3–5min 5–200mg/min i.v. infusion, 5mg/min increase
every 5min
Headache, reflex
tachycardia
Nitroprusside Immediate 1–2min 0.3–10mg/kg/min i.v. infusion, increase by
0.5mg/kg/min every 5min until goal BP
Liver/kidney failure (relative) Cyanide intoxication
Enalaprilat 5–15min 4–6 h 0.625–1.25mg i.v. bolus History of angioedema
Urapidil 3–5min 4–6 h 12.5–25mg i.v. bolus; 5–40mg/h as
continuous infusion
Clonidine 30min 4–6 h 150–300mg i.v. bolus over 5–10min Sedation, rebound
hypertension
Phentolamine 1–2min 10–30min 0.5–1mg/kg i.v. bolus OR 50–300mg/kg/min
i.v. infusion
Tachyarrhythmias,
chest pain
AV, atrioventricular; BP, blood pressure; i.v., intravenous.
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Management of white coat and masked hypertension
Management of white-coat hypertension
Recommendations a LevelClass b
In white-coat hypertensive patients, it is rec-
ommended to implement lifestyle changes
aimed at reducing cardiovascular risk as well
as regular follow-up with periodic out-of-
office BP monitoring.
I C
In patients with white-coat hypertension:
• Drug treatment may be considered in
people with evidence of HMOD or in
whom cardiovascular risk is high or very
high.
IIb C
• Routine drug treatment is not indicated. III C
Management of masked hypertension
Recommendations
In masked hypertension, lifestyle changes
are recommended to reduce cardiovascular 
risk, with regular follow-up, including
periodic out-of-office BP monitoring.
I C
Antihypertensive drug treatment should be
considered in masked hypertension to nor-
malize the out-of-office BP, based on the
prognostic importance of out-of-office BP
elevation.
IIa C
Antihypertensive drug uptitration should be
considered in treated patients whose out-
of-office BP is not controlled (i.e. masked
uncontrolled hypertension), because of the
high cardiovascular risk of these patients.
IIa C
BP, blood pressure; HMOD, hypertension-mediated organ damage.
aClass of recommendation.
bLevel of evidence.
is elevated and thus uncontrolled according to out-of-
office BP measurements (ABPM or HBPM) [84]. Registry-
based studies in Spain have suggested that MUCH occurs
in as many as 30% of treated hypertensive patients [84],
and is more common with comorbidities such as diabetes
and CKD and in those at highest risk. Moreover, MUCH
was more commonly due to poorly controlled nocturnal
rather than daytime pressures on ABPM. Presently, no
data are available from outcome trials for patients with
MUCH; however, mindful of their high cardiovascular
risk, treatment uptitration should be considered to
ensure that that both office and out-of-office BP are
controlled [84].
8.7 Hypertension in younger adults (age <50
years)
The prevalence of hypertension increases with age. Most
hypertension across the age span is due to systolic
hypertension; however, elevations of DBP and isolated
diastolic hypertension, when they occur, are more common
in younger rather than older patients [211]. There is a
greater likelihood of detecting secondary hypertension in
younger patients (<50 years), where the prevalence of
secondary hypertension may be as high as 10% and should
be considered, especially in those with more severe hyper-
tension (see Section 3).
All younger adults with grade 2 or more severe hyper-
tension should be offered lifestyle advice and drug treat-
ment, as well as high-risk younger adults with grade 1
hypertension (i.e. with HMOD, CVD, diabetes, CKD, or
those at high CVD risk, although cardiovascular risk is often
underestimated in younger adults over shorter-term pro-
jections, such as 10 years) [35].
There is controversy about whether younger adults
with uncomplicated grade 1 hypertension should be
treated because of the obvious difficulty in conducting
conventional clinical outcome trials in younger adults in
whom the outcomes only occur after many years [424].
There is little doubt that treating stage 1 hypertension in
older patients, even those at low–moderate-risk, reduces
cardiovascular morbidity and mortality [425]. Moreover,
long-term epidemiological studies have demonstrated a
clear relationship between BP and longer-term risk of
cardiovascular events and mortality in young adults with
a BP more than 130/80mmHg [424,426]. Furthermore,
earlier treatment [23] can prevent more severe hyperten-
sion [427] and the development of HMOD, which may not
be completely reversible with later treatment. Thus,
despite the absence of RCT evidence demonstrating the
benefits of antihypertensive treatment in younger adults
with uncomplicated grade 1 hypertension, treatment with
BP-lowering drugs may be considered prudent. If a
decision is taken not to offer treatment or treatment is
declined, lifestyle advice should be prescribed, and lon-
ger-term follow-up is essential as BP will invariably rise.
In younger patients with hypertension treated with BP-
lowering medication, office BP should be reduced to at
least 130/80mmHg if treatment is well tolerated. Other
interventions, for example statins or antiplatelet therapy,
should also be considered for higher-risk patients (see
Section 7.2.5).
8.7.1 Isolated systolic hypertension in the young
Some young, healthy people, and men in particular, may
present with isolated grade 1 systolic hypertension (i.e.
brachial SBP at least 140–159mmHg and a normal DBP
<90mmHg), and this may be associated with a normal
central aortic SBP due to excessive peripheral systolic
pressure amplification [428]. It is unclear whether isolated
systolic hypertension in the context of a normal aortic
pressure is benign. A recent examination of prospective
data from the Chicago Heart Association Detection Project
found that young men with isolated systolic hypertension
had a cardiovascular risk similar to that of individuals with
high–normal BP and that isolated systolic hypertension in
the young was closely associated with smoking [429]. On
the basis of current evidence, these young individuals
should receive recommendations on lifestyle modification
(particularly cessation of smoking); whether they should
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receive drug treatment is unclear, but they do require
longer-term follow-up as many will develop sustained
hypertension [430].
8.8 Hypertension in older patients
(age 65 years)
The prevalence of hypertension increases with age, with a
prevalence of 60% over the age of 60 years and 75% over the
age of 75 years. For the purposes of these Guidelines, older
is defined as at least 65 years and the very old as at least
80 years.
For many years, advanced age has been a barrier to the
treatment of hypertension because of concerns about
potentially poor tolerability, and even harmful effects of
BP-lowering interventions in people inwhommechanisms
preserving BP homeostasis and vital organ perfusion may
be more frequently impaired. This approach is not appro-
priate, because evidence from RCTs has shown that in old
and very old patients, antihypertensive treatment substan-
tially reduces cardiovascular morbidity and cardiovascular
and all-causemortality [220,431] (see Section 7). Moreover,
treatment has been found to be generally well tolerated.
However, older patients are more likely to have comor-
bidities such as renal impairment, atherosclerotic vascular
disease, and postural hypotension, which may be wors-
ened by BP-lowering drugs. Older patients also frequently
take othermedications, whichmay negatively interact with
those used to achieve BP control. A further important
caveat is that RCTs have not included very frail patients,
dependent patients, and patients with postural hypoten-
sion. It is thus uncertain whether, and to what extent, such
patients would benefit from BP-lowering treatment in the
context of their comorbidities and reduced life expectancy.
Thus, in older hypertensive patients, treatment presents
more difficulties than in younger people, because the
decision to treat hypertension must take into account
the patient’s clinical condition, concomitant treatments,
and frailty. That said, age alone must never be a barrier
to treatment because high BP is an important risk factor
even at the most advanced ages. Furthermore, a recent
study of a cohort of older patients from the general popu-
lation (thus including those with frailty) has shown that
better adherence to antihypertensive treatment was asso-
ciated with a reduced risk of cardiovascular events and
mortality, evenwhen age wasmore than 85 years (mean 90
years) [432].
It is recommended that older patients are treated accord-
ing to the treatment algorithm outlined in Section 7. In very
old patients, it may be appropriate to initiate treatment with
monotherapy. In all older patients, when combination
therapy is used, it is recommended that this is initiated at
the lowest available doses. In all older patients, and espe-
cially very old or frail patients, the possible occurrence of
postural BP should be closely monitored and symptoms of
possible hypotensive episodes checked by ABPM. Unless
required for concomitant diseases, loop diuretics and
alpha-blockers should be avoided because of their associ-
ation with injurious falls [433,434]. Renal function should be
frequently assessed to detect possible increases in serum
creatinine and reductions in eGFR as a result of BP-related
reductions in renal perfusion. When treated, BP should be
lowered to a systolic value of 130–139mmHg and a dia-
stolic value of less than 80mmHg if tolerated. Treated SBP
values of less than 130mmHg should be avoided. A key
emphasis in treating older patients, and especially the very
old, is to carefully monitor for any adverse effects or
tolerability problems associated with BP-lowering treat-
ment, keeping in mind that adverse effects can be more
frequent than reported in RCTs, in which specific medical
expertise and close patient supervision may minimize
adverse effects and tolerability problems.
An important consideration is frail, dependent older
patients, including those with orthostatic hypotension.
These have been excluded from RCTs. The SPRINT trial
showed the benefits of BP-lowering treatment being
extended to recruited patients who were at the frailer
end of the spectrum, including those with reduced gait
speed [215]. This suggests that the benefit of treatment is not
limited to fit and independent older patients; however, to
what extent BP-lowering treatment benefits the very frail
[214] and institutionalized patients remains to be deter-
mined.
In some patients, the best achievable BP may be
higher than the recommended target, but it should be
recognized that any amount of BP lowering is likely to be
worthwhile and associated with a reduced risk of major
cardiovascular events (especially stroke and heart failure)
and mortality.
8.9 Women, pregnancy, oral contraception and
hormone-replacement therapy
8.9.1 Hypertension and pregnancy
Hypertensive disorders in pregnancy affect 5–10% of
pregnancies worldwide and remain a major cause of
maternal, foetal, and neonatal morbidity and mortality.
Maternal risks include placental abruption, stroke,multiple
organ failure, and disseminated intravascular coagulation.
The fetus is at high risk of intrauterine growth retardation
(25% of cases of preeclampsia), prematurity (27% of cases
of preeclampsia), and intrauterine death (4% of cases of
preeclampsia) [435].
8.9.1.1 Definition and classification of hypertension
in pregnancy
The definition of hypertension in pregnancy is based on
office BP values, SBP at least 140mmHg and/or DBP at least
90mmHg [436,437], and is classified as mild (140–159/90–
109mmHg) or severe (160/110mmHg), in contrast to the
conventional hypertension grading.
Hypertension in pregnancy is not a single entity but
comprises:
1. Preexisting hypertension: precedes pregnancy or
develops before 20 weeks of gestation, and usually
persists for more than 6 weeks postpartum and may
be associated with proteinuria.
2. Gestational hypertension: develops after 20 weeks
of gestation and usually resolves within 6 weeks
postpartum.
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3. Preexisting hypertension plus superimposed
gestational hypertension with proteinuria.
4. Preeclampsia: gestational hypertension with signif-
icant proteinuria (>0.3 g/24 h or30mg/mmol ACR).
It occurs more frequently during the first pregnancy,
in multiple pregnancy, in hydatidiform mole, in
antiphospholipid syndrome, or with preexisting
hypertension, renal disease, or diabetes. It is often
associated with foetal growth restriction due to pla-
cental insufficiency and is a common cause of pre-
maturity [438]. The only cure for preeclampsia is
delivery. As proteinuria may be a late manifestation
of preeclampsia, it should be suspected when de-
novo hypertension is accompanied by headache,
visual disturbances, abdominal pain, or abnormal
laboratory tests, specifically low platelets and/or
abnormal liver function.
5. Antenatally unclassifiable hypertension: this
term is used when BP is first recorded after 20 weeks
of gestation and it is unclear if hypertension was
preexisting. Reassessment 6 weeks postpartum will
help distinguish preexisting from gestational hyper-
tension.
8.9.1.2 Blood pressure measurement in pregnancy
BP in pregnancy should be measured in the sitting posi-
tion (or the left lateral recumbent during labour) with an
appropriately sized arm cuff at heart level and using
Korotkoff V for DBP. Manual auscultation remains the
gold standard for BP measurement in pregnancy, because
automated devices tend to under-record the BP and are
unreliable in severe preeclampsia. Only validated devices
should be used in pregnancy [439]. ABPM is superior to
office BP measurement for the prediction of pregnancy
outcome [440]. ABPM devices recommended for use in
pregnancy are more accurate than those used for office
measurement or HBPM. ABPM helps avoid unnecessary
treatment of white-coat hypertension, and is useful in
the management of high-risk pregnant women with
hypertension and those with diabetic or hypertensive
nephropathy.
8.9.1.3 Investigation of hypertension in pregnancy
Basic laboratory investigations recommended for monitor-
ing pregnant hypertensive women include urine analysis,
blood count, haematocrit, liver enzymes, serum creatinine
and serum uric acid (increased in clinically evident pre-
eclampsia). Hyperuricaemia in hypertensive pregnancies
identifies women at increased risk of adverse maternal and
foetal outcomes [441].
All pregnant women should be assessed for proteinuria
in early pregnancy to detect preexisting renal disease and,
in the second half of pregnancy, to screen for preeclampsia.
A dipstick test of at least 1þ should prompt evaluation of
ACR in a single spot urine sample and a value less than
30mg/mmol can reliably rule out proteinuria in pregnancy
[442].
In addition to basic laboratory tests, the following inves-
tigations may be considered:
1. Ultrasound investigation of the kidneys and adrenals,
and plasma or urinary fractionated metanephrine
assays in pregnant women with a history suggestive
of phaeochromocytoma.
2. Doppler ultrasound of uterine arteries (performed
after 20 weeks of gestation) to detect those at higher
risk of gestational hypertension, preeclampsia, and
intrauterine growth retardation [443].
3. A soluble fms-like tyrosine kinase 1:placental growth
factor ratio of at least 38 can be used to exclude the
development of preeclampsia in the next week when
suspected clinically [444].
8.9.1.4 Prevention of hypertension and
preeclampsia
Women at high or moderate-risk of preeclampsia should be
advised to take 100–150mg of aspirin daily fromweeks 12–
36 [445]. High risk of preeclampsia includes any of the
following:
1. Hypertensive disease during a previous pregnancy
2. CKD
3. Autoimmune disease such as systemic lupus eryth-
ematosus or antiphospholipid syndrome
4. Type 1 or type 2 diabetes
5. Chronic hypertension
Moderate-risk of preeclampsia includes one or more of
the following risk factors:
1. First pregnancy
2. Age of at least 40 years
3. Pregnancy interval of more than 10 years
4. BMI of at least 35 kg/m2 at first visit
5. Family history of preeclampsia
6. Multiple pregnancy
8.9.1.5 Clinical management of hypertension in
pregnancy
Mild hypertension of pregnancy (BP 140–159/
90–109mmHg) The goal of drug treatment of hyperten-
sion in pregnancy is to reduce maternal risk; however, the
agents selected must be safe for the fetus. The benefits of
drug treatment for mother and fetus in hypertension in
pregnancy have not been extensively studied, with the best
data from a single trial using alpha-methyldopa, performed
40 years ago [446–448]. A further study suggested that
tighter vs. less tight control of BP in pregnancy showed
no difference in the risk of adverse perinatal outcomes and
overall serious maternal complications. However, second-
ary analysis suggested that tighter control of BP may reduce
the risk of developing more severe hypertension and pre-
eclampsia [446].
Most women with preexisting hypertension and normal
renal function will not have severe hypertension and are a
low risk for developing complications during pregnancy.
Indeed, some of these women may be able to withdraw
their medication in the first half of pregnancy because of the
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physiological fall in BP. Despite the paucity of evidence,
European Guidelines [17,449,450] have recommended ini-
tiating drug treatment:
1. In all women with persistent elevation of BP at least
150/95mmHg;
2. In women with gestational hypertension (with or
without proteinuria), preexisting hypertension with
the superimposition of gestational hypertension, or
hypertension with subclinical HMOD, when BP is
more than 140/90mmHg.
Women with preexisting hypertension may continue
their current antihypertensive medication, but ACE inhib-
itors, ARBs, and direct renin inhibitors are contraindicated
due to adverse foetal and neonatal outcomes. Methyldopa,
labetalol, and CCBs are the drugs of choice. Beta-blockers
may induce foetal bradycardia; consequently, if used, their
type and dose should be carefully selected, with atenolol
best avoided. Diuretic therapy is generally avoided because
plasma volume is reduced in women who develop pre-
eclampsia.
There are no data to define the optimal BP treatment
target in pregnant women. Nevertheless, for pragmatic
reasons, if treatment is initiated it is important to
suggest a treatment target to calibrate how much
treatment to give. A BP target of less than 140/90 is
suggested for pregnant women receiving antihyperten-
sive therapy.
Severehypertensionofpregnancy (160/110mmHg).
There is no agreed definition of severe hypertension, with
values ranging between 160 and 180mmHg/more than
110mmHg. The 2018 ESC Task Force on CVD during preg-
nancy [435] considers an SBP of at least 170mmHg or DBP of
at least 110mmHg an emergency in a pregnant woman, who
should be immediately admitted to hospital for treatment.
The selection of the antihypertensive drug and its route of
administration depends on the expected time of delivery.
Pharmacological treatment with i.v. labetalol, oral methyl-
dopa, or CCB should be initiated. Intravenous hydralazine is
no longer the drug of choice as it is associated with more
perinatal adverse effects than other drugs [451]. However,
hydralazine is still usedwhenother treatment regimens fail to
achieve adequate BP control. Intravenous urapidil can also
be considered.
In hypertensive crises, that is in patients with eclamp-
sia or severe preeclampsia (with or without haemolysis,
elevated liver enzymes, and low platelets syndrome),
hospitalization and BP-lowering therapy is essential,
and delivery needs to be considered after the maternal
condition has stabilized [435]. Intravenous magnesium
sulfate is recommended for the prevention of eclampsia
and treatment of seizures. The consensus is to lower BP
to less than 160/105mmHg to prevent acute hypertensive
complications in the mother. Both labetalol and nicardi-
pine have shown to be safe and effective for the treat-
ment of severe preeclampsia if i.v. BP-lowering therapy is
necessary [452]. In both cases, monitoring of foetal heart
rate is necessary. To prevent foetal bradycardia, the
cumulative dose of labetalol should not exceed
800mg/24 h. Intravenous sodium nitroprusside is contra-
indicated in pregnancy because of an increased risk of
foetal cyanide poisoning. The drug of choice when
preeclampsia is associated with pulmonary oedema is
nitroglycerin (glyceryl trinitrate), given as an i.v. infusion
of 5mg/min, and gradually increased every 3–5min to a
maximum dose of 100mg/min.
Delivery is indicated urgently in preeclampsia with
visual disturbances or haemostatic disorders, and at 37
weeks in asymptomatic women [453].
Blood pressure postpartum. Postpartum hyperten-
sion is common in the first week. Any drug recommended
can be used according to the hypertension treatment algo-
rithm shown in Figure 4, with the caveats: methyldopa
should be avoided because of the risk of postpartum
depression and consideration should be given to drug
choice in breastfeeding women.
8.9.1.6 Hypertension and breastfeeding
All antihypertensive drugs taken by the nursing mother are
excreted into breast milk. Most are present at very low
concentrations except for propranolol and nifedipine, with
breast milk concentrations similar to those in maternal
plasma. Reference to prescribing information in breastfeed-
ing women is important.
8.9.1.7 Risk of recurrence of hypertensive disorders
in a subsequent pregnancy
Women experiencing hypertension in their first pregnancy
are at increased risk in a subsequent pregnancy. The earlier
the onset of hypertension in the first pregnancy, the higher
the risk of recurrence in a subsequent pregnancy.
8.9.1.8 Long-term cardiovascular consequences of
gestational hypertension
Women who develop gestational hypertension or pre-
eclampsia are at increased risk of hypertension, stroke,
and ischaemic heart disease in later adult life [454,455].
Lifestyle modifications are indicated to avoid complications
in subsequent pregnancies and to reduce maternal cardio-
vascular risk in the future. Therefore, annual visits to a
primary care physician to check BP and metabolic factors
are recommended for these patients.
Further detail on the management of hypertension and
other cardiovascular disorders in pregnancy is available
[435].
2018 ESC/ESH Guidelines for the management of arterial hypertension
Journal of Hypertension www.jhypertension.com 2005
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Management of hypertension in pregnancy
Recommendations Classa Levelb
In women with gestational hypertension, pre-existing hypertension superimposed by gestational hyperten-
sion, or with hypertension and subclinical organ damage or symptoms, initiation of drug treatment is recom-
mended when SBP is >_ 140 mmHg or DBP >_ 90 mmHg.
I C
In all other cases, initiation of drug treatment is recommended when SBP is >_ 150 mmHg or DBP is >_ 95
mmHg.
I C
Methyldopa, labetalol, and CCBs are recommended as the drugs of choice for the treatment of hypertension in
pregnancy [447,448].
I
B
(methyldopa)
I
C
(labetalol or CCBs)
ACE inhibitors, ARBs, or direct renin inhibitors are not recommended during pregnancy. III C
SBP >_ 170 mmHg or DBP >_ 110 mmHg in a pregnant woman is an emergency, and admission to hospital is
recommended.
I C
In severe hypertension, drug treatment with i.v. labetalol, oral methyldopa, or nifedipine is recommended. I C
The recommended treatment for hypertensive crisis is i.v. labetalol or nicardipine and magnesium. I C
In pre-eclampsia associated with pulmonary oedema, nitroglycerin given as an i.v. infusion is recommended. I C
In women with gestational hypertension or mild pre-eclampsia, delivery is recommended at 37 weeks [453]. I B
It is recommended to expedite delivery in pre-eclampsia with adverse conditions, such as visual disturbances
or haemostatic disorders. I C
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DBP, diastolic blood pressure; i.v., intravenous; SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
8.9.2 Oral contraceptive pills and hypertension
Combined oestrogen–progesterone oral contraceptive pills
can be associated with a small but significant increase in BP
and the development of hypertension in about 5% of users
[456,457]. BP usually decreases promptly following cessa-
tion of these pills; consequently, BP should be monitored
before and during oral contraceptive pill treatment. The rise
in BP appears to be related to the oestrogen content and
may be less likely with the progestogen-only oral con-
traceptive pill. Older studies have demonstrated a relation-
ship between the oral contraceptive pill and venous
thrombosis and venous thromboembolism, and, to a lesser
extent, myocardial infarction (especially with concomitant
smoking history) and stroke [458]. More recent studies with
newer-generation oral contraceptive pills have reported
conflicting results. Thus, the use of oral contraceptives
should consider the risks and benefits for the individual
patient. Changes in BP should be carefully evaluated with
follow-up readings [459]. Concomitant cardiovascular risk
factors (e.g. smoking history) should be assessed and oral
contraceptive pill use is not recommended if BP is elevated.
In such patients, alternative forms of contraception should
be offered. Discontinuation of combined oestrogen–
progestin oral contraceptives in women with hypertension
may improve their BP control [460].
8.9.3 Hormone-replacement therapy and
hypertension
Cross-sectional studies have long established that meno-
pause doubles the risk of developing hypertension, even
after adjusting for factors such as age and BMI [461].
Although hormone-replacement therapy contains oestro-
gens, there is no convincing evidence that significant rises
in BP will occur in otherwise normotensive menopausal
women due to this therapy, or that BP will increase further
due to hormone-replacement therapy in menopausal
hypertensive women [462]. Hormone-replacement therapy
and selective oestrogen receptor modulators should not be
used for primary or secondary prevention of CVD. In
summary, current evidence suggests that the use of hor-
mone-replacement therapy is not associated with an
increase in BP. Moreover, it is not contraindicated in
women with hypertension, and women with hypertension
may be prescribed hormone-replacement therapy as
long as BP levels can be controlled by antihypertensive
medication.
8.10 Hypertension in different ethnic groups
In comparison with the nonblack population, hypertension
is more prevalent in the black population living in Europe
[463], similarly to that reported for the USA [464]. As for the
European white population, the black European popula-
tion is heterogenous in nature [463], although in almost all
European countries the largest ethnic group originates from
the Sub-Saharan African region [463]. Hypertension epide-
miology, diagnosis, and treatment have been thoroughly
studied in black (i.e. Afro-American) US patients [464], in
contrast to the much scarcer database available for Euro-
pean black people, and thus we extrapolate from US data.
However, this extrapolation requires some caution as
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differences between the North American and the European
black population exist, especially with regard to socioeco-
nomic status, cardiovascular risk [465,466], and the
response to antihypertensive drug treatment [467]. BP-
related HMOD, as well as cardiovascular and renal com-
plications, are more common and severe in black patients
compared with age-matched white patients at any BP level
[464]. Black hypertensive patients exhibit a similar propor-
tional reduction of cardiovascular and renal events in
response to BP-lowering treatment as white patients, with
somewhat different treatment modalities. However, to
achieve an effective BP reduction and BP control, salt
restriction is particularly important in black patients, in
whom it may lead to greater BP falls and more favourably
impact on the effectiveness of BP-lowering drug treatment
[468]. Hypertensive black patients also show a reduced
antihypertensive response to RAS-blocker monotherapy,
whereas they usually respond more effectively to thiazide
or thiazide-like diuretics and CCBs [316,469,470], which in
black patients may be combined with each other or with a
RAS blocker, making the latter more effective. Angioedema
appears more common with ACE inhibitors in black
patients, which may favour the preferred use of ARBs in
this population. Despite some progress in recent years, data
on hypertension prevalence, management, and control in
European black patients (and in other immigrant popula-
tions such as European individuals from South Asia) are still
scarce [463,471], which makes this field an important area
for future research. There is no evidence that the BP
response to treatment in other ethnic groups differs from
that reported in the general population in Europe.
Hypertension in ethnic groups
Recommendations Classa Levelb
It is recommended that a two-drug combi-
nation, usually as an SPC, is used as initial
therapy for most black patients.c
I C
In black patients, initial antihypertensive
treatment should include a diuretic or a
CCB, either in combination or with a RAS
blocker [316,469].d
I B
In other ethnic groups, BP-lowering treat-
ment may be based on the core treatment
algorithm (see Figure 4).
IIb C
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood
pressure; CCB, calcium channel blocker; RAS, renin–angiotensin system; SPC, single-pill
combination.
aClass of recommendation.
bLevel of evidence.
cExcept in patients with low grade 1 hypertension or frail older patients, in whom initial
treatment with a single drug may be more appropriate.
dAngioedema is more common with ACE inhibitors and thus ARBs may be preferred.
8.11 Hypertension in diabetes mellitus
High BP is a common feature of type 1 and, particularly,
type 2 diabetes. Moreover, masked hypertension and a
blunted nocturnal fall in BP are not infrequent in people
with diabetes [472]. Recording 24 h ABPM in apparently
normotensive people with diabetes may be a useful
diagnostic procedure, especially in those with HMOD.
Substantial evidence supports the benefits of BP reduc-
tion in people with diabetes to reduce major macro-
vascular and microvascular complications of diabetes,
as well as reducing mortality. Proven benefits of BP-
lowering treatment in diabetes also include a significant
reduction in the rate of end-stage renal disease [231,235],
retinopathy [1], and albuminuria [1]. Diabetic neuropathy
has never been included as an outcome in RCTs of BP-
lowering treatment.
When considering treatment for hypertension, it is
important to exclude significant postural hypotension,
which can be marked in people with diabetes due to
autonomic neuropathy [235]. Initiation of antihyperten-
sive drug therapy is recommended when the office BP is
more than 140/90mmHg. Alongside lifestyle interven-
tions, treatment should usually be initiated with a two-
drug combination of an ACE inhibitor or ARB with a CCB
or thiazide/thiazide-like diuretic, and treatment escalated
according to the recommended treatment algorithm (see
Section 7). This approach ensures that the treatment
strategy includes an ACE inhibitor or ARB, which has
been shown to reduce albuminuria and the appearance
or progression of diabetic nephropathy more effectively
than other drug classes [235]. Combination of an ACE
inhibitor with an ARB is contraindicated because it is
accompanied by an excess of renal adverse events
[298,473,474].
Recent RCTs have shown that some antidiabetic
agents (the selective inhibitors of sodium glucose
cotransporter 2 in the kidney) can reduce office and
ambulatory BP by severalmmHg [475,476], and that this
occurs even when people are treated with antihyperten-
sive drugs. This may help improve BP control (see
below), which is especially difficult in diabetes [477],
and may reduce the progression of CKD [478–481]
(see also Section 8.12).
There has been considerable debate about the target
BP that should be achieved in people with diabetes
(see Section 7). We recommend that in people with
diabetes, the first objective should be to lower BP
to less than 140/80mmHg, aiming at an SBP of
130mmHg. Provided that the treatment is well tolerated,
treated SBP values of less than 130mmHg should be
considered because of the benefits on stroke preven-
tion. Achieved SBP values of less than 120mmHg should
always be avoided. BP targets for renoprotection for
patients with diabetic kidney disease are discussed in
Section 8.12.
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Treatment strategies in people with diabetes
Recommendations a LevelClass b
Antihypertensive drug treatment is recom-
mended for people with diabetes when
office BP is >_ 140/90 mmHg [1,226,235,482].
I A
In people with diabetes receiving BP-lower-
ing drugs it is recommended:
• To target SBP to 130 mmHg and
< 130mmHg if tolerated, but not
< 120 mmHg [1,231,235].
I A
• In older people (aged >_ 65 years aged), to
target to an SBP range of 130–139
mmHg [1,205,235].
I A
• To target the DBP to < 80 mmHg, but
not < 70 mmHg.
I C
It is recommended to initiate treatment
with a combination of a RAS blocker with a
CCB or thiazide/thiazide-like diuretic
[1,175,205].
c
I A
Simultaneous administration of two RAS
blockers, e.g. an ACE inhibitor and ARB, is
not indicated [291,298,299].
III A
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood
pressure; CCB, calcium channel blocker; DBP, diastolic blood pressure; eGFR, estimated
glomerular filtration rate; RAS, renin-angiotensin system; SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
cWhen eGFR <30ml/min/1.73m2, avoid thiazide/thiazide-like diuretics and consider using
a loop diuretic when a diuretic is required.
8.12 Hypertension and chronic kidney disease
Hypertension is a major risk factor for the development and
progression of CKD, irrespective of the cause of CKD. In
patients with CKD, resistant hypertension, masked hyper-
tension, and elevated nighttime BP are common, and are
associated with a lower eGFR, higher levels of albuminuria,
and HMOD [483,484].
The effects of lowering BP in patients with CKD have
been the subject of many meta-analyses. A recent meta-
analysis has shown that BP lowering significantly reduced
end-stage renal disease in patients with CKD, but only in
those with albuminuria and without any beneficial effect on
cardiovascular events [203]. However, a more recent and
larger meta-analysis has shown a significant reduction in
all-cause mortality following BP reduction in patients with
CKD [485].
Reduction of albuminuria has also been considered as
a therapeutic target. Analyses of data from RCTs have
reported that changes in urinary albumin excretion are
predictors of renal and cardiovascular events [186,486].
However, there are also studies in which treatment
that was less effective at reducing albuminuria was
more effective at reducing cardiovascular events [175]
and vice versa [176,291]. Thus, whether reducing albu-
minuria per se is a proxy for CVD prevention remains
unresolved.
Patients with CKD should receive lifestyle advice,
especially sodium restriction, and drug treatment when
their office BP is more than 140/90mmHg. Achieving
recommended BP targets in CKD usually requires com-
bination therapy, which should be initiated as a combi-
nation of a RAS blocker with a CCB or diuretic in these
patients. The combination of two RAS blockers is not
recommended [291]. Loop diuretics should replace thia-
zide diuretics when the estimated GFR is less than 30ml/
min/1.73m2.
The evidence with respect to BP targets in patients
with CKD is complex. In patients with nondiabetic CKD,
one meta-analysis showed that the slowest progression
on CKD was obtained with a treated SBP in the range of
110–119mmHg in patients with albuminuria more than
1 g/day [487]. In contrast, in patients with a proteinuria
less than 1 g/day, the lowest risk of developing CKD
(not cardiovascular risk) was obtained with an SBP of
less than 140mmHg [487]. Another systematic review
failed to demonstrate that a BP target of less than 130/
80mmHg improved clinical outcomes more than a target
of less than 140/90mmHg in nondiabetic CKD [488]. In a
large retrospective cohort containing 398 419 treated
hypertensive patients (30% with diabetes), the nadir
SBP and DBP for the lowest risk of end-stage renal
disease and mortality were 137 and 71mmHg, respec-
tively, with a clear increase in mortality risk at SBP less
than 120mmHg [489].
Current evidence suggests that in patients with CKD,
BP should be lowered to less than 140/90mmHg and
towards 130/80mmHg. Lifestyle advice, especially
sodium restriction, may be especially effective at aiding
BP lowering in patients with CKD. Because BP lowering
reduces renal perfusion pressure, it is expected and not
unusual for eGFR to be reduced by 10–20% in patients
treated for hypertension. Thus, careful monitoring of
blood electrolytes and eGFR is essential, but clinicians
should not be alarmed by the anticipated decline in GFR
when treatment is initiated. This decline usually occurs
within the first few weeks of treatment and stabilizes
thereafter. If the decline in GFR continues or is more
severe, the treatment should be stopped, and the patient
investigated to determine the presence of renovascular
disease.
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Therapeutic strategies for treatment of hypertension in CKD
Recommendations a LevelClass b
In patients with diabetic or non-diabetic
CKD, it is recommended that an office BP
of >_ 140/90 mmHg be treated with lifestyle
advice and BP-lowering medication
[9,203,485].
I A
In patients with diabetic or non-diabetic
CKD:
• It is recommended to lower SBP to a
range of 130–139 mmHg [9,487,489].
I A
• Individualized treatment should be con-
sidered according to its tolerability and
impact on renal function and electrolytes.
IIa C
RAS blockers are more effective at reducing
albuminuria than other antihypertensive
agents, and are recommended as part of the
treatment strategy in hypertensive patients
in the presence of microalbuminuria or
proteinuria [487,489].
I A
A combination of a RAS blocker with a
CCB or a diureticc is recommended as initial
therapy [175].
I A
A combination of two RAS blockers is not
recommended [298]. III A
BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; eGFR,
estimated glomerular filtration rate; RAS, renin-angiotensin system; SBP, systolic blood
pressure.
aClass of recommendation.
bLevel of evidence.
cIn case of eGFR <30ml/min/1.73m2, avoid thiazide/thiazide-like diuretics and consider
using a loop diuretic if required.
8.13 Hypertension and chronic obstructive
pulmonary disease
Hypertension is the most frequent comorbidity in patients
with COPD, and coincidence of the two diseasesmay affect
2.5% of the adult population [490]. Patients with hyperten-
sion and COPD are at particularly high cardiovascular risk
[490,491]. Both conditions share similar environmental
risks and, in addition, hypoxia may exacerbate the risk
[490,491]. Treatment of COPD with anticholinergic agents
and long-acting beta-2 adrenoceptor agonists may
adversely affect the cardiovascular system (increase heart
rate and BP). The presence of COPD also has an impact on
the selection of antihypertensive drugs, which should
consider their effects on pulmonary function. Concern
has been predominantly directed to the use of beta-block-
ers, although there is evidence that in COPD these drugs
maintain their cardiovascular-protective effects [492,493].
Beta-blockers may negatively affect the reduced basal lung
function in patients with COPD, diminish the effectiveness
of emergency beta-agonist administration, reduce the ben-
efit of long-acting beta-agonist treatment, and make the
discrimination of asthma and COPD more difficult. That
said, when tolerated, the use of cardiac beta1-selective
beta-blockers in patients with COPD has proven to be safe
in different settings, including hypertension [494]. It should
also be noted that diuretics may decrease the plasma level
of potassium (in addition to the hypokalaemic effects of
glucocorticoids and beta2-adrenoceptor agonists), worsen
carbon dioxide retention (including metabolic alkalosis-
related hypoxia in hypoventilated patients), increase hae-
matocrit, and deteriorate mucus secretion in bronchi.
Therefore, in general, diuretics are not recommended
for widespread use in hypertensive patients with COPD
[490,495].
In conclusion, management of hypertensive patients
with COPD should include lifestyle changes, among which
cessation of smoking is essential. CCBs, ARBs or ACEIs, or
the CCB/RAS blocker combination are recommended as the
initial drugs of choice. If the BP response is poor,
or depending on other comorbidities, thiazides or
thiazide-like diuretics and beta1-selective beta-blockers
can be considered.
8.14 Hypertension and heart disease
8.14.1 Coronary artery disease
There are strong epidemiological relationships between
CAD and hypertension. The INTERHEART study showed
that 50% of the population-attributable risk of a myocardial
infarction can be accounted for by lipids, with hypertension
accounting for 25% [10]. Another registry-based study of
over 1 million patients showed that ischaemic heart disease
(angina and myocardial infarction) accounted for most
(43%) of the CVD-free years of life lost due to hypertension
from the age of 30 years [7].
More compelling is the beneficial effect of BP treat-
ment on reducing the risk of myocardial infarction. A
recent meta-analysis of RCTs of antihypertensive ther-
apy showed that for every 10mmHg reduction in SBP,
CAD was reduced by 17% [2]. A similar risk reduction
has been reported by others with more intensive BP
control [496]. The benefits of reducing cardiac events are
also evident in high-risk groups, such as those with
diabetes [231,425].
There remains some inconsistency over the optimal BP
target in less than patients with overt CAD, and especially
whether there is a J-curve relationship between achieved
BP and cardiovascular outcomes in CAD [497–500]. A
recent analysis [501] of 22 672 patients with stable CAD
who were treated for hypertension found that, after a
median follow-up of 5.0 years, an SBP of at least
140mmHg and a DBP of at least 80mmHg were each
associated with increased risk of cardiovascular events.
An SBP of less than 120mmHg was also associated with
increased risk, as was a DBP of less than 70mmHg.
Similar findings were also reported from another analysis
of RCT data evaluating the relationships between
achieved BP and risks of cardiovascular outcomes
[222]. Whether a J-curve phenomenon exists in patients
with CAD who have been revascularized remains uncer-
tain. Other analyses do not support the existence of a J-
curve, even in hypertensive patients at increased cardio-
vascular risk [239]. For example, in patients with CAD and
initially free from congestive heart failure enrolled in
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Therapeutic strategies in hypertensive patients with CAD
Recommendations a LevelClass b
In patients with CAD receiving BP-lowering drugs, it is
recommended:
• To target SBP to <_ 130 mmHg if toler-
ated, but not < 120 mmHg [2,496].
I A
• In older patients (aged >_ 65 years), to tar-
get to an SBP range of 130–140
mmHg [2,496].
I A
• To target DBP to < 80 mmHg, but not
< 70 mmHg.
I C
In hypertensive patients with a history of
myocardial infarction, beta-blockers and
RAS blockers are recommended as part of
treatment [503].
I A
In patients with symptomatic angina, beta-
blockers and/or CCBs are
recommended [503].
I A
BP, blood pressure; CAD, coronary artery disease; CCB, calcium channel blocker; DBP,
diastolic blood pressure; RAS, renin–angiotensin system; SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
ONTARGET, a BP reduction from baseline over the exam-
ined BP range had little effect on the risk of myocardial
infarction and predicted a lower risk of stroke [502]. Thus, a
target BP of approximately less than 130/80mmHg in
patients with CAD appears safe and can be recommended,
but achieving a BP less than 120/80mmHg is not-
recommended.
In hypertensive patients with CAD, beta-blockers
and RAS blockers may improve outcomes in postmyo-
cardial infarction [503]. In patients with symptomatic
angina, beta-blockers and calcium antagonists are
the preferred components of the drug treatment
strategy.
8.14.2 Left ventricular hypertrophy and heart
failure
Hypertension is the leading risk factor for the development
of heart failure [7], and most patients with heart failure will
have a history of hypertension. This may be a consequence
of CAD, which results in HFrEF. Hypertension also causes
LVH, which impairs left ventricular relaxation (so-called
diastolic dysfunction) and is a potent predictor of heart
failure, even when left ventricular systolic function is nor-
mal and there is no preceding myocardial infarction
(HFpEF). Hypertension-dependent fibrosis and structural
alteration of large and small arteries (microvascular disease)
also contribute.
Treating hypertension has a major impact on reducing
the risk of incident heart failure and heart failure hospitali-
zation, especially in old and very old patients [51,213,316].
This has been observed using diuretics, beta-blockers, ACE
inhibitors, or ARBs, with CCBs being less effective in
comparative trials [504].
Reducing BP can also lead to the regression of LVH,
which has been shown to be accompanied by a reduction
of cardiovascular events and mortality [125]. The magnitude
of LVH regression is associated with baseline left ventricular
mass, duration of therapy, the SBP reduction [505,506], and
the drugs used, with ARBs, ACE inhibitors, and CBBs
causing more effective LVH regression than beta-blockers
[173] or diuretics.
In patients with HFrEF, antihypertensive drug treat-
ment should start (if not already initiated) when BP is
more than 140/90mmHg. It is unclear how low BP should
be lowered in patients with heart failure. Outcomes for
patients with heart failure have repeatedly been shown to
be poor if BP values are low, which suggests (although
data interpretation is made difficult by the possibility of
reversed causality) that it may be wise to avoid actively
lowering BP to less than 120/70mmHg. However, some
patients may achieve even lower BP levels than this
because of the desirability to remain on treatment with
guideline-directed heart failure medications, which, if
tolerated, should be continued because of their protec-
tive effect [136].
Heart failure guideline-directed medications are rec-
ommended for the treatment of hypertension in patients
with HFrEF [136]. ACE inhibitors, ARBs, beta-blockers,
and MRAs (e.g. spironolactone and epleronone) are all
effective in improving clinical outcome in patients with
established HFrEF, whereas for diuretics, evidence is
limited to symptomatic improvement. If further BP low-
ering is required, a dihydropyridine CCB may be consid-
ered. Sacubutril/valsartan lowers BP has also been shown
to improve outcomes in patients with HFrEF, and is
indicated for the treatment of HFrEF as an alternative
to ACE inhibitors or ARBs [507]. Nondihydropiridine
CCBs (diltiazem and verapamil), alpha-blockers, and
centrally acting agents, such as moxonidine, should
not be used.
Antihypertensive treatment is commonly needed in
patients with HFpEF; the same BP threshold and target
for drug treatment indicated for HFrEF should be used. The
optimal treatment strategy for hypertensive patients with
HFpEF is not known, but the strategy outlined above for
HFrEF patients might also be the one to adopt in HFpEF
patients. HFpEF patients commonly have multiple comor-
bidities that may adversely affect outcomes and complicate
management.
Williams et al.
2010 www.jhypertension.com Volume 36  Number 10  October 2018
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Therapeutic strategies in hypertensive patients with heart failure or LVH
Recommendations a LevelClass b
In hypertensive patients with heart failure
(with reduced or preserved ejection frac-
tion), BP-lowering treatment should be con-
sidered if BP is >_ 140/90 mmHg [136].c
IIa B
In patients with HFrEF, it is recommended
that BP-lowering treatment comprises an
ACE inhibitor or ARB, and a beta-blocker
and diuretic and/or MRA if required [136].
I A
Dihydropyridine CCBs may be added if BP
control is not achieved.d
IIb C
In patients with HFpEF, BP treatment
threshold and target values should be the
same as for HFrEF [136].
IIa B
Because no specific drug has proven its
superiority, all major agents can be used.
I C
In all patients with LVH:
• It is recommended to treat with an RAS
blocker in combination with a CCB or
diuretic [504].
• SBP should be lowered to a range of
120–130 mmHg [504,506].
I A
IIa B
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood
pressure; CCB, calcium channel blocker; HFrEF, heart failure with reduced ejection
fraction; HFpEF, heart failure with preserved ejection fraction; LVH, left ventricular
hypertrophy; MRA, mineralocorticoid receptor antagonist; RAS, renin–angiotensin
system; SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
cA lowest safety BP value is not given as many patients receiving intensive treatment for
heart failure may achieve much lower BP levels than recommended BP targets.
dNon-dihydropyridines are not recommended in HFrEF but may be used in HFpEF.
8.15 Cerebrovascular disease and cognition
Hypertension is a major risk factor for haemorrhagic and
ischaemic stroke, and a risk factor for recurrent stroke. BP
management during the acute phase of haemorrhagic and
ischaemic stroke remains an area of uncertainty. BP is often
elevated at presentation with acute stroke, but often
declines without intervention [508].
8.15.1 Acute intracerebral haemorrhage
In acute intracerebral haemorrhage, an increased BP is
common and is associated with a greater risk of haematoma
expansion, increased riskof death, and aworseprognosis for
neurological recovery [509,510]. Results from an RCT sug-
gested that immediate BP lowering (within 6h) to less than
140/90mmHg did not show benefit on the primary outcome
of disability or death at 3 months, but might reduce haema-
toma expansion and improve functional recovery, and was
generally safe [511]. A subsequent RCT, in which SBP was
immediately reduced (<4.5h) from a mean of 200mmHg to
two different target intervals (140–170 vs. 110–139mmHg),
showed that more intensive BP lowering had no benefit on
the same primary outcome and was associated with more
renal adverse events [512]. Thus, we do not recommend
treatment to immediately lower BP in patients with acute
intracerebral haemorrhage. One possible caveat to this rec-
ommendation is patients with acute intracerebral haemor-
rhage and very severe hypertension (SBP 220mmHg), for
whom there are much fewer data. A meta-analysis [513] and
secondary outcome data from one RCT [511] have suggested
a possible benefit on functional recovery at 3 months, and
that acute lowering of SBP to less than 180mmHg in these
patientsmight be beneficial. Thus, careful lowering of BP via
i.v. infusion may be considered in patients with markedly
elevated BP (SBP 220mmHg).
8.15.2 Acute ischaemic stroke
The beneficial effects of BP reduction are even less clear in
acute ischaemic stroke. A key consideration is whether the
patient will receive thrombolysis, because observational
studies have reported an increased risk of intracerebral
haemorrhage in patients with a markedly elevated BP
who received thrombolysis [514,515]. In patients receiving
i.v. thrombolysis, BP should be lowered and maintained at
less than 180/105mmHg for at least the first 24 h after
thrombolysis. The benefit of acute BP lowering in patients
with acute ischaemic stroke who do not receive thrombol-
ysis is uncertain. A meta-analysis suggested that BP lower-
ing early after acute ischaemic stroke had a neutral effect on
the prevention of death or dependency [516,517]. In such
patients with markedly elevated SBP or DBP (i.e. 220 or
120mmHg, respectively), clinical judgement should
define whether to intervene with drug therapy, in which
case a reasonable goal may be to lower BP by 15%, with
close monitoring, during the first 24 h after stroke onset
[516,518–520]. Patients with acute ischaemic stroke and a
BP lower than this in the first 72 h after stroke do not seem
to benefit from the introduction or reintroduction of BP-
lowering medication [516,521]. For stable patients who
remain hypertensive (140/90mmHg) more than 3 days
after an acute ischaemic stroke, initiation or reintroduction
of BP-lowering medication should be considered [522].
8.15.3 Previous stroke or transient ischaemic attack
RCTs of antihypertensive treatment (placebo controlled) in
patients with a previous stroke or TIA, in a stable clinical
condition, and with BP more than 140/90mmHg, have
shown that BP lowering reduces the risk of recurrent stroke
[338,523]. No evidence is yet available that recurrent stroke
is prevented by initiating therapy when BP is in the high–
normal range. We recommend resumption of BP-lowering
therapy several days after stroke, or immediately after TIA,
for previously treated or untreated patients with hyperten-
sion, for prevention of both recurrent stroke and other
cardiovascular events.
The appropriate BP targets to prevent recurrent stroke
are uncertain, but should be considered in the context of a
consistent finding in many meta-analyses that stroke is the
one major cardiovascular event that is reduced at lower
achieved BP levels. This is supported by the results from the
recent Secondary Prevention of Small Subcortical Strokes 3
study [244,524] in patients with a recent lacunar stroke,
which suggested an SBP target of less than 130mmHg [525],
and other studies [526].
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Therapeutic strategies in hypertensive patients with acute stroke and cerebrovascular disease
Recommendations Classa Levelb
In patients with acute intracerebral haemorrhage:
• Immediate BP lowering is not recommended for patients with SBP < 220 mmHg [509–513]. III A
• In patients with SBP >_ 220 mmHg, careful acute BP lowering with i.v. therapy to < 180 mmHg should be considered
[509–513]. IIa B
In acute ischaemic stroke, routine BP lowering with antihypertensive therapy is not recommended [516,517],
with the exceptions:
III A
• In patients with acute ischaemic stroke who are eligible for i.v. thrombolysis, BP should be carefully lowered and maintained
at < 180/105 mmHg for at least the first 24 h after thrombolysis [514,515].
IIa B
• In patients with markedly elevated BP who do not receive fibrinolysis, drug therapy may be considered, based on clinical
judgement, to reduce BP by 15% during the first 24 h after the stroke onset.
IIb C
In hypertensive patients with an acute cerebrovascular event, antihypertensive treatment is recommended:
• Immediately for TIA [526].
I A
• After several days in ischaemic stroke [526]. I A
In all hypertensive patients with ischaemic stroke or TIA, an SBP target range of 120–130 mmHg should be
considered [244,524,526].
IIa B
The recommended antihypertensive drug treatment strategy for stroke prevention is a RAS blocker plus a CCB or a thiazide-
like diuretic [338]. I A
BP, blood pressure; CCB, calcium channel blocker; i.v., intravenous; RAS, renin–angiotensin system; SBP, systolic blood pressure; TIA, transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
Prevention of stroke is a consistent benefit of antihy-
pertensive therapy and has been observed in all large RCTs
using different drug regimens. However, individual RCTs
comparing modern treatment regimens [317,527] and
meta-analyses suggest that beta-blockers are less effective
at stroke prevention than other classes of antihypertensive
agents [2,528]. Although the beta-blocker in these studies
was atenolol, there are no data with more modern beta-
blockers with regards to stroke prevention in hyperten-
sion. Thus, optimal antihypertensive treatment for stroke
prevention should not include beta-blockers unless
there is a compelling indication for their use, mindful of
the fact that the most common recurrent event after
stroke is a further stroke rather than myocardial infarction
[529].
8.15.4 Cognitive dysfunction and dementia
Several epidemiological and clinical studies have shown
that hypertension in midlife predicts cognitive decline and
dementia (both Alzheimer’s disease and vascular dementia)
in older patients [530–533]. However, evidence on the
beneficial effects of BP lowering on cognitive decline is
scant and conflicting. A meta-analysis [534] of 12 studies
investigating the impact of different antihypertensive drugs
on dementia and cognitive function concluded that BP
lowering reduced the incidence and risk of cognitive
impairment and dementia by 9%. One study showed that
achieving better BP control over 4 years reduced the
progression of cerebral white matter lesions and the
decrease in global cognitive performance [535].
Trials are urgently needed to better define the potential
impact of BP lowering on preventing cognitive decline or
in delaying dementia when cognitive dysfunction is
already present.
8.16 Hypertension, atrial fibrillation, and other
arrhythmias
Hypertension predisposes to cardiac arrhythmias, including
ventricular arrhythmias, but most commonly AF [536–538],
which should be considered a manifestation of hyperten-
sive heart disease [539]. Even high–normal BP is associated
with incident AF [540,541], and hypertension is the most
prevalent concomitant condition in AF patients. AF adds to
the risk of stroke and heart failure. AF necessitates stroke
prevention with oral anticoagulation, with monitoring of
the associated risks and prevention of bleeding [542].
Most patients show a high ventricular rate with AF [542]
and, in such patients, beta-blockers or nondihydropyridine
calcium antagonists (e.g. diltiazem and verapamil) are
recommended as antihypertensive agents. Nondihydropyr-
idine CCBs should be avoided in patients with reduced left
ventricular systolic function and may precipitate heart fail-
ure in some patients. Beta-blockers are often indicated in
these patients, and may need to be combined with digoxin
to gain rate control [542].
In RCTs of hypertensive patients with LVH and/or high
cardiovascular risk [543,544], RAS blockers have been
shown to reduce first occurrence of AF, compared with
beta-blockers or CCBs, consistent with similar effects of RAS
blockers in patients with heart failure [545–547]. RAS block-
ers do not prevent recurrence of paroxysmal or persistent
AF [548–550]. In patients with heart failure, beta-blockers
[551] and MRAs [552] may also prevent AF. The preventive
effect of RAS blockers against the development of AF is
indirectly supported by a general practice database in the
UK, with approximately 5 million patient records, which
has reported that ACE inhibitors, ARBs, and beta-blockers
are associated with a lower risk of AF compared with CCBs
[553]. Hence, RAS blockers should be considered as part of
Williams et al.
2012 www.jhypertension.com Volume 36  Number 10  October 2018
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
the antihypertensive treatment strategy in hypertensive
patients with a high risk of AF (e.g. LVH), to prevent
incident AF.
8.16.1 Oral anticoagulants and hypertension
Many patients requiring oral anticoagulants (e.g. with AF)
will be hypertensive. Hypertension is not a contraindication
to oral anticoagulant use. However, although its role has
been unappreciated in most old and more recent RCTs on
anticoagulant treatment [537], hypertension does substan-
tially increase the risk of intracerebral haemorrhage when
oral anticoagulants are used, and efforts should be directed
towards achieving a BP goal of less than 130/80mmHg in
patients receiving oral anticoagulants. Detailed information
on hypertension and oral anticoagulants has been pub-
lished recently [526,536]. Anticoagulants should be used to
reduce the risk of stroke in most AF patients with hyper-
tension, including those with AF in whom hypertension is
the single additional stroke risk factor [554,555]. BP control
is important to minimize the risks of AF-related stroke and
oral anticoagulant-related bleeding. Until more data are
available, BP values in AF patients taking oral anticoagu-
lants should be at least less than 140mmHg for SBP and less
than 90mmHg for DBP. Oral anticoagulants should be used
with caution in patients with persistent uncontrolled hyper-
tension (SBP 180mmHg and/or DBP 100mmHg), and
urgent efforts to control BP should be made.
8.17 Hypertension and vascular disease
8.17.1 Carotid atherosclerosis
A small number of studies have reported the effects of the
various pharmacological classes of antihypertensive drugs
on carotid IMT, and very few on carotid plaques. Reducing
BP regresses carotid IMT and may delay the intimal athero-
sclerotic process. There appear to be differential drug
effects on IMT regression, with CCBs having greater efficacy
than diuretics and beta-blockers [146], and ACE inhibitors
more than diuretics [557]. However, the relevance of these
findings is unclear because most patients receive combi-
nations of treatment and the progression or treatment-
induced changes in carotid IMT are poorly predictive of
future cardiovascular events [184,558]. Patients with carotid
plaques are at high risk of atheroembolic stroke and car-
diovascular events, and BP lowering should be comple-
mented by lifestyle advice and treatment with statins and
antiplatelet therapy. A common conundrum faced by clini-
cians is the hypertensive patient with a tight carotid steno-
sis, especially when bilateral. No study has addressed this
scenario and therefore advice is necessarily pragmatic, and
we recommend a more cautious approach to BP lowering,
initiating with monotherapy and carefully monitoring for
adverse effects.
8.17.2 Arteriosclerosis and increased arterial
stiffness
Large artery stiffening is a major factor contributing to the
rise in SBP and fall in DBP with ageing. Arterial stiffness is
usually measured in studies as PWV. Arterial stiffening
results from arteriosclerotic structural changes in large
conduit arteries, leading to a loss of arterial elasticity,
and the distending force resulting from the pressure exerted
on the arterial wall. Thus, all antihypertensive drugs, by
reducing BP, reduce arterial stiffness, as the reduction in BP
unloads the stiff components of the arterial wall, leading to
a passive decrease in PWV. Pharmacodynamic RCTs [559]
and meta-analyses [560,561] suggest that ACE inhibitors and
ARBs may reduce PWV beyond the effect of BP lowering on
a long-term basis. Whether RAS blockers are more effective
than other antihypertensive drugs in this regard has not
been demonstrated. Moreover, whether any long-term
reduction in aortic stiffness [562] translates into a reduction
in cardiovascular events beyond the impact of BP lowering
alone [563] has not been demonstrated.
Therapeutic strategies in hypertensive patients with AF
Recommendation Classa Levelb
In patients with AF, screening for hypertension is recommended [536]. I C
A beta-blocker or non-dihydropyridine CCB should be considered as part of the treatment of hypertension if rate control is
needed [536]. IIa B
Stroke prevention with oral anticoagulation is recommended in patients with AF and hypertension, and a CHA2DS2-VASc
score of >_ 2 in men and >_ 3 in women [536, 556].
I A
Stroke prevention with oral anticoagulants should be considered in AF patients with hypertension, even when hypertension is
the single additional risk factor (CHA2DS2-VASc score of 1) [536, 556].
IIa B
Oral anticoagulants should be used with caution in patients with marked BP elevation (SBP >_ 180 mmHg and/or DBP
>_ 100 mmHg); the aim should be to lower SBP to at least < 140 mmHg, and SBP lowering to < 130 should be considered.
If this is not possible, then patients should make an informed decision that they accept that the stroke protection
provided by the anticoagulant will be associated with higher bleeding risk [536].
IIa B
AF, atrial fibrillation; BP, blood pressure; CCB, calcium channel blocker; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age 75 years, Diabetes mellitus, Stroke, Vascular
disease, Age 65–74 years, Sex category (female); DBP, diastolic blood pressure; SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
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8.17.3 Lower extremity arterial disease
LEAD is often a manifestation of more widespread ath-
erosclerosis and especially atherosclerotic renal artery
disease [564], and these patients are at very high cardio-
vascular risk [190]. BP control is an important part of the
cardiovascular risk-reduction strategy in these patients.
Beta-blockers have not been shown to worsen the symp-
toms of claudication in two meta-analyses [565,566]. Thus,
beta-blockers remain a treatment option in hypertensive
patients with LEAD when there is a specific indication for
their use. When critical limb ischaemia is present, BP
reduction should be instituted slowly as it may worsen
ischaemia. In patients with LEAD, antihypertensive treat-
ment should be complemented by lifestyle changes and
especially smoking cessation, as well as statin and anti-
platelet therapy [190].
Therapeutic strategies in hypertensive patients with LEAD
Recommendations a LevelClass b
BP-lowering treatment is recommended to
reduce CV risk [2,190,503].
I A
A combination of a RAS blocker, CCB, or
diuretic should be considered as initial
therapy [2].
IIa B
Beta-blockers may also be considered [566]. IIb C
BP, blood pressure; CCB, calcium channel blocker; CV, cardiovascular; LEAD, lower
extremity arterial disease; RAS, renin–angiotensin system.
aClass of recommendation.
bLevel of evidence.
8.18 Hypertension in valvular disease and
aortopathy
8.18.1 Coarctation of the aorta
When feasible, treatment of aortic coarctation is predom-
inantly surgical and usually done in childhood. Even after
surgical correction, these patients may develop systolic
hypertension at a young age and require long-term
follow-up. Few patients with aortic coarctation remain
undetected until adult life, and by then often have severe
hypertension, HMOD (especially LVH and left ventricular
dysfunction), and an extensive collateral circulation
below the coarctation. Such patients should be evaluated
in a specialist centre. The medical therapy for hyperten-
sion in patients with aortic coarctation should follow the
treatment algorithm outlined in Section 7, as there have
been no formal RCTs to define optimal treatment strate-
gies [567].
8.18.2 Prevention of aortic dilation and dissection
in high-risk subjects
Chronic hypertension can be associated with modest
aortic root dilatation. When more extensive aortic root
dilatation is present or the dilatation extends beyond the
aortic root, an additional cause for aortopathy should be
sought. All hypertensive patients with aortic dilatation,
whether associated with Marfan syndrome, bicuspid aor-
tic valve disease, or not, should have their BP controlled
130/80mmHg [568]. In patients with Marfan syndrome,
prophylactic use of ACE inhibitors, ARBs, or beta-block-
ers seems to be able to reduce either the progression of
the aortic dilation or the occurrence of complications
[568–570]. However, there is no evidence for the specific
efficacy of these treatments in aortic disease of
other aetiologies.
8.18.3 Hypertension bicuspid aortic valve-related
aortopathy
Bicuspid aortic valve disease occurs in 1 in 100 people,
more often men, and is associated with coexistent aortic
coarctation, which should be excluded in patients with
bicuspid aortic valve disease. Bicuspid aortic valve dis-
ease is associated with an aortopathy, and the risk of
development of aortic dilation is higher in patients with
bicuspid aortic valve disease than in the normal popula-
tion [571] and is probably exacerbated by hypertension.
Beyond aortic dilation and aneurysm formation, bicuspid
aortic valve disease is also a risk factor for dissection and
rupture [572]. Thus, BP should be tightly controlled in
patients with bicuspid aortic valve disease and targeted
130/80mmHg if tolerated. There is popular misconcep-
tion that BP-lowering treatment has deleterious effects in
patients with aortic stenosis and hypertension, when in
fact it is well tolerated even in patients with severe aortic
stenosis. Moreover, vasodilating drugs (including RAS
blockers) also appear to be well tolerated. Thus, treat-
ment of hypertension should be considered in these
patients [573].
8.19 Hypertension and sexual dysfunction
Sexual dysfunction may have an important negative effect
on the quality of life of both men and women. Compared
with the normotensive population, the prevalence of sexual
dysfunction is greater in hypertensive individuals, in whom
it presents an important cause of low adherence to or
discontinuation of antihypertensive treatment [574]. A large
meta-analysis of prospective cohort studies has provided
strong evidence that in men, erectile dysfunction (i.e.
inadequate penile erection) is a significant independent
risk factor for cardiovascular events and mortality [575],
which means that it may be viewed as an early marker of
vascular damage [576]. Sexual dysfunction may be triggered
or aggravated by treatment with thiazide or thiazide-like
diuretics, conventional beta-blockers, or centrally acting
agents (e.g. clonidine), while ACE inhibitors, ARBs, CCBs,
or vasodilating beta-blockers may have neutral or even
beneficial effects [574,577]. Phosphodiesterase-5 inhibitors
are effective against erectile dysfunction in patients with
hypertension. They should be given only in the absence of
nitrate administration, but prescription also appears to be
safe in patients with multidrug BP-lowering treatment [578],
with some caution if treatment includes alpha-blockers
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[577]. However, it seems prudent for unstable patients with
high cardiovascular risk or severe uncontrolled hyperten-
sion to defer sexual activity until their condition is stabi-
lized and treatment for erectile dysfunction can be initiated
[575]. Overall, studies on the effects of hypertension and
antihypertensive therapy on female sexual dysfunction are
limited, and the situation is thus less clear than in men
[577,579], although in a recent cross-sectional analysis
among middle-aged and older treated hypertensive
women in the SPRINT trial, neither BP values nor antihy-
pertensivemedicationwas associatedwith sexual dysfunc-
tion [579].
It is recommended that information on sexual dys-
function is collected in all hypertensive patients at diag-
nosis and regularly at the follow-up visits, with special
attention to its possible relationship with reluctance to
start or adherence to drug treatment. In men reporting
sexual dysfunction, the antihypertensive agents more
likely to be associated with this effect (e.g. beta-blockers
and thiazide diuretics) should be avoided or replaced,
unless strictly necessary for the patient’s clinical
condition.
8.20 Hypertension and cancer therapy
Hypertension is the most common cardiovascular comor-
bidity reported in cancer registries, in which an elevated
BP is usually found in more than one-third of the patients
[580]. This can be due to the high prevalence of hyper-
tension at an age in which cancer is also common.
However, it is also due to the pressor effect of two
groups of widely used anticancer drugs, the inhibitors
of the vascular endothelial growth factor signalling path-
way (bevacizumab, sorafenib, sunitinib, and pazopanib)
and the proteasome inhibitors (carfilzomib). While the
former group of drugs inhibits the production of nitric
oxide in the arterial wall, the latter reduces the vasodila-
tor response to acetylcholine, favouring vasoconstriction
and vasospasm [581].
In patients under treatment with the above-men-
tioned anticancer drugs, a BP increase has been
reported in a variable but overall high percent of
patients (30%). The increase frequently occurs during
the first months after starting the anticancer therapy, the
temporal association providing evidence for the anti-
cancer drug’s pathophysiological role. It follows that
office BP should be measured weekly during the initial
part of the first cycle of therapy and at least every 2–3
weeks thereafter [582]. After the first cycle is completed
and BP values appear to be stable, BP can be measured
at the time of the routine clinical evaluations or assessed
by HBPM. Patients developing hypertension (140/
90mmHg), or showing an increase in DBP 20mmHg
compared with pretreatment values, should initiate or
optimize antihypertensive therapy, for which RAS block-
ers and CCBs may be considered the preferred drugs,
and a RAS blocker-CCB combination is a frequently
needed strategy. CCBs should only be of the dihydro-
piridine type, because diltiazem and verapamil block the
CYP3A4 isoenzyme, which is involved in the metabolic
pathway of sorafenib, increasing the drug’s levels and
leading to potential toxicity [583]. Although anticancer
therapy takes an obvious priority, its temporary discon-
tinuation may be considered when BP values are
exceedingly high despite multidrug treatment, in the
presence of severe hypertension-generated symptoms,
or when there is a cardiovascular event requiring an
immediate effective BP control [584].
8.21 Perioperative management of
hypertension
With the increasing number of patients undergoing sur-
gery, management of hypertension in the perioperative
period (a term that includes the intraoperative phase) has
emerged as an important issue in clinical practice [585].
ESC Guidelines have been issued for the assessment of
cardiovascular variables, risk, and disease management
of patients undergoing noncardiac surgery [586]. While a
BP elevation is per se not a strong risk factor for cardio-
vascular complications in noncardiac surgery, overall
cardiovascular risk assessment, including the search for
HMOD, is important in treated and untreated hyperten-
sive patients, and mandatory when a BP elevation is
newly detected [537,586]. Postponing necessary surgery
is usually not warranted in patients with grade 1 or 2
hypertension, whereas in those with an SBP at least
180mmHg and/or DBP at least 110mmHg, deferring
the intervention until BP is reduced or controlled is
advisable, except for emergency situations. What seems
to be also important is to avoid large perioperative BP
fluctuations [537,586]. This approach is supported by the
findings from a recent RCT that has shown that in patients
undergoing abdominal surgery, an individualized intra-
operative treatment strategy, which kept BP values within
a 10% difference from the preoperative office SBP,
resulted in reduced risk of postoperative organ dysfunc-
tion [587]. There is no clear evidence in favour or against
one vs. another antihypertensive treatment mode in
patients undergoing noncardiac surgery, and thus the
general drug treatment algorithms apply to these patients
as well [588,589]. However, the perioperative use of beta-
blockers has been the object of controversy for many
years, and the concern has recently been revived by
meta-analyses showing some increase in the risk of
hypotension, stroke, and mortality in patients on periop-
erative beta-blockers vs. placebo [586,588,589]. Continu-
ation of beta-blockers is nevertheless recommended in
hypertensive patients on chronic beta-blocker treatment
[586] in whom their abrupt discontinuation may lead to
BP or heart rate rebounds [537]. This may also occur with
the abrupt discontinuation of central agents such as
clonidine. More recently, the question has been raised
whether RAS blockers should be discontinued before
surgery to reduce the risk of intraoperative hypotension
[586,590]. Preoperative discontinuation of these drugs has
also been supported by a recent international prospective
cohort study, in a heterogenous group of patients, in
which withholding ACE inhibitors or ARBs 24 h before
noncardiac surgery was associated with a significant
reduction in cardiovascular events and mortality 30 days
after the intervention [591].
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Perioperative management of hypertension
Recommendations Classa Levelb
It is recommended that newly diagnosed hypertensive patients who are scheduled for elective surgery should be preoperatively
screened for HMOD and cardiovascular risk.
I C
It is recommended to avoid large perioperative BP fluctuations during the perioperative period [587]. I C
Non-cardiac surgery may not be deferred in patients with grade 1 or 2 hypertension (SBP < 180 mmHg; DBP < 110 mmHg). IIb C
Perioperative continuation of beta-blockers is recommended in hypertensive patients on chronic treatment with these
drugs [592,593].
I B
Abrupt discontinuation of beta-blockers or centrally acting agents (e.g. clonidine) is potentially harmful and is not
recommended [589,594].
III B
Transient preoperative discontinuation of RAS blockers should be considered in patients with hypertension undergoing non-
cardiac surgery. IIa C
BP, blood pressure; DBP, diastolic blood pressure; HMOD, hypertension-mediated organ damage; RAS, renin–angiotensin system; SBP, systolic blood pressure.
aClass of recommendation.
bLevel of evidence.
9 MANAGING CONCOMITANT
CARDIOVASCULAR DISEASE RISK
9.1 Statins and lipid-lowering drugs
Patients with hypertension, and more so those with type 2
diabetes or metabolic syndrome, often have atherogenic
dyslipidaemia characterized by elevated triglycerides and
LDL cholesterol (LDL-C), and low HDL cholesterol (HDL-C)
[595]. The benefit of adding a statin to antihypertensive
treatment was well established in the ASCOT-Lipid Lower-
ing Arm study [596] and further studies, as summarized in
previous European Guidelines [16,35]. The beneficial effect
of statin administration to patients without previous car-
diovascular events [targeting an LDL-C value of less than
3.0mmol/l (115mg/dl)] has been strengthened by the find-
ings from the Justification for the Use of Statins in Preven-
tion: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) [597] and HOPE-3 studies [343,598], showing
that lowering LDL-C in patients with baseline values less
than 3.4mmol/l (130mg/dl) reduced the incidence of car-
diovascular events by between 44 and 24%. This justifies the
use of statins in hypertensive patients who have moderate–
high cardiovascular risk [599].
As detailed in the recent ESC/EAS Guidelines [599], when
overt CVD is present and the cardiovascular risk is very
high, statins should be administered to achieve LDL-C levels
of less than 1.8mmol/l (70mg/dl) or a reduction of at least
50% if the baseline LDL-C is between 1.8 and 3.5mmol/l (70
and 135mg/dl) [600–602]. In patients at high cardiovascular
risk, an LDL-C goal of less than 2.6mmol/l (100mg/dl) or a
reduction of at least 50% if the baseline LDL-C is between
2.6 and 5.2mmol/l (100 and 200mg/dl) is recommended
[602]. Beneficial effects of statin therapy have also been
shown in patients with a previous stroke with LDL-C targets
less than 2.6mmol/l (100mg/dl) [525]. Whether they also
benefit from a target of less than 1.8mmol/l (70mg/dl) is
open to future research. The summary of the available
evidence suggests that many patients with hypertension
would benefit from statin therapy.
9.2 Antiplatelet therapy and anticoagulant
therapy
The most common complications of hypertension are
related to thrombosis [603]. Hypertension predisposes to
a prothrombotic state [603], and also predisposes to LEAD,
heart failure, or AF, which are common conditions associ-
ated with thromboembolism, whether systemic or venous.
Antiplatelet and anticoagulant therapy use in patients
with hypertension was addressed in a Cochrane systematic
review [604], which included four randomized trials with a
combined total of 44 012 patients. The authors concluded
that overall acetylsalicylic acid (aspirin) did not reduce
stroke or cardiovascular events compared with placebo
in primary prevention patients with elevated BP and no
previous CVD [604]. For secondary prevention, antiplatelet
therapy in patients with elevated BP was reported as
causing an absolute reduction in vascular events of 4.1%
compared with placebo [604].
Benefit has not been demonstrated for anticoagulation
therapy, alone or in combination with aspirin, in patients
with hypertension in the absence of other indications requir-
ing anticoagulants, such as AF or venous thromboembolism
[604]. In anticoagulated patients, uncontrolled hypertension
is one of the independent risk factors for intracranial hae-
morrhage and major bleeding [605]. In such patients, atten-
tion to modifiable bleeding risk factors should be made
during all patient contacts. Bleeding risk assessment with
clinical risk scores such as the HAS-BLED [Hypertension,
Abnormal renal/liver function (1 point each), Stroke, Bleed-
inghistoryorpredisposition, Labile INR,Older (>65),Drugs/
alcohol concomitantly (1 point each)] score, includes uncon-
trolled hypertension (defined as SBP>160mmHg) as one of
the risk factors for bleeding [606]; these should be used to
‘flag up’ patients at particularly high risk (e.g. HAS-BLED3)
for more regular review and follow-up [607].
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Treatment of CV risk factors associated with hypertension
Recommendations a LevelClass b
Cardiovascular risk assessment with the SCORE
system is recommended for hypertensive
patients who are not already at high or very
high risk due to established CVD, renal disease,
or diabetes [33].
I B
For patients at very high cardiovascular risk,
statins are recommended to achieve LDL-C
levels of <1.8 mmol/L (70 mg/dL), or a reduction
of >_ 50% if the baseline LDL-C is 1.8–3.5
mmol/L (70–135 mg/dL) [596,599,602].
I B
For patients at high cardiovascular risk, statins
are recommended to achieve an LDL-C goal of
< 2.6 mmol/L (100 mg/dL), or a reduction of
>_ 50% if the baseline LDL-C is 2.6–5.2
mmol/L (100–200 mg/dL) [599,602].
I B
For patients at low–moderate cardiovascular 
risk, statins should be considered to achieve an
LDL-C value of < 3.0 mmol/L (115 mg/
dL) [598].
IIa C
Antiplatelet therapy, in particular low-dose
aspirin, is recommended for secondary pre-
vention in hypertensive patients [35,604].
I A
Aspirin is not recommended for primary
prevention in hypertensive patients without
CVD [35,604].
III A
CVD, cardiovascular disease; LDL-C, LDL cholesterol; SCORE, Systematic COronary Risk
Evaluation.
aClass of recommendation.
bLevel of evidence.
In summary, aspirin is not recommended for primary
prevention in hypertensive patients without CVD [35]. For
secondary prevention, the benefit of antiplatelet therapy in
patients with hypertension may be greater than the harm
[35,604]. Ticlopidine, clopidogrel, and newer antiplatelet
agents such as prasugrel and ticagrelor have not been
sufficiently evaluated in patients with high BP.
9.3 Glucose-lowering drugs and blood pressure
The impact of new glucose-lowering drugs on BP and the
reduction in cardiovascular and renal risk, beyond their
effect of glucose control, have received attention after the
publication of the US Food and Drug Administration rec-
ommendations for evaluating cardiovascular risk in new
therapies to treat type 2 diabetes. New generations of
antidiabetes drugs, that is dipeptidyl peptidase 4 inhibitors
and glucagon-like peptide 1 agonists, slightly reduce BP,
and also body weight with glucagon-like peptide 1 ago-
nists. Two glucagon-like peptide 1 agonists (liraglutide and
semaglutide) reduced cardiovascular and total mortality,
but not heart failure, in patients with type 2 diabetes
[608,609]. More data are required with respect to the capac-
ity of glucagon-like peptide 1 agonists and dipeptidyl
peptidase 4 inhibitors to prevent heart failure.
Inhibitors of sodium-glucose co-transporter-2 are the only
glucose-lowering drug class to reduce BP beyond the pro-
jected impact ofweight reductiononBP. Empaglifozine [475]
and canagliflozin [476] have demonstrated a reduction in
heart failure and total and cardiovascular mortality, and a
protective effect on renal function. Several mechanisms may
account for these effects, and increased sodium excretion
and improvements in tubuloglomerular balance reducing
hyperfiltration are suggested mechanisms for the observed
cardiovascular and renal protection, respectively.
10 PATIENT FOLLOW-UP
10.1 Follow-up of hypertensive patients
After the initiation of antihypertensive drug therapy, it is
important to revisit the patient at least once within the first 2
months to evaluate the effects on BP and assess possible
side effects until BP is under control. The frequency of
revisting will depend on the severity of hypertension, the
urgency to achieve BP control, and the patient’s comorbid-
ities. SPC therapy should reduce BP within 1–2 weeks and
may continue to reduce BP over the next 2 months. Once
the BP target is reached, a visit interval of a few months is
reasonable and evidence has been obtained that no differ-
ence exists in BP control between 3-month and 6-month
intervals [610]. Depending on the local organization of
health resources, many of the later visits may be performed
by nonphysician health workers such as nurses [611]. For
stable patients, HBPM and electronic communication with
the physician may also provide an acceptable alternative to
reduce the frequency of visits [60,612,613]. It is nevertheless
advisable to assess risk factors and asymptomatic organ
damage at least every 2 years.
10.2 Follow-up of subjects with high–normal
blood pressure and white-coat hypertension
Patients with high–normal BP or white-coat hypertension
frequently have additional risk factors, including HMOD,
and have a higher risk of developing sustained hyperten-
sion [427,614–618] (see Section 4). Thus, even when
untreated, they should be scheduled for regular follow-
up (at least annual visits) to measure office and out-of-office
BP, as well as to check the cardiovascular risk profile. At
annual visits, recommendations on lifestyle changes, which
represent the appropriate treatment in many of these
patients, should be reinforced.
10.3 Elevated blood pressure at control visits
The finding of an elevated BP should always lead physi-
cians to search for the cause(s), particularly the most
common ones such as poor adherence to the prescribed
treatment regimen, persistence of a white-coat effect, and
occasional or more regular consumption of salt, drugs, or
substances that raise BP or oppose the antihypertensive
effect of treatment (e.g. alcohol or nonsteroidal anti-inflam-
matory drugs). This may require tactful but stringent ques-
tioning of the patient (and his/her relatives) to identify
interfering factors, as well as repeated measurements of
BP in the following weeks to ensure that BP has returned to
controlled values. If ineffective treatment is regarded as the
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reason for inadequate BP control, the treatment regimen
should be uptitrated in a timely fashion (see Section 7); this
avoids clinical inertia, a major contributor to poor BP
control worldwide [311].
10.4 Improvement in blood pressure control in
hypertension: drug adherence
There is growing evidence that poor adherence to treat-
ment – in addition to physician inertia (i.e. lack of thera-
peutic action when the patient’s BP is uncontrolled) – is the
most important cause of poor BP control [293,619–621].
Nonadherence to antihypertensive therapy correlates with
higher risk of cardiovascular events [312,622].
Early discontinuation of treatment and suboptimal daily
use of the prescribed regimens are themost common facets of
poor adherence. After 6 months, more than one-third, and
after 1 year, about one-half of patients may stop their initial
treatment [623]. Studies based on the detection of antihyper-
tensive medications in blood or urine have shown that low
adherence to theprescribedmedications can affect or less 50%
of patients with apparently resistant hypertension [352,624],
and that poor adherence is strongly and inversely correlated
with thenumber of pills prescribed. Early recognitionof a lack
of adherencemight reduce thenumberof costly investigations
and procedures (including interventional treatment), and
avoid the prescription of unnecessary drugs [625].
A major emphasis of these Guidelines has been to
simplify the treatment strategy to try and improve adher-
ence to treatment and BP control, by prescribing a single
pill to most patients with hypertension. This is a response to
the fact that despite the clear-cut benefits of BP treatment in
trials, most treated patients do not achieve recommended
BP targets in real life. The lower BP targets recommended in
these Guidelines will mean that BP control rates will be
even worse unless action is taken to ensure that patients are
more likely to adhere to logical combinations of treatment.
Several methods are available to detect poor adherence,
but most are indirect, poorly reliable, and provide little
information on the most important issue: dosing history.
Today, the most accurate methods that can be recom-
mended, despite their limitations, are the detection of
prescribed drugs in blood or urine samples. Directly
observed treatment, followed by BP measurement over
subsequent hours via HBPM or ABPM, can also be very
useful to determine if BP really is poorly controlled despite
witnessed consumption of medication in patients with
apparent resistant hypertension. In contrast, questionnaires
frequently overestimate drug adherence. The assessment of
adherence should be improved with the development of
cheaper and more reliable methods of detection that are
easily applicable in daily practice [354,626].
Barriers to optimal adherence may be linked with phy-
sician attitudes, patient beliefs and behaviour, the complex-
ity and tolerability of drug therapies, the healthcare system,
and several other factors. Therefore, the assessment of
adherence should always be conducted in a no-blame
approach, and should favour an open discussion to identify
the specific barriers limiting the patient’s ability to follow
the therapeutic recommendations. Individualized solutions
should be found. Patients should be encouraged to take
responsibility for their own cardiovascular health.
Patient adherence to therapy can be improved by several
interventions. The most useful interventions are those link-
ing drug intake with habits [347], those giving adherence
feedback to patients, self-monitoring of BP [64] using pill
boxes and other special packaging, and motivational inter-
viewing. Increasing the integration among healthcare pro-
viders with the involvement of pharmacists and nurses
increases drug adherence. Using multiple components
has a greater effect on adherence, as the effect size of each
intervention is generally modest. Recent data suggest that
adherence to treatment may also be improved with the use
of telemetry for transmission of recorded home values,
maintaining contact between patients and physicians,
and studies are ongoing [627].
Prescription of an appropriate therapeutic regimen is cru-
cial [389]. This might be achieved through: possible drug-
related adverse events, using long-acting drugs that require
once daily dosage [628,629], avoiding complex dosing sched-
ules, using SPCs whenever possible, and taking into consid-
eration the effect of treatment on a patient’s budget.
Compared with the large number of trials for individual
drugs and treatments, there are only a limited number of
rigorous trials on adherence interventions. Thus, the level
of evidence indicating that a sustained improvement in
medication adherence can be achievedwithin the resources
available today in clinical practice is low. This is essentially
due to the short duration of most studies, their heteroge-
neity, and their questionable designs. Whether available
interventions ameliorate treatment outcomes remains to be
demonstrated in adequate trials.
A list of the interventions associated with improved
patient adherence to treatment is shown in Table 33.
TABLE 33. Interventions that may improve drug adherence in
hypertension
Physician level
 Provide information on the risks of hypertension and the benefits of
treatment, as well as agreeing a treatment strategy to achieve and
maintain BP control using lifestyle measures and a single-pill-based
treatment strategy when possible (information material, programmed
learning, and computer-aided counselling)
 Empowerment of the patient
 Feedback on behavioural and clinical improvements
Assessment and resolution of individual barriers to adherence
Collaboration with other healthcare providers, especially nurses and
pharmacists
Patient level
 Self-monitoring of BP (including telemonitoring)
Group sessions
 Instruction combined with motivational strategies
 Self-management with simple patient-guided systems
Use of reminders
Obtain family, social, or nurse support
 Provision of drugs at worksite
Drug treatment level
 Simplification of the drug regimen favouring the use of SPC therapy
Reminder packaging
Health system level
 Supporting the development of monitoring systems (telephone
follow-up, home visits, and telemonitoring of home BP)
 Financially supporting the collaboration between healthcare providers
(e.g. pharmacists and nurses)
Reimbursement of SPC pills
Development of national databases, including prescription data,
available for physicians and pharmacists
Accessibility to drugs
BP, blood pressure; SPC, single-pill combination.
Williams et al.
2018 www.jhypertension.com Volume 36  Number 10  October 2018
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
10.5 Continued search for asymptomatic
hypertension-mediated organ damage
The importance and need to detect HMOD at initial assess-
ment to help risk stratify the patient, and to review the
progression or regression of HMOD during follow-up, have
been described in Section 4. The presence of HMOD
demonstrates that BP is elevated and that the patient would
benefit from treatment. The regression of asymptomatic
organ damage occurring during treatment can often indi-
cate an improved prognosis (see Section 5).
10.6 Can antihypertensive medications be
reduced or stopped?
In some patients in whom treatment is accompanied by
effective BP control for an extended period, it may be
possible to reduce the number and/or dosage of drugs.
This may particularly be the case if BP control is accompa-
nied by healthy lifestyle changes such as weight loss,
exercise habit, and a low-fat and low-salt diet, which
remove environmental pressor influences. A reduction of
medications should be made gradually, and the patient
should be checked frequently because reappearance of
hypertension can occur quickly, within weeks, or may take
many months. Patients with prior HMOD or previous
accelerated hypertension should not have their treatment
withdrawn.
11 GAPS IN THE EVIDENCE
Gaps in the evidence and need for further studies
What is the optimal population screening programme for detecting
hypertension?
What is the optimal method to measure BP in patients with AF?
What is the incremental benefit for cardiovascular risk prediction of the
addition of out-of-office BP (HBPM and ABPM) to office BP measurement?
What is the incremental benefit, over the SCORE system, of measures of
HMOD in reclassifying the cardiovascular risk of patients with hypertension?
What are the appropriate BP thresholds and targets for drug treatment in
younger hypertensive patients?
What are the optimal BP treatment targets according to HBPM and ABPM?
What are the outcome benefits associated with antihypertensive treatment
in patients with resistant hypertension?
What are the benefits of BP treatment for patients with BP in the high–
normal range?
What baseline level of cardiovascular risk predicts treatment benefit?
More data on the benefits of BP treatment in the very elderly and the
influence of frailty
Outcome-based comparison between office BP and out-of-office BP-guided
treatment
Outcome-based comparison between treatments guided by BP control and
by HMOD reductions, especially in younger patients
More outcome studies of the optimal SBP treatment target for patients at
different levels of baseline cardiovascular risk and with different comor-
bidities, including diabetes and CKD
More outcome studies of the optimal DBP treatment target
Impact of single-pill vs. multidrug treatment strategies on adherence to
treatment, BP control, and clinical outcomes
Outcome-based comparison between treatment strategies based on initial
monotherapy vs. initial combination therapy
What is the optimal salt intake to reduce cardiovascular and mortality risk?
What are the long-term outcome benefits resulting from the recommended
lifestyle changes?
Outcome-based comparison between treatments based on thiazide vs.
thiazide-like diuretics
Incremental value of central vs. peripheral BP in risk estimation and risk
reduction by treatment
Outcome-based comparison of BP treatment with classical vs. vasodilator
beta-blockers
TABLE 1 (Continued)
Gaps in the evidence and need for further studies
Optimal BP treatment targets in specific clinical conditions (e.g. diabetes,
CKD, and post-stroke)
Protective effect of antihypertensive treatment in patients with cognitive
dysfunction or dementia
Role of antihypertensive treatment in white-coat hypertension
Role of antihypertensive treatment in masked hypertension
Optimal treatment of hypertension in different ethnic groups
ABPM, ambulatory blood pressure monitoring; AF, atrial fibrillation; BP, blood pressure;
CKD, chronic kidney disease; DBP, diastolic blood pressure; HBPM, home blood pressure
monitoring; HMOD, hypertension-mediated organ damage; SBP, systolic blood pressure;
SCORE, Systematic COronary Risk Evaluation.
12 KEY MESSAGES
1. BP, epidemiology, and risk. Globally, over 1
billion people have hypertension. As populations
age and adopt more sedentary lifestyles, the world-
wide prevalence of hypertension will continue to
rise towards 1.5 billion by 2025. Elevated BP is the
leading global contributor to premature death,
accounting for almost 10 million deaths in 2015,
4.9 million due to ischaemic heart disease and 3.5
million due to stroke. Hypertension is also a major
risk factor for heart failure, AF, CKD, PAD, and
cognitive decline.
2. Definition of hypertension. The classification of
BP and the definition of hypertension is unchanged
from previous European Guidelines, and is defined
as an office SBP at least 140 and/or DBP at least
90mmHg, which is equivalent to a 24 h ABPM
average of at least 130/80mmHg, or a HBPM aver-
age at least 135/85mmHg.
3. Screening and diagnosis of hypertension.
Hypertension is usually asymptomatic (hence the
term ‘silent killer’). Because of its high prevalence,
screening programmes should be established to
ensure that BP is measured in all adults at least
every 5 years, and more frequently in people with
a high–normal BP. When hypertension is suspected
because of an elevated screening BP, the diagnosis
of hypertension should be confirmed either by
repeated office BP measurements over a number
of visits or by out-of-office BP measurement using
24 h ABPM or HBPM.
4. The importance of cardiovascular risk assess-
ment and detection of HMOD. Other cardiovas-
cular risk factors such as dyslipidaemia and
metabolic syndrome frequently cluster with hyper-
tension. Thus, unless the patient is already at high or
very high risk due to established CVD, formal car-
diovascular risk assessment is recommended using
the SCORE system. However, it is important to
recognize that the presence of HMOD, especially
LVH, CKD, or advanced retinopathy, further
increases the risk of cardiovascular morbidity and
mortality, and should be screened for as part of risk
assessment in hypertensive patients because the
SCORE system alone may underestimate their risk.
5. Think: could this patienthave secondaryhyper-
tension? For most people with hypertension, no
(Continued )
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underlying cause will be detected. Secondary (and
potentially remediable) causes of hypertension are
more likely to be present in people with young
onset of hypertension (<40 years), people with
severe or treatment-resistant hypertension, or peo-
ple who suddenly develop significant hypertension
in midlife on a background of previously normal BP.
Such patients should be referred for specialist
evaluation.
6. Treatment of hypertension: importance of life-
style interventions. The treatment of hyperten-
sion involves lifestyle interventions and drug
therapy. Many patients with hypertension will
require drug therapy, but lifestyle interventions
are important because they can delay the need for
drug treatment or complement the BP-lowering
effect of drug treatment. Moreover, lifestyle inter-
ventions such as sodium restriction, alcohol moder-
ation, healthy eating, regular exercise, weight
control, and smoking cessation all have health ben-
efits beyond their impact on BP.
7. When to consider drug treatment of hyperten-
sion. The treatment thresholds for hypertension are
now less conservative than they were in previous
Guidelines. We now recommend that patients with
low-moderate-risk grade 1 hypertension (office BP
140–159/90–99), even if they do not have HMOD,
should now receive drug treatment if their BP is not
controlled after a period of lifestyle intervention
alone. For higher-risk patients with grade 1 hyper-
tension, including those with HMOD, or patients
with higher grades of hypertension (e.g. grade 2
hypertension, 160/100mmHg), we recommend
initiating drug treatment alongside lifestyle interven-
tions. These recommendations apply to all adults
aged <80 years.
8. Special considerations in frail and older
patients. It is increasingly recognized that biologi-
cal rather than chronological age, as well as con-
sideration of frailty and independence, are
important determinants of the tolerability of and
likely benefit from BP-lowering medications. It is
important to note that even in the very old (i.e. >80
years), BP-lowering therapy reduces mortality,
stroke, and heart failure. Thus, these patients should
not be denied treatment or have treatment with-
drawn simply on the basis of age. For people more
than 80 years who have not yet received treatment
for their BP, treatment is recommended when their
office SBP is at least 160mmHg, provided that the
treatment is well tolerated.
9. How low should SBP be lowered? This has been a
hotly debated topic. A key discussion point is the
balance of potential benefits vs. potential harm or
adverse effects. This is especially important when-
ever BP targets are lowered, as there is a greater
potential for harm to exceed benefit. Thus, in these
Guidelines, we recommend a target range. The
evidence strongly suggests that lowering office
SBP to <140mmHg is beneficial for all patient
groups, including independent older patients. There
is also evidence to support targeting SBP to
130mmHg for most patients, if tolerated. Even lower
SBP levels (<130mmHg) will be tolerated and
potentially beneficial for some patients, especially
to further reduce the risk of stroke. SBP should not
be targeted to less than 120mmHg because the
balance of benefit vs. harm becomes concerning
at these levels of treated SBP.
10. BP targets in old and very old patients. As
discussed above, independence, frailty, and comor-
bidities will all influence treatment decisions, espe-
cially in older (65 years) and very old (>80 years)
patients. The desired SBP target range for all patients
aged more than 65 years is 130–139mmHg. This is
lower than in previous Guidelines and may not be
achievable in all older patients, but any BP lowering
towards this target is likely to be beneficial provided
that the treatment is well tolerated.
11. BP targets in patients with diabetes and/or
CKD. The BP treatment targets for patients with
diabetes or kidney disease have been a moving
target in previous Guidelines because of seemingly
contradictory results from major outcome trials and
meta-analyses. For diabetes, targeting the SBP to less
than 140mmHg and towards 130mmHg, as recom-
mended for all other patient groups, is beneficial on
major outcomes. Moreover, targeting SBP to less
than 130mmHg, for those who will tolerate it,
may further reduce the risk of stroke but not other
major outcomes. SBP should not be less than
120mmHg. For patients with CKD, the evidence
suggests that the target BP range should be 130–
139mmHg.
12. How low should DBP be lowered? The optimal
DBP target has been less well defined, but a DBP
target of less than 80mmHg is recommended. Some
patients with stiff arteries and isolated systolic
hypertension will already have DBP levels below
this target. These are high-risk patients and the low
DBP should not discourage treatment of their ele-
vated SBP to the recommended target, provided that
treatment is well tolerated.
13. The need to do better on BP control. A key
message in these Guidelines is the need to do better
at improving BP control rates. Despite the over-
whelming evidence of treatment benefit, on aver-
age, less than 50% of patients with treated
hypertension achieve an SBP target of less than
140mmHg. Physician inertia (inadequate uptitration
of treatment, especially from monotherapy) and
poor patient adherence to treatment (especially
when based on multiple pills) are now recognized
as the major factors contributing to poor BP control.
14. Start treatment in most patients with two
drugs, not one.Monotherapy is usually inadequate
therapy for most people with hypertension; this will
be especially true now that the BP treatment targets
for many patients are lower than in previous Guide-
lines. These Guidelines have set out to normalize the
concept that initial therapy for the majority of
patients with hypertension should be with a
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combination of two drugs, not a single drug. The
only exception would be in a limited number of
patients with a lower baseline BP close to their
recommended target, who might achieve that target
with a single drug, or in some frailer old or very old
patients in whom more gentle reduction of BP may
be desirable. Evidence suggests that this approach
will improve the speed, efficiency, and consistency
of initial BP lowering and BP control, and is well
tolerated by patients.
15. A single-pill strategy to treat hypertension.
Poor adherence to longer-term BP-lowering medi-
cation is now recognized as a major factor contrib-
uting to poor BP control rates. Research has shown a
direct correlation between the number of BP-low-
ering pills and poor adherence to medications.
Moreover, SPC therapy has been shown to improve
adherence to treatment. SPC therapy is now the
preferred strategy for initial two-drug combination
treatment of hypertension and for three-drug com-
bination therapy when required. This will control
the BP of most patients with a single pill and could
transform BP control rates.
16. A simplified drug treatment algorithm.We have
simplified the treatment strategy so that patients
with uncomplicated hypertension and many
patients with a variety of comorbidities (e.g. HMOD,
diabetes, PAD, or cerebrovascular disease) receive
similar medication. We recommend a combination
of an ACE inhibitor or ARB with a CCB or thiazide/
thiazide-like diuretic as initial therapy for most
patients. For those requiring three drugs, we rec-
ommend a combination of an ACE inhibitor or ARB
with a CCB and a thiazide/thiazide-like diuretic. We
recommend that beta-blockers be used when there
is a specific indication for their use (e.g. angina,
postmyocardial infarction, HFrEF, or when heart
rate control is required).
17. Hypertension in women and in pregnancy. In
women with hypertension who are planning
pregnancy, ACE inhibitors or ARBs and diuretics
should be avoided, and the preferred medications
to lower BP, if required, include alpha-methyl dopa,
labetalol, or CCBs. The same drugs are suitable if BP
lowering is required in pregnant women. ACE inhib-
itors or ARBs should not be used in pregnant
women.
18. Is there a role for device-based therapy for the
treatment of hypertension? A number of
device-based interventions have been developed
and studied for the treatment of hypertension. To
date, the results from these studies have not pro-
vided sufficient evidence to recommend their rou-
tine use. Consequently, the use of device-based
therapies is not recommended for the routine
treatment of hypertension, unless in the context
of clinical studies and RCTs, until further evidence
regarding their safety and efficacy becomes
available.
19. Managing cardiovascular disease risk in hyper-
tensive patients beyond BP: statins. For hyper-
tensive patients at moderate CVD risk or higher, or
those with established CVD, BP lowering alone will
not optimally reduce their risk. These patients
would also benefit from statin therapy, which fur-
ther reduces the risk of a myocardial infarction by
approximately one-third and stroke by approxi-
mately one-quarter, even when BP is controlled.
Similar benefits have been seen in hypertensive
patients at the border between low and moderate-
risk. Thus, many more hypertensive patients would
benefit from statin therapy than are currently receiv-
ing this treatment.
20. Managing cardiovascular disease risk in hyper-
tensive patients beyond BP: antiplatelet ther-
apy. Antiplatelet therapy, especially low-dose
aspirin, is recommended for secondary prevention
in hypertensive patients, but is not recommended
for primary prevention (i.e. in patients without
CVD).
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13 ‘WHAT TODO’AND ‘WHAT NOT TODO’ MESSAGES FROM THE GUIDELINES
Recommendations Classa Levelb
Classification of BP
It is recommended that BP be classified as optimal, normal, or high–normal, or grades 1–3 hypertension, according to office
BP.
I C
Screening for hypertension
Screening programmes for hypertension are recommended. All adults (>_18 years) should have their office BP measured and
recorded in their medical file, and be aware of their BP.
I B
Diagnosis of hypertension
It is recommended to base the diagnosis of hypertension on:
• Repeated office BP measurements on more than one visit, except when hypertension is severe (e.g. grade 3 and especially
in high-risk patients). At each visit, three BP measurements should be recorded, 1–2 min apart, and additional measure-
ments performed if the first two readings differ by > 10 mmHg. The patient’s BP is the average of the last two BP readings.
I C
OR
• Out-of-office BP measurement with ABPM and/or HBPM, provided that these measurements are logistically and economi-
cally feasible.
I C
Office BP thresholds for the initiation of drug treatment for hypertension
Prompt initiation of BP-lowering drug treatment is recommended in patients with grade 2 or 3 hypertension at any level of CV
risk, simultaneously with the initiation of lifestyle changes.
I A
In patients with grade 1 hypertension:
• Lifestyle interventions are recommended to determine if this will normalize BP.
I B
• In patients with grade 1 hypertension at low-moderate-risk and without evidence of HMOD, BP-lowering drug treatment is
recommended if the patient remains hypertensive after a period of lifestyle intervention.c
I A
• In patients with grade 1 hypertension at high risk or with evidence of HMOD, prompt initiation of drug treatment is recom-
mended simultaneously with lifestyle interventions.
I A
In fit older patients with hypertension (even if aged > 80 years), BP-lowering drug treatment and lifestyle intervention are rec-
ommended when SBP is >_ 160 mmHg.
I A
BP-lowering drug treatment and lifestyle intervention are recommended in fit older patients (> 65 years but not > 80 years)
when SBP is in the grade 1 range (140–159 mmHg), provided that treatment is well tolerated.
I A
In patients with high–normal BP (130–139/85–89 mmHg), lifestyle changes are recommended. I A
Withdrawal of BP-lowering drug treatment on the basis of age, even when patients attain an age of >_ 80 years, is not recom-
mended, provided that treatment is well tolerated.
III A
Office BP treatment targets
It is recommended that the first objective of treatment should be to lower BP to < 140/90 mmHg in all patients, and provided
that the treatment is well tolerated, treated BP values should be targeted to 130/80 mmHg or lower in most patients.
I A
In patients < 65 years receiving BP-lowering drugs, it is recommended that SBP should be lowered to a BP range of 120–129
mmHg in most patients.d
I A
In older patients (aged >_ 65 years) receiving BP-lowering drugs, it is recommended that SBP should be targeted to a BP range of
130–139 mmHg. I A
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Salt restriction to < 5 g per day is recommended. I A
It is recommended to restrict alcohol consumption to < 14 units per week for men and < 8 units per week for women. I A
Increased consumption of vegetables, fresh fruits, fish, nuts, unsaturated fatty acids (olive oil); low consumption of red meat;
and consumption of low-fat dairy products are recommended.
I A
Body weight control is indicated to avoid obesity (BMI > 30 kg/m2, or waist circumference > 102 cm in men and > 88 cm in
women) and aim for healthy BMI (about 20–25 kg/m2) and waist circumference values (< 94 cm in men and < 80 cm in women)
to reduce BP and cardiovascular risk.
I A
Regular aerobic exercise (e.g. >_ 30 min of moderate dynamic exercise on 5–7 days per week) is recommended. I A
Smoking cessation and supportive care and referral to smoking cessation programmes are recommended. I B
It is recommended to avoid binge drinking. III A
Treatment of hypertension: drug treatment
Combination treatment is recommended for most hypertensive patients as initial therapy. Preferred combinations should com-
prise a RAS blocker (either an ACE inhibitor or an ARB) with a CCB or diuretic. Other combinations of the five major classes
can be used.It is recommended that beta-blockers are combined with any of the other major drug classes when there are spe-
cific clinical situations (e.g. angina, post-myocardial infarction, heart failure, or heart rate control).
I A
I A
It is recommended to initiate antihypertensive treatment with a two-drug combination, preferably in an SPC. Exceptions are
frail older patients and those at low risk and with grade 1 hypertension (particularly if SBP is < 150 mmHg) [342,346,351].
I B
It is recommended that if BP is not controllede with a two-drug combination, treatment should be increased to a three-drug
combination, usually a RAS blocker with a CCB and thiazide/thiazide-like diuretics, preferably as an SPC.
I A
It is recommended that if BP is not controllede with a three-drug combination, treatment should be increased by the addition
of spironolactone or, if not tolerated, other diuretics such as amiloride or higher doses of other diuretics, a beta-blocker, or an
alpha-blocker.
I B
The combination of two RAS blockers is not recommended. III A
Treatment of hypertension: device-based therapies
Use of device-based therapies is not recommended for the routine treatment of hypertension, unless in the context of clinical
studies and RCTs, until further evidence regarding their safety and efficacy becomes available.
III B
Management of CVD risk in hypertensive patients
Cardiovascular risk assessment with the SCORE system is recommended for hypertensive patients who are not already at high
or very high risk due to established CVD, renal disease, or diabetes.
I B
For patients at high or very high cardiovascular risk, statins are recommended. I B
Antiplatelet therapy, in particular low-dose aspirin, is recommended for secondary prevention in hypertensive patients. I A
Aspirin is not recommended for primary prevention in hypertensive patients without CVD. III A
Routine genetic testing for hypertensive patients is not recommended. III C
Treatment of hypertension: lifestyle interventions
ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel
blocker; CVD, cardiovascular disease; HBPM, home blood pressure monitoring; HMOD, hypertension-mediated organ damage; RAS, renin–angiotensin system; RCT, randomized
controlled trial; SBP, systolic blood pressure; SCORE, Systematic COronary Risk Evaluation; SPC, single-pill combination.
aClass of recommendation.
bLevel of evidence.
cIn patients with grade 1 hypertension and low-moderate-risk, drug treatment may be preceded by a prolonged period of lifestyle intervention to determine if this will normalize BP.
The duration of the lifestyle intervention alone will depend on the level of BP within the grade 1 range (i.e. the likelihood of achieving BP control with lifestyle intervention alone) and
the opportunities for significant lifestyle change in individual patients.
dLess evidence is available for this target in low-moderate-risk patients.
eAdherence to medication should be checked.
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